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ABSTRACT OF DISSERTATION

EPIGENETIC MODIFICATIONS TO CYTOSINE AND ALZHEIMER’S DISEASE: A
QUANTITATIVE ANALYSIS OF POST-MORTEM TISSUE

Alzheimer’s disease (AD) is the most common form of dementia and the sixth
leading cause of death in the United States, with no therapeutic option to slow or halt
disease progression. Development of two characteristic pathologic lesions, amyloid beta
plaques and neurofibrillary tangles, in the brain are associated with synaptic dysfunction
and neuron loss leading to memory impairment and cognitive decline. Although mutations
in genes involved in amyloid beta processing are linked to increased plaque formation in
the inherited familial form of AD, the more common idiopathic form, termed sporadic AD,
develops in the absence of gene mutations. In contrast, alterations in gene expression and
transcription occur in plaque and tangle susceptible brain regions of sporadic AD subjects,
even in the earliest stages of development of pathologic burden, and may give insight into
the pathogenesis of AD. Epigenetic modifications to cytosine are known to alter
transcriptional states and gene expression in embryonic development as well as in cancer
studies. With the discovery of enzymatically oxidized derivatives of 5-methylcytosine (5mC), the most common epigenetic cytosine modification, a probable demethylation
pathway has been suggested to alter transcriptional states of DNA. The most abundant 5mC derivative, 5-hydroxymethylcytosine (5-hmC), while expressed at low concentrations
throughout the body, is expressed at high concentrations in brain cells.
To determine the role cytosine modifications play in AD, this study was directed at
the quantification of epigenetic modifications to cytosine in several stages of AD
progression using global, genome-wide, and gene-specific studies. To determine global
levels of each cytosine derivative in brain regions relevant to AD progression, a gas
chromatography/mass spectrometry quantitative analysis was utilized to analyze cytosine,
5-mC, and 5-hmC in tissue specimens from multiple brain regions of AD subjects,
including early and late stages of AD progression. To determine the genome-wide impact
of 5-hmC on biologically relevant pathways in AD, a single-base resolution sequencing
analysis was used to map hydroxymethylation throughout the hippocampus of late stage
AD subjects. Finally, to determine gene-specific levels of cytosine, 5-mC, and 5-hmC, a
quantitative polymerase chain reaction (qPCR) protocol was paired with specific restriction

enzyme digestion to analyze target sequences within exons of genes related to sporadic
AD. Results from these studies show epigenetic modifications to cytosine are altered on
the global, genome-wide, and gene-specific levels in AD subjects compared to normal
aging, particularly in early stages of AD progression, suggesting alterations to the
epigenetic landscape may play a role in the dysregulation of transcription and the
pathogenesis of AD.

KEYWORDS: cytosine, 5-hydroxymethylcytosine, 5-methylcytosine, Alzheimer’s
disease, epigenetic modifications
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CHAPTER 1: INTRODUCTION AND BACKGROUND
1.1 Alzheimer’s disease
1.1.1 History of Alzheimer’s disease
Dr. Alois Alzheimer, a psychiatrist and neuropathologist in Germany in the early
1900s, was the first to describe plaque and tangle pathology in post-mortem brain tissue
of his former patient, Mrs. Auguste Deter, who exhibited memory loss, deficits in
cognition, and psychoses at the age of 51 [1, 2]. While dementia, referred to as senile
dementia at the time, was a common ailment in the early 1900s for elderly patients near
70 years old, the young age of symptom onset and the severity of memory loss in Mrs.
Deter’s case was unprecedented. However, little research effort was put forth to
understand Dr. Alzheimer’s discovery for the next half century, and was generally
referred to as a rare form of senile dementia for the next 50 years. Research interest in
Alzheimer’s disease (AD) was reignited in the late 1960s, when two groups published
images of strange neuropathological lesions in AD brain tissue [3-5] and again in the
1970s, when an editorial was published that pointed out the potential public health crisis
Alzheimer’s disease would likely inflict [6]. However, it wasn’t until the late 1980s when
the identities of aggregated proteins comprising plaques and tangles were discovered that
the stage was set for current Alzheimer’s disease research [7-12].
Today, Alzheimer’s disease ranks as the sixth leading cause of death in the United
States, accounts for 60-80% of all dementia cases, and is the only disease on the list of
the top ten causes of death with no therapeutic option to slow or halt progression [13].
Over 5 million patients currently suffer from Alzheimer’s dementia in the US, and that
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number is projected to grow to more than 13 million by 2050. The anticipated annual cost
for caring for AD and dementia patients in 2017 is more than $250 billion [13], and in the
wake of the baby-boom generation approaching the age of onset of AD, the future impact
on the healthcare system in the US alone will be astronomical with no therapeutic option
to slow or halt degeneration.
1.1.2 Familial and Sporadic AD
The majority of information and breakthroughs in understanding the pathogenesis
of AD has largely come from studies of mutations in genes inherited in family groups.
These deterministic genes are involved in the production of one of the key pathologic
features of AD, senile plaques. Mutations in presenilin-1 (PS1) [14, 15], presenilin-2
(PS2) [16, 17], and the amyloid precursor protein (APP) [9, 18] increase plaque
formation and are thought to lead to the inherited form of AD, known as familial AD
[19]. In Down’s syndrome, a trisomy disease where an extra copy of chromosome 21
leads to neurological dysfunction, similar neuropathologic lesions occur as in AD. It is
believed that the extra copy of chromosome 21, where APP is encoded, causes plaque
formation to be evident in brain regions as early as teen years, with eventual AD
diagnosis in Down’s syndrome patients in their fifties [20-23]. The manipulation of genes
involved in plaque formation, both by mutations and increased copy number of APP, are
likely causal to the early-onset form of AD, however more research into the how these
mechanisms lead to neurodegeneration is needed.
While familial AD occurs before age 65 and is responsible for less than 5% of all
AD cases [13], the remaining 95% of diagnoses are idiopathic, often termed late onset
AD (LOAD) or sporadic AD. The sporadic form of AD lacks causal gene mutations and
2

yet shows the same clinical symptoms and neuropathological features, with the exception
of symptom onset occurring after age 65 [24]. However, despite the discovery of gene
mutations indicating eventual development of familial AD, current pharmaceutical
options only produce symptom relief and have no measureable effect on disease
progression in the familial or sporadic form.
1.1.3 Clinical symptoms
While Alzheimer’s disease is the most common form of dementia, some of the
clinical symptoms overlap with other types of neurodegeneration. Symptoms of possible
AD can be detected in clinical examinations of cognitive performance and memory
evaluations, although definitive diagnosis of AD is only confirmed at autopsy upon
analysis of neuropathological features in post-mortem brain tissue. Typically, the first
clinical indication of AD is a memory complaint by a family member, specifically related
to the development of new memories [25]. Early symptoms of AD include difficulty
remembering recent interactions, i.e. conversations, events, and names, as well as
behavioral changes such as depression and apathy [13]. While some symptoms can be
explained by age-related changes in memory, most early AD symptoms cause disruptions
and difficulties in activities of daily living. These include difficulty following a
conversation or problem solving, the inability to retrace ones steps, confusion in normally
familiar locations, as well as struggling with vocabulary and remembering the correct
term for an object [13].
As the patient ages and the disease progresses, symptoms include increasing
memory loss, progressive deficits in cognitive performance, and neurobehavioral
changes, for example alterations to sleep patterns, enhanced agitation, and delusions [13].
3

Upon clinical diagnosis of either mild cognitive impairment (MCI) or dementia, the
average duration of disease is 4-8 years, with much of this time spent in the final stage of
progression where cognitive decline and advanced memory loss result in constant care
[13]. While AD is the underlying cause of death, the primary cause is typically
pneumonia which is prevalent in bed-ridden patients where immobility and malnutrition
cause rapid decline.
1.1.4 Disease Progression
The extent of AD pathology is generally determined histochemically, where
tangles and plaques are stained and counted in AD-pathology susceptible brain regions.
Senile plaques fall into two categories, diffuse plaques and neuritic plaques. While
diffuse plaques are common in the brains of elderly individuals with no indication of
cognitive impairment, neuritic plaques containing dystrophic neurites are associated with
cognitive decline [26, 27]. For tangle burden counts, pathologic progression is
determined by guidelines described by Braak et al., where severity is depicted based on
the Braak staging scale of 0-VI, with 0 being little to no tangles near the hippocampus
and VI being heavy tangle counts present in all susceptible brain regions [28]. A diagram
demonstrating the progression of pathologic lesions throughout the brain is shown in
Figure 1.1, where increasing color density depicts pathologic burden severity at each
stage of progression.
One of the earliest brain regions affected by AD pathology is the hippocampus,
the center for memory formation, and as such, is thought to be the reason why a memory
complaint is the first clinical indication of AD. As pathology progresses from the
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Figure 1.1 Braak Staging Scores. As a measure of pathologic burden in AD, Braak et
al. [28] developed a scale to rate neurofibrillary tangle burden progression in AD.
Tangles begin to form in the transentorhinal cortex (I-II), spreading to limbic regions (IIIIV), with eventually development of NFTs throughout the neocortex (V-VI). Increasing
color density denotes severity of NFT burden.
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entorhinal cortex (Braak Stage I-II) to limbic regions (Braak Stage III-IV), decreasing
cognitive performance is likely evident in clinical medical exams, eventually leading to a
clinical diagnosis of probable AD. As the severity of the pathologic burden increases and
spreads to isocortical regions (Braak Stage V-VI), this stage of progression likely leads to
memory loss and cognitive decline (Figure 1.1). While increasing Braak Stage scores are
correlated with decreasing performance on memory and cognition exams [27-30], it
should be noted that pathologic burden and cognitive performance do not always
correlate, but can be variable for individual subjects. Some subjects with significant
pathologic burden at autopsy (Braak Stage IV-V) showed no indication of memory
impairment upon clinical examinations [31]. This is one of the reasons why confirmation
of AD occurs post-mortem, using clinical and neuropathological patient data.
The progression of AD is characterized into three stages: preclinical AD (PCAD),
mild cognitive impairment due to AD (MCI), and dementia due to AD (NIA guidelines
2012). Upon post-mortem analysis, PCAD subjects exhibit heavy pathologic burden yet
show no clinical indication of memory loss or cognitive impairment [31]. Some
researchers and clinicians have attributed this to increased “cognitive reserve” where
advanced education and life-long learning may build a tolerance to memory impairment
caused by increased pathologic burden in susceptible brain regions [30, 32, 33]. While
the preclinical stage often goes undetected as pathologic burden increases, likely 15-20
years before symptom onset [34], clinical diagnosis typically occurs later in the MCI
stage. In MCI, increased plaque and tangle burden coincide with neuronal injury and cell
loss, producing symptoms of memory loss and decreased cognitive performance, but not
to an extent that warrants a clinical diagnosis of dementia. MCI subjects begin to show
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memory loss symptoms, specifically the inability to form new memories, as well as
alterations in established sleep patterns and some behavioral changes [35, 36]. As cell
loss and neuronal injury spread throughout the brain, memory and cognition continue to
decline until the patient is diagnosed with dementia with probable AD to be confirmed at
autopsy.
1.1.5 Pathologic features
The two main pathologic markers of AD include neurofibrillary tangles (NFTs)
composed of hyperphosphorylated tau fibrils and senile plaques (SPs) comprised of
amyloid beta (Aβ) peptide. The accumulation of these neuropathologic lesions likely
occurs in brain regions decades before deficits in cognition, alterations in reasoning, and
memory loss present as clinical symptoms of dementia [34]. Formation of senile plaques
begins with the cleavage of Aβ from APP (amyloid precursor protein) by a family of
secretase enzymes (Figure 1.2). While APP is likely involved in central nervous system
(CNS) development, synaptic plasticity, and neuroprotection [37], the exact physiological
function is uncertain. The cleavage site of α-secretase lies within the Aβ domain of APP
and sequential cleavage by α-secretase and the γ-secretase complex produce non-amyloid
fragments, termed the nonamyloidogenic pathway. In contrast, initial cleavage by βsecretase followed by γ-secretase produces Aβ fragments between 38-43 amino acids in
length that are released extracellularly. In AD, β-secretase activity is increased, pushing
the amyloidogenic pathway and increasing cleavage of Aβ. Mutations in proteins that
comprise the γ-secretase complex, including PS1 and PS2, are prevalent in familial AD
and increase the production of longer Aβ fragments, mainly Aβ1-42. In familial and
sporadic AD, there is an increase in the production of Aβ1-42, which is prone to
7

Figure 1.2 Secretase cleavage of APP. A family of secretase enzymes cleave APP at
specific locations along extracellular and membrane bound regions. Sequential cleavage
of β-Secretase followed by γ-Secretase produces Aβ fragments of 38-43 amino acids in
length released extracellularly. AICD: APP intracellular domain.
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aggregation and thought to be a major player in plaque formation [38-40]. The most
common theory of how these pathological features cause neurodegeneration is termed the
amyloid hypothesis [41-43].
The amyloid hypothesis theorizes that Aβ fragments aggregate to form
protofibrils or oligomeric Aβ, shown to be toxic in cell culture models [41, 44].
Oligomeric Aβ then aligns into β-sheet fibrils and finally aggregates into plaques in
extracellular spaces between neurons (Figure 1.3a). Similar to senile plaque formation,
the aggregation of tau is theorized to be the beginning of tangle pathology. The tau
protein, typically between 350-440 amino acids in length, stabilizes microtubules within
neurons. However, in AD, tau becomes hyperphosphorylated and dissociates from
microtubules to form soluble aggregates or oligomers. These aggregates bind together to
form paired helical filaments that eventually produce intracellular NFTs [41, 45, 46]
(Figure 1.3b). This combination of intracellular and extracellular protein aggregation is
hypothesized to lead to cell death and neuron loss within affected brain regions. While
the amyloid hypothesis is the reigning theory in AD, some studies have suggested a
cholinergic pathway where initial dysfunction and loss of cholinergic neurons, prior to
amyloid deposition, contributes to cognitive decline and AD [47].
While the mechanism of action is still not fully understood that leads to plaque
and tangle pathology, downstream effects of these markers have been demonstrated in
cell culture and animal models as well as in post-mortem tissue of AD subjects [48].
Other pathologic features include brain atrophy [49], severe neuron loss [50], chronic
inflammatory response [51], increased levels of reactive oxygen species [52-55],
deregulation of calcium signaling [56, 57], as well as alterations in gene expression and
9

Figure 1.3 Plaque and tangle formation. The amyloid hypothesis suggests aggregation
of amyloid beta fragments (a) and hyperphosphorylated tau (b) lead to development of
characteristic pathologic lesions in susceptible brain regions of AD subjects. Adapted
from Graham et al.
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transcription mechanisms [58, 59]. The combination of dysfunction in numerous
biological mechanisms likely causes the rapid decline associated with late stage AD,
however, more research is essential to understanding how these mechanisms are
deregulated in AD progression.
1.1.6 AD and Gene Expression
Several studies show biological pathways relevant to sporadic AD have altered
transcription throughout progression of the disease [59-67]. In a genome-wide expression
study of AD and NC subjects with Braak staging scores between 0-VI, Bossers et al.
showed altered expression of genes essential to synaptic plasticity and activity,
transcriptional regulation, cell differentiation/ proliferation, and inflammation pathways
throughout the advancement of tangle pathology burden (increasing Braak staging scores)
in the medial frontal gyrus [58]. In a microarray study of hippocampal mRNA
(messenger ribonucleic acid) in sporadic AD subjects, Blalock et al. found genes
involved in cell growth, differentiation, and tumor suppression were activated, while
genes involved in protein transport, energy metabolism, and signaling were repressed
[59].
The heterogeneity of cell types within the brain, including neuronal and nonneuronal cells like glia and astrocytes, complicate gene expression data where alterations
in gene expression likely vary between cell types. However, some cell specific studies
have clarified this complication. A cell specific study of astrocytes showed altered
expression of immune response and mitochondrial genes in the cortex of AD subjects
[60], while neurons in multiple brain regions of AD subjects showed altered expression in
transport, metabolism, neurotransmitter secretion, and synaptic transmission in another
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study [62, 68]. It is clear that the deregulation of transcription plays a role throughout the
progression of AD, in multiple brain regions, and across cell types. The extent of this role
and the implications for the disease mechanism, however, remain unclear.
1.1.7 Risk factors
Advanced age remains the most significant risk factor for developing AD [69]. A
family history of AD increases the risk, as well as several genetic components, including
deterministic genes and risk genes. Deterministic genes lead to a small portion of AD
cases known as familial AD, where mutations in APP, PS1, and PS2 lead to eventual
development of the disease, while sporadic AD has no known genetic mutation
component to lead to plaque formation.
Several risk genes have been identified that increase the likelihood of developing
AD, but do not guarantee eventual diagnosis. One of these genes, a cholesterol
transporter protein, apolipoprotein E allele Ԑ4 (APOE-Ԑ4), is thought to contribute to 25%
of sporadic AD cases [13, 70]. Recently, several other genes were implicated through
meta-analysis of single nucleotide polymorphism (SNP) data of sporadic AD subjects.
SNPs are single nucleotide variations in DNA sequences common among a significant
portion of the population. The genes identified by the meta-analysis may play a role in
the progression of pathology in AD, where dysfunction in these genes increase the risk of
developing AD [71, 72]. Most of these risk genes fall into four biological pathways:
endocytosis, immune function, lipid processing, and clearance mechanisms [73].
However, the percent of the population with identified SNPs in risk genes accounts for on
average only 12% (excluding APOE-Ԑ4) of sporadic AD cases [73, 74], indicating that
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AD is more complicated than gene variations alone and more study into the biological
mechanism of AD is needed.
While age and some genetic factors increase the risk of developing sporadic AD,
several factors have been shown to be protective, including advanced education and
continued learning throughout one’s life, sometimes termed “cognitive reserve” [32, 33].
Healthy diet and exercise, as well as factors that are recommended for cardiovascular
health [75] may also reduce one’s risk of developing dementia. Some studies indicate a
benefit of resveratrol, a compound found in red grapes, as well as a Mediterranean diet,
where fish is the main source of protein, help to reduce the risk of developing AD [7678]. Like many idiopathic diseases, where the biological mechanisms of dysfunction are
elusive, preventative methods are typically associated with general well-being and
maintaining healthy habits.
1.1.8 Other neurodegenerative diseases
While AD is the most common type of dementia, several neurodegenerative
diseases lead to nerve cell damage and cell death. Some neurological disorders classically
affect motor neurons, including Parkinson’s disease (PD), Huntington’s disease, and
amyotrophic lateral sclerosis, while others may affect motor functions, speech and
language, memory and/or cognition, including progressive supranuclear palsy,
corticobasal degeneration, Creutzfeldt-Jakob disease, vascular dementia, dementia with
Lewy bodies (DLB), and frontotemporal lobar degeneration (FTLD) [13, 79-82].
Although each disease exhibits unique features in the clinical setting as well as upon
analysis of neuropathologic features, some share similarities with AD, including DLB
and FTLD. Although considered separate diseases, nearly half of AD cases show
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coexisting pathologic features across different dementias, usually DLB, and can be
diagnosed as mixed dementia in clinical settings and confirmed post-mortem [13].
Aggregation of the misfolded protein alpha-synuclein leads to pathologic lesions
termed Lewy bodies in the cortex of DLB subjects [83-85]. Although several clinical
symptoms are similar to AD, DLB patients initially show increased sleep disturbances,
motor function impairments, and visual hallucinations sometimes prior to memory
impairment [86, 87]. Lewy bodies also form in PD, although clinical symptom onset
differs in PD compared to DLB. Motor function impairment is usually the first clinical
symptom in PD, while decreased cognitive performance is typically associated with
DLB.
For FTLD subjects, memory impairment typically occurs later in disease
progression, where initial clinical symptoms include personality and behavior changes
accompanied by difficulties with language comprehension [13]. Degeneration of nerve
cells in the frontal and temporal lobes of the brain lead to atrophy, and similar to AD, tau
protein aggregates form in the cortex [88, 89]. Unlike AD, most FTLD patients display
clinical symptoms between age 45-60 and accounts for only 10% of dementia cases [13].
Although many neurological disorders, including DLB and FTLD, contribute to
the overall global pool of dementia patients, AD diagnoses far outweigh other forms of
neurodegeneration. Some pathologic features and clinical symptoms, as well deregulated
biological systems such as inflammation, oxidative damage, and transcription, overlap
between neurodegenerative diseases [13]. Recently, it was shown that several SNPs
overlap between dementia types and may share common genes in altered pathways
leading to degeneration [90]. Thus, research into the pathological mechanism of
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dysfunction in AD could lead to breakthroughs in other types of dementia as well, but
only time will tell.
1.1.9 AD therapeutic options
After the discovery of genetic mutations in APP, PS1, and PS2 in familial AD, the
development of cell culture and animal models to mimic AD progression has led to the
production of over 244 unique pharmaceutical compounds tested in more than 400
clinical trials to aid AD patients [91]. The majority of these pharmaceuticals aim to
improve cognitive performance or use small molecules to modify the disease (typically
targeting Aβ), while a minority of clinical trials use immunotherapies to modify the
disease [91]. Between the years of 2002-2012, the success rate of a drug advancing
through FDA (Federal Drug Administration) approval was 0.4% with memantine, an
NMDA receptor agonist regulating glutaminergic pathways, gaining approval in 2004
[91]. Currently, only five FDA approved therapeutics including memantine (the other
four are tacrine, donepezil, rivastigimine, and galantamine which target cholinergic
systems to provide symptom relief) are available for patients, while more than 100 drugs
are currently in Phase 0-4 trials [46].
The failure of so many clinical trials was suggested to be attributed to a lack of
mechanistic understanding of the progression of sporadic AD [92], an over reliance on
the gene mutation model attributed to familial AD rather than upstream gene mechanisms
that play a role in Aβ processing, over simplified animal and cell models that do not
account for the multifaceted nature of AD, as well as treatments that attempt to intervene
late in disease progression where ample synapse loss and cell death likely prevent
recovery [46, 91, 92]. Moving forward, a better understanding of the biological pathways
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involved early in disease progression, as well as mechanisms that deregulate genes within
these pathways, will be key to developing therapeutic options to combat AD. One such
mechanism of interest includes epigenetic modifications to cytosine, known to alter
transcription of genes involved in cancer pathways, but may also play a role in the
deregulation of genes in neurological disorders like AD.

1.2 Epigenetic Modifications
1.2.1 Categories of Epigenetic Modification
While the definition of epigenetic modifications has evolved since its inception in
1942 [93], it currently refers to potentially heritable changes in gene expression without
mutations to the DNA sequence [94]. Epigenetic modifications can be classified into
three categories: histone modifications, non-coding RNAs, and DNA methylation. These
epigenetic mechanisms play a role in gene expression and regulation, although how this
occurs and the extent to which each form of epigenetic regulation works cohesively
remains elusive [95, 96]. Each category of epigenetic regulation is discussed briefly
below.
The methylation and acetylation of histones regulates the compaction and release
of chromatin structures from DNA. Histone proteins associate together in groups of eight
to form chromatin structures, where DNA wraps around the histone complex to compact
the DNA with the nucleus. While the release of chromatin leads to an open conformation
allowing transcription of DNA to occur, the compaction of chromatin hides the DNA
structure, resulting in gene silencing [97]. Acetylation of histone tails is generally
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correlated with increased gene expression, while the regulation provided by the
methylation of histone tails is more complicated. The singular methylation of one
particular site at histone 3 lysine 27 (H3K27me1) correlates with actively transcribed
promoter regions [98], however, triple methylation of the same site (H3K27me3) leads to
repressed gene expression [99].
Regulatory non-coding RNAs (ncRNA), not related to translation, participate in
epigenetic mechanisms and are classified into two categories, long ncRNA and short
ncRNA. Long ncRNAs form complexes with proteins to modify chromatin states, trigger
histone methylation, and regulate transcription [100]. Short ncRNAs, including short
interfering RNAs (siRNAs) and micro RNAs (miRNAs), bind to messenger RNA
(mRNA) targets to either degrade mRNA or regulate protein translation [101]. While
siRNAs are used extensively in cell culture experiments to knockdown gene expression,
miRNAs were shown to regulate gene expression in tumor suppression and activation
pathways in cancer models [102-104].
The third category of epigenetic modification is methylation of the fifth position
of the ring structure of cytosine. A family of DNA methyltransferase (DNMT) enzymes
modify cytosine to 5-methylcytosine (5-mC) by the donation of a methyl group from Sadenosyl methionine (SAM) as it is converted to S-adenosyl homocysteine (SAH) within
the methionine cycle (Figure 1.4). While DNMT3a and DNMT3b generate new
methylation patterns in DNA, DNMT1 is responsible for maintaining the existing
methylation pattern throughout DNA replication [105]. Using dnmt1 knockout mice, Li et
al. showed loss of methylation caused reactivation of innately inactive genes, suggesting
DNA methylation works to silence genes in biological systems [106].
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Figure 1.4 Simplified methionine cycle. The loss of a methyl group results in
conversion of S-adenosyl methionine (SAM) to S-adenosyl homocysteine by several
methyltransferase enzymes. Initiating DNA methylation, transfer of the methyl group
from SAM to cytosine produces 5-methylcytosine. A methyl group is reintroduced into
the methionine cycle by removal of a methyl group from 5-methyltetrahydrofolate to
produce tetrahydrofolate by several enzymes from the folic acid cycle. Transfer of this
methyl group to homocysteine produced methionine to continue the cycle.
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While all three epigenetic mechanisms likely work cohesively to regulate gene
expression, the etiology of how this process occurs is unknown. This dissertation focuses
on cytosine modifications and the likely role this category of epigenetic modifications
play in neurodegeneration, specifically AD. Detail into the proposed mechanisms of
DNA methylation and the role cytosine modifications play in regulating transcription is
described below.
1.2.2 Methylation and Demethylation of Cytosine
5-mC was discovered in genomic DNA in 1950 [107, 108] and was studied
extensively in mammalian, bacterial, and plant DNA [109-111]. The removal of the 5mC mark was suggested to occur through passive demethylation mechanisms, where
DNA replication would eventually dilute 5-mC to unmodified cytosine. While the first
indication of an oxidized derivative of 5-mC in mammals was introduced in 1972 [112],
it wasn’t until the rediscovery of oxidized 5-mC compounds in 2009 that an active
demethylation mechanism was suggested [113-115].
The enzymatic oxidation of 5-mC by the ten-eleven translocase (TET) family of
enzymes leads to several derivatives: 5-hydroxymethylcytosine (5-hmC), 5formylcytosine (5-fC), and 5-carboxylcytosine (5-caC). These TET enzymes (TET1,
TET2, and TET3) are activated by alpha keto-glutarate (αKG) and iron (II) cofactors and
participate in an active cytosine demethylation pathway (Figure 1.5). Recently, it was
shown that 5-mC is oxidized by TET1 to produce 5-hmC, while TET2 and TET3
convert5-hmC to 5-fC and 5-fC to 5-caC in a cancer cell model [116]. However, other
studies have shown that all three TET enzymes can oxidize 5-mC to 5-hmC [114, 117],
thus the exact mechanism of TET demethylation remains unclear.
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Figure 1.5 TET demethylation cycle. As a methyl group is transferred from the
methionine cycle to DNA, the methylation of cytosine by a family of DNA
methyltransferase (DNMT) enzymes produces 5-mC. Oxidation of 5-mC by a family of
ten-eleven translocase (TET) enzymes yields 5-hydroxymethylcytosine (5-hmC), 5formylcytosine (5-fC) and 5-carboxylcytosine (5-caC). Along with TET demethylation,
enzymes within base excision repair mechanisms, namely TDG (thyamine DNAglycosylase), can demethylate cytosine from 5-fC or 5-caC.
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Additionally, several other enzymes have been identified to play a possible role in
the demethylation of cytosine. 5-hmC can be deaminated by base-excision repair (BER)
enzymes to 5-hydroxymethyluracil, followed by thyamine DNA glycosylase (TDG) to
produce an abasic site, replaced by unmodified cytosine. TDG also plays a role in the
TET pathway, where 5-fC and 5-caC were shown to be susceptible to TDG abasic site
production, eventually producing unmodified cytosine (Figure 1.5) [118]. A less
supported theory involves an unknown decarboxylase enzyme to convert 5-caC to
cytosine directly, similar to the removal of a carboxyl group in the thymidine salvage
pathway via iso-orotate decarboxylase in fungi [119, 120]. While the exact mechanism is
unknown, the active demethylation of cytosine by oxidized derivatives of 5-mC likely
plays a role in the pliability of regulating transcription mechanisms within cells [121,
122].
1.2.3 Detection methods of 5-mC
Current detection methods for 5-mC modifications can be separated into two
groups, global and sequencing studies. While global studies typically utilize
immunohistochemical/immunofluorescent techniques to label analytes in mammalian
tissue, some studies have used chromatography and mass spectrometry to quantify levels
of the epigenetic mark. For sequencing studies, the gold standard technique for
quantifying 5-mC uses bisulfite conversion. Sodium sulfite converts unmodified cytosine
to uracil via sulphonation and deamination mechanisms, while 5-mC bases are not
converted and read as cytosine during sequencing. The treated and the control libraries
can then be compared to determine locations of cytosine methylation throughout the
genome [123, 124].
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Disadvantages of immunochemical techniques include the potential for nonspecific binding, variation in antigen retrieval techniques in tissue mounted slides,
disparity in processing and quantification of analyte signals, and the inherent semiquantitative nature of immunochemical studies. In addition, bisulfite sequencing does not
distinguish between 5-mC and 5-hmC, and is better described as a detection method for
modified cytosine rather than solely cytosine methylation [125]. To decipher the exact
role 5-mC plays in regulating gene expression, improvements in detection techniques for
5-mC need to be expanded upon, both in global and sequencing studies.
1.2.4 Cytosine modifications and gene regulation
Generally thought of as a mark of gene repression and silencing, 5-mC is
associated with a compacted confirmation of chromatin and the methylation of histone
protein tails. Several theories as to how this cytosine modification regulates transcription
include interference in transcription factor binding, aiding mechanisms of chromatin
remodeling, and playing a role in gene splicing pathways [126]. Specific genomic regions
with cytosine modifications were also associated with gene expression regulation.
Several of these studies are described below.
Several studies showed variations in methylation of CpG (cytosine–phosphate–
guanine) sequences within the major and minor grooves of DNA altered chromatin and
histone positioning. Structurally, 5-mC modifications were suggested to increase rigidity
of the DNA backbone, to increase base pair stacking, and to alter water-mediated
hydrogen bonding interactions within the major groove [127-130]. Collings et al. showed
methylation of CpGs within the minor groove stabilized the nucleosome [131], while
unmodified minor groove CpGs were not associated with histone binding sites [131,
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132]. Methylation of CpGs in the major groove near the histone complex, however, were
associated with an open chromatin structure [133] and projection of the 5-mC group from
the major groove likely promoted interactions with methyl binding proteins [134]. The
role 5-mC plays in remodeling chromatin structures will become clearer as this field of
research develops.
Transcription factor (TF) binding appears to be regulated by cytosine
modifications depending on the location of 5-mC and the TF binding site. Fujimoto et al.
showed 5-mC modifications adjacent to the core binding motif of activator protein-1
blocked the TF complex from binding in a cancer cell line [135], while Zhu et al. showed
similar results in methylated regions near the specificity protein 1/ specificity protein 3
binding region in lung cancer cells [136]. However, in more than 150 DNA/TF binding
sites, 5-mC either enhanced the interaction or prevented binding of TFs to DNA target
sites in human embryonic H1 cells [137]. While DNA methylation clearly plays a role in
TF binding, it may depend on individual genes rather than a “one size fits all” model, but
more research is needed to address the relationship between 5-mC modifications and
TF/DNA interactions.
While the field of splice variant research has made strides in the last 40 years,
many questions remain unanswered. One new area of interest is the role cytosine
modifications play in DNA splicing and gene expression. Enrichment of 5-mC within
gene bodies was associated with gene splicing [138], particularly enrichment of 5-mC
near known splice sites [139, 140]. Wan et al. showed differentially methylated cytosine
modifications preferred protein-coding genes with splice variants in mouse brain and eye
DNA [141]. In studies of 5-mC modifications and protein-DNA interactions as they
23

relate to splice variant production, an increase in 5-mC blocked CTCF binding, increased
the activity of RNA Polymerase II to ultimately cause exon exclusion in various cell lines
[142]. In contrast, increased levels of 5-mC in several cell lines increased MeCP2
(methyl CpG binding protein-2) binding, recruitment of histone acetylation enzymes,
decreased RNA Polymerase II binding, thereby increasing exon inclusion [143]. While
more research is needed to understand the role epigenetic modifications to cytosine play
in DNA splicing mechanisms, these initial studies, while contradictory, suggest a major
role.
Placement of 5-mC in specific genomic regions seems to regulate gene expression
as well. Enrichment of 5-mC upstream of transcription start sites within coding genes led
to gene repression [134, 144]. In a genome-wide study of 5-mC levels in human blood
cells, highly methylated genes showed very low expression levels while highly expressed
genes showed low methylation levels, confirming previous studies correlating 5-mC with
gene silencing [145]. However, in the same study, gene body methylation was a better
indicator of expression rather than promoter levels, even in the extreme highly
methylated/rarely methylated distributions [145]. With the advancement of sequencing
technologies in mapping 5-mC across the genome at single-base resolution, the role 5mC locations play in regulating transcription will become clear, particularly within gene
bodies.
It should also be noted that the majority of sequencing studies analyzing
methylation levels and correlating gene expression mechanisms used bisulfite sequencing
to map 5-mC throughout the genome. As stated previously, this technique is unable to
distinguish 5-mC from 5-hmC. This is an issue due to the seemingly opposing roles 5-mC
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and 5-hmC play in regulating transcription. Where increased levels of 5-hmC within the
gene body of highly expressed genes correlated with open chromatin confirmations and
histone acetylation, minimal levels of 5-hmC were found in genes with low transcription
levels [96]. However, the hydroxymethylation of promoter regions was shown to
correlate with increased expression as well as decreased expression in cell culture models
[144, 146, 147]. 5-hmC marks were also more related to exon-intron boundaries in recent
studies [146-148], possibly playing a role in splicing events.
While the exact mechanism of deregulating transcription by cytosine
modifications is not well understood, it is clear that 5-mC and 5-hmC likely play a role in
altering gene expression. While many of the previously mentioned studies have begun to
unravel how gene expression is regulated by epigenetic modifications, going forward, it
is essential to utilize techniques capable of distinguishing between various cytosine
derivatives to elucidate the mechanism of interaction of 5-mC and 5-hmC and gene
expression. Given that gene expression alterations are a common pathologic feature of
each stage of AD progression, examination of the role epigenetic modifications to
cytosine may play in deregulating transcription in neurodegenerative diseases is worth
exploring.

1.3 Epigenetics and Neurodegeneration
1.3.1 Cytosine modifications and neurological disorders
Epigenetic modifications were studied extensively in cancer research and in
embryonic development, but only recently in neurodegeneration. While cytosine
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methylation levels are relatively stable across most tissues, levels of 5-hmC were 10 fold
higher in brain than in other mammalian organs [149-151]. Where 5-hmC accounts for
less than 10% of total DNA in heart and breast cells [121, 122, 152], in the brain, some
report 40% of total 5-mC was actually hydroxymethylated [149, 153]. Increased levels of
5-hmC were shown in neurons, as well as non-neuronal cells like microglia and
astrocytes, compared to other cell types, including muscle and adipose cells [122, 149,
153]. Since neurons do not replicate, it is plausible that mechanisms that regulate
transcription and methods to adapt to the microenvironment are enhanced in the brain.
Alterations in genes that regulate epigenetic mechanisms contribute to mental
retardation in neurological disorders such as X-linked and Rett syndromes [97, 154, 155].
Furthermore, genes that play a role in neuropsychological disorders including
schizophrenia and depression [156] and deregulate neuronal activity in learning and
memory [154, 157, 158] also regulate epigenetic mechanisms. Several of these genes
play key roles in the epigenetic modification machinery, including an αKG regulator
isocitrate dehydrogenase (IDH), the DNMT family of cytosine methylation enzymes, the
TET family of 5-mC oxidation enzymes, and MeCP2 which contributes to gene silencing
by binding to 5-mC modifications [96, 97].
In addition to specific genes that regulate epigenetic mechanisms in neurological
disorders and processes, metabolites that feed relevant biological pathways in
neurodegeneration are also linked to epigenetic regulation. In mouse models, as well as in
post-mortem brain tissue of AD subjects, levels of homocysteine, a key metabolite
compound in the methionine cycle (refer to Figure 1.4) were elevated [159, 160]. Along
with homocysteine, levels of SAM and SAH were deregulated in sporadic AD patients
26

[161-163] as well as in numerous cell culture and animal models of AD [164]. Due to the
involvement of the methionine cycle in the methylation of cytosine, ultimately affecting
the levels of oxidized derivatives of 5-mC (e.g. 5-hmC, 5-fC, and 5-caC), it is probable
that epigenetic modifications to cytosine are altered in AD.
1.3.2 Aging and Epigenetic Drift
For most idiopathic neurodegenerative diseases, age is a common risk factor
[165]. Several studies confirmed that age corresponds to altered levels of epigenetic
modifications and likely plays a role in natural aging mechanisms [166, 167]. Termed
“epigenetic drift”, several studies suggest that as one ages naturally, the distribution of
epigenetic modifications shifts to regulate transcription of biological pathways relevant to
aging and healthy cellular maintenance [166, 167]. Because advanced age is the most
important risk factor for developing AD, it has been suggested that alterations in levels of
epigenetic marks merely reflect the advanced age of AD patients rather than playing a
direct role in the disease, however more research is needed to determine if alterations in
epigenetic marks are relevant to AD or are merely a consequence of aging.
1.3.3 TET dependent oxidation of 5-mC
Since oxidative damage is a key feature of AD, it was suggested that oxidation of
5-mC may be a consequence of these pathways. Whether or not oxidation of cytosine
occurs enzymatically or is a result of external oxidative sources, e.g. increased reactive
oxygen species, is of interest, particularly in neurodegenerative disorders where reactive
oxygen species are elevated. In cell culture models, compounds known to increase ROS
activity, including ascorbate [168], hydroquinones [169, 170], benzoquinones [170], and
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5-fluorouracil [171], also increased global levels of 5-hmC, but only in the presence of
active TET enzymes. In an in vitro study, oxidized derivatives of 5-mC were increased
with extreme radiation levels without TET enzymes [172]. However, these conditions do
not reflect or mimic a biological system suggesting it is unlikely that oxidation of 5-mC
occurs without TET in physiological conditions. Thus, while oxidative damage
mechanisms may increase the activity of TET, the formation of oxidized derivatives of 5mC is the result of enzymatic oxidation mechanisms.
1.3.4 Global 5-mC and 5-hmC studies in AD
Recent interest in quantifying global levels of 5-mC and 5-hmC modification in
post-mortem AD brain tissues was sparked in the early 2010s, with preliminary findings
suggesting alterations in 5-mC in sporadic AD brain tissue [173-175]. However, after
multiple contradicting studies from different research groups, the results were
inconclusive and conflicting. While some studies reported increased levels of 5-mC
and/or 5-hmC in brain regions susceptible to plaque and tangle pathology, others reported
a global decrease in 5-mC and/or 5-hmC, while one study showed no difference between
AD and NC subjects. These studies are briefly discussed below.
Increased methylation and hydroxymethylation were reported in the hippocampus
of PCAD and LOAD subjects compared to NC using immunohistochemical techniques
by Bradley-Whitman et al. [176], as well as in the middle temporal gyrus and middle
frontal gyrus of early onset and late onset AD subjects using immunofluorescent
antibodies by Coppieters et al. [177]. Coppieters et al. found low levels of 5-mC and 5hmC in astrocytes and microglial cells, but enrichment in both markers in neurons. In
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addition to these, Bakulski et al. reported increased 5-mC in the frontal cortex of LOAD
subjects compared to NC using a bisulfite conversion technique [175].
In contrast, several studies report decreased levels of epigenetic marks in AD
brain. In glial cells and neurons of the hippocampus of LOAD subjects, Chouliares et al.
found decreased levels of 5-mC and 5-hmC using fluorescently labeled antibodies [173].
Using fluorescently labeled antibodies to tag 5-mC and 5-hmC in the entorhinal cortex
(EC) and the cerebellum (CER) of LOAD subjects, two studies reported various results.
Condliffe et al. found decreased levels of 5-hmC in the EC and CER of LOAD subjects
with no change in 5-mC in either region [178], while Mastroeni et al. found decreased
levels of 5-mC in the EC with no change in the CER [174]. Contrary to all of these
studies, Lashley et al. found no significant difference of 5-mC and 5-hmC levels in CER
or EC of LOAD compared to NC subjects using an ELISA [179].
The majority of these studies used antibody techniques to label 5-mC or 5-hmC in
fixed tissue or use an ELISA platform to semi-quantify epigenetic marks. Differences in
tissue processing procedures, including antigen retrieval techniques, analysis of
fluorescence or staining procedures, as well as non-specific binding of antibodies must be
considered as a possible source for the conflicting results. Apart from antibody
techniques, these studies also cover multiple brain regions including the prefrontal cortex,
cerebellum, entorhinal cortex, hippocampus, and temporal lobe. Levels of 5-mC and 5hmC vary across brain regions [180, 181], therefore caution should be taken when
extrapolating trends to AD of semi-quantitative results from one brain region. It is clear
that a specific and quantitative technique to analyze global levels of 5-mC and 5-hmC in
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multiple brain regions of AD subjects is needed to shed light on the role epigenetic
modifications likely play in the various stages of AD progression.
1.3.5 Genome-wide methylation studies in AD
While some studies analyzed global levels of epigenetic marks in AD, very few
sequencing studies have occurred. Two methylation studies in cortical regions of the AD
genome produced target genes that may be relevant to the mechanism of
neurodegeneration in sporadic AD [182, 183]. Many of these genes overlapped with
targets in a genome-wide associate study of SNPs related to AD [71]. In a methylation
sequencing study of three regions of the cortex (entorhinal cortex, superior temporal
gyrus, and prefrontal corex), Lunnon et al. found two differentially methylated regions in
ankryin 1, a cytoskeleton regulation protein, associated with Braak staging scores in three
independent cohorts of AD subjects using bisulfite sequencing techniques [182]. In a
similar study of prefrontal cortex methylation, De Jager et al. found seven genes
associated with NP burden, AD diagnosis, as well as altered mRNA expression in two
independent cohorts of subjects using bisulfite conversion of 5-mC. The seven genes
(ankryin 1, cadherin related 23, disco interacting protein 2 homolog A, rhomboid family
member 2, ribosomal protein L13, serpin family F member 1, and serpin family F
member 2) identified by De Jager et al. are suggested to be involved in signaling,
amyloid processing, and trafficking pathways in AD [183].
While both studies highlight specific gene targets that were epigenetically
regulated in cortical regions of AD compared to NC subjects, defining these results as
“methylation” is erroneous due to the lack of specificity in bisulfite conversion and is
better described as cytosine modifications. Additionally, each study used the Illumina
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450k sequencing platform, limiting the analyses to a fraction of the genome (485,577
CpG sites) and may be overlooking differentially modified regions relevant to AD.
Despite the limitations, these studies do highlight the probable role epigenetic
modifications play in AD progression. Moving forward, due to the seemingly opposing
roles epigenetic modifications play in regulating gene expression, techniques capable of
distinguishing methylation from hydroxymethylation are essential to defining biological
pathways and target genes epigenetically regulated in sporadic AD.
1.4 Dissertation Overview/ Hypothesis Statements
To better understand the role cytosine modifications likely play in the
deregulation of transcription in sporadic AD, the aim of this dissertation was to analyze
levels of epigenetic marks in DNA of post-mortem sporadic AD tissues (i) globally, (ii)
across the genome, and (iii) at loci-specific levels in target genes relevant to AD.
Technical descriptions of each analytical method for global, genome-wide, and gene
specific studies are detailed in the following chapter. Specific aims of each study and
detailed descriptions of brain regions analyzed and patient groups included in the
analyses are discussed in the following chapter as well.
For global analysis of epigenetic modifications, levels of cytosine, 5-mC, and 5hmC were quantified in DNA extracted from multiple brain regions susceptible to AD
pathologic features in different stages of AD progression. While alterations in global
levels would not give gene specific information, this study would determine brain regions
with altered epigenomes in stages of AD progression for future intensive gene specific
studies. To determine the role hydroxymethylation of cytosine plays in AD, 5-hmC
modifications were sequenced across the genome of hippocampal DNA in LOAD
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subjects compared to NC. Unlike previous AD methylation studies using bisulfite
conversion, a new sequencing technique specific to 5-hmC sites will determine genes
with differentially hydroxymethylated regions to identify biological pathways
epigenetically modified in AD. Finally, to analyze loci-specific levels of cytosine, 5-mC,
and 5-hmC at different stages of AD progression, DNA was extracted from SMTG
specimens of AD and NC subjects. Sites of potential epigenetic modifications in two
genes relevant to sporadic AD were analyzed to determine how site-specific changes in
epigenetic marks may correlate to alterations in protein levels.
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CHAPTER 2: PROJECTS
2.1 Overview of Projects
Rampant deregulation of key genes involved in biological pathways related to
sporadic AD is a common symptom throughout all stages of disease progression [58, 59].
While the exact function of each epigenetic modification to cytosine in regulating normal
transcription mechanisms is not well understood, 5-mC and 5-hmC play a role in altering
gene expression in healthy cellular function as well as in disease [144]. Global
distributions and correlations to gene expression of 5-mC and 5-hmC marks were studied
extensively in cancer and embryonic development, and as technological advancements
and technique specificity increase, the role these epigenetic marks play will become clear.
Levels of 5-hmC were enriched in the CNS compared to other tissues [149, 151],
sparking interest in the possibility of linking epigenetic modifications to the deregulation
of genes in neurological disorders. Since neuronal cells do not replicate, a mechanism to
adapt to a changing microenvironment by internally regulating transcription processes
seems likely, particularly in diseases like AD where pathologic features occur in the
intracellular and extracellular spaces of neurons. Preliminary studies of semi-quantitative
levels of 5-mC and 5-hmC in AD brain regions and bisulfite sequencing studies of the
AD genome have produced conflicting results, leading to the need of a specific and
quantitative method to decipher the role cytosine modifications likely play in AD.
To better understand the role epigenetic modifications to cytosine play in sporadic
AD, levels of cytosine modifications were analyzed globally (Project I), across the
genome (Project II), and at loci-specific levels in specific target genes relevant to AD
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(Project III). While global levels would highlight brain regions with an altered epigenetic
landscape, genome-wide alterations and loci-specific levels would give gene targets and
biological pathways deregulated by epigenetic mechanisms in sporadic AD, potentially
leading to possible therapeutic options. An introduction and technical overview of each
project is discussed in detail below.

2.2 Project I: Quantification of global levels of cytosine, 5-mC, and 5-hmC in multiple
brain regions at different stages of AD progression and other types of neurodegeneration
Several immunochemical studies of AD brain tissue reported levels of 5-mC and
5-hmC, however results were conflicting. Studies reported elevated levels [175-177],
decreased levels [173, 174, 178], or no significant difference in either mark in AD [179].
One reason may be the non-specificity of the techniques applied, mainly the use of
antibodies to tag 5-mC or 5-hmC for immunohistochemical or immunofluorescent
studies. These techniques, which are inherently semi-quantitative, are dependent on
antigen retrieval processes and results can vary depending on signal quantification
analysis and processing procedures. A second reason could be the differences in brain
regions analyzed in the various studies, where alteration of cytosine modification levels
may be brain region dependent, possibly related to region susceptible to AD pathology.
To clarify the possible role global levels of 5-mC and 5-hmC play in AD, it was
the goal of this study to determine levels of each cytosine modification using a specific
and quantitative technique, gas chromatography mass spectrometry (GC/MS), in multiple
brain regions of various stages of sporadic AD progression. To determine if global levels

34

of 5-mC and 5-hmC were representative of disease stage or merely reflected age related
epigenetic alterations, tissue specimens from age-matched normal control subjects were
obtained and analyzed in parallel with subjects of AD progression. To determine if
alterations in global levels of cytosine modifications were specific to AD or common to
neurodegenerative diseases, tissue specimens from two other forms of dementia, Frontal
temporal lobar degeneration (FTLD) and Dementia with Lewy Bodies (DLB), were
obtained and analyzed with AD and NC tissue.
2.2.1 Gas Chromatography Mass Spectrometry
GC/MS is a combination of a separation technique (gas chromatography) paired
with a mass detection system (mass spectrometry) to quantify organic compounds in a
complex mixture (Figure 2.1). In the analysis, a small volume of a liquid sample is
injected through a heated septum, vaporized, and carried into a column by an inert carrier
gas, typically high purity helium (99.999%). Chromatographic separation of analytes in a
solution is achieved by chemical interactions of the compounds with the stationary phase
of a capillary column and temperature gradients designed to separate compounds by
boiling point. The stationary phase of the column, comprised of a ratio of solid packed
5% phenyl and 95% dimethylpolysiloxane, provides a surface for non-covalent chemical
interactions with analytes. Throughout the column, analytes are in equilibrium with the
stationary phase of the column and the mobile phase (helium carrier gas) depending on
chemical composition and similarity to the chemical properties of the stationary phase.
Increased interactions with the stationary phase causes analytes to remain in the column,
producing longer retention times and separation of the analytes in the mixture.
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Figure 2.1 GC/MS Instrument Schematic. Samples are carried into the column by a
carrier gas (ultra-high purity (UHP) helium) and are separated based on chemical
interactions with the stationary phase and eluted into the mass spectrometer. Electron
ionization of the analytes allowes for mass selection by a quadrupole mass analyzer and
detection using an electron multiplier.
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Since analyte boiling point is a key component of separation, volatilization is
essential to gas chromatography. Polar compounds can be chemically altered to increase
nonpolar properties, allowing gas separation within the column. This technique, termed
derivatization, replaces labile hydrogen atoms of the analyte with a nonpolar group, e.g.
trimethylsilyl (–Si(CH3)3), to increase compound volatility and thermal stability [184]
(Figure 2.2). This technique was particularly helpful in analyzing individual bases of
DNA, including DNA oxidation markers [185, 186].
Once separated by chemical composition in the column, analytes enter the
ionization chamber of the mass spectrometer. Electrons are ejected from a metal filament
to produce an ion beam where interactions of an analyte electron cloud with the ion beam
results in electrostatic repulsion of an outer shell electron from the analyte to produce a
molecular ion. The highly excited molecular ion can then relax and fragment to produce
daughter ions. The most statistically probable fragmentation pattern will result in the
most abundant ion detected for the analysis. After ionization of analyte, mass selection is
performed using two sets of hyperbolic rods, termed a quadrupole, with adjustable radio
frequency (RF) and direct current (DC) voltages. By adjusting the RF/DC voltage
applied, designated ions with stable trajectories within the quadrupole pass through the
center of the rods, while ions outside of the desired m/z window are unstable and
annihilated on the surface of the quadrupole. An electron multiplier behind the
quadrupole mass analyzer detects stable ions, i.e. desired m/z ratios, and abundance and
signal intensities are recorded and displayed as lines in a mass spectrum. Detection of
separated compounds eluting from the column, measured chronologically, ultimately
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Figure 2.2 Derivatization of cytosine bases. To increase volatility of cytosine bases for
GC/MS analyses, labile hydrogens were replaced with trimethylsilyl groups using
BSTFA:TMCS derivatization protocol.
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results in a chromatogram of individual signal peaks at specific retention times (Figure
2.3).
Identification of analytes occurs by pairing the separation efficiency of gas
chromatography with the specificity in mass analysis of the mass spectrometer, while
quantification is achieved by comparing signal intensity to isotopically labeled standards
of known concentration and response (i.e. standard response curves). The advantage of
incorporating isotopically labeled standards includes identical chemical separation within
the GC column, but a slightly altered m/z ratio directly related to the change in mass of
the isotope. Thus, known concentrations of stable labeled standards can be characterized
and standard response curves produced to develop a quantitative method to analyze
specific compounds.
2.2.2 Summary of Project I
To quantify global levels of 5-mC and 5-hmC in AD, tissue specimens from four
brain regions (hippocampus/parahippocampal gyrus (HPG), superior and middle
temporal gyrus (SMTG), inferior parietal lobe (IPL), and cerebellum (CER)) (Figure 2.4)
were obtained from three stages of AD (preclinical AD (PCAD), mild cognitive
impairment due to AD (MCI), and dementia due to AD or late onset AD (LOAD)).
Because epigenetic modifications to cytosine are altered in aged brain, tissue specimens
from age-matched normal control (NC) subjects were obtained to determine whether
changes in global levels merely reflect aging epigenetic drift or are relevant to disease
progression. To determine if alterations in 5-mC and 5-hmC levels were AD specific,
tissue specimens from two other forms of dementia, FTLD and DLB, were obtained.
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Figure 2.3 Total Ion Chromatogram. Well separated chromatographic peaks of (a)
cytosine (~17 min), (b) 5-mC (~19 min), and (c) 5-hmC (~37 min) were analyzed using
single ion monitoring (SIM) mode in GC/MS analyses.
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Figure 2.4 Schematic of brain regions analyzed. Tissue specimens from subjects were
analyzed from four brain regions, including hippocampus/parahippocampal gyrus (HPG,
purple), superior and middle temporal gyrus (SMTG, green), inferior parietal lobe (IPL,
blue) and cerebellum (CER, orange).
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Using GC/MS and stable isotopically labeled commercially available standards for
cytosine, 5-mC, and 5-hmC (Figure 2.5), global levels of epigenetic marks were
quantified throughout the stages of AD across multiple brain regions susceptible to AD
pathologic features.

2.3 Project II: Single-base resolution mapping of 5-hmC in hippocampus of LOAD
subjects
While global levels of epigenetic modifications give insight into regions of the
brain affected by alterations in 5-mC and 5-hmC, bulk analysis provides no information
on specific genes with altered epigenetic marks and possible contribution to the
progression of AD. Thus, sequencing of epigenetic modifications throughout the AD
genome is an important area of interest to decipher gene specific roles in the deregulation
of transcription in sporadic AD. With the discovery that bisulfite conversion alone does
not distinguish between 5-mC and 5-hmC modifications [125], several sequencing
techniques were developed to analyze 5-hmC throughout the genome. Three of these
techniques include oxBS-Seq (oxidative bisulfite sequencing), TAB-Seq (TET-assisted
bisulfite sequencing), and RRHP (reduced representation hydroxymethyaltion profiling).
While oxBS-Seq and TAB-Seq use harsh chemical labeling to quantify levels of 5-hmC
modification [187], RRHP utilizes glucose protection of hydroxymethylation sites paired
with specific restriction enzyme digestion to analyze counts of 5-hmC throughout the
genome, and is suggested to be the most sensitive and reproducible single-base resolution
hydroxymethylation sequencing technique to date [188].
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Figure 2.5 Stable labeled cytosine bases. Commercially available stable labeled
cytosine, 5-mC, and 5-hmC were used for GC/MS analyses. Cytosine and 5-hmC were
labeled with 13C and 15N atoms, while 5-mC was labeled with deuterium (2H) atoms.
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To better understand the role 5-hmC modifications play in regulating transcription
in the hippocampus of LOAD subjects compared to NC, we sought to map 5-hmC across
the AD genome using Zymo Research Corporation’s in-house RRHP technique. From the
list of genes with altered hydroxymethylomes, we hypothesized that a list of biologically
relevant pathways related to sporadic AD would be produced to provide possible gene
targets for further study and possible development of therapeutic options in the future.
2.3.1 RRHP and the Illumina platform
The RRHP genome-wide mapping approach uses the specificity of restriction
enzyme digestion paired with the deep sequencing capability of the Illumina platform to
count sites of 5-hmC modifications at CCGG sequences throughout the genome [188].
Originally found in bacteria to provide a defensive mechanism against viral infection
[189, 190], restriction endonuclease enzymes recognize specific DNA sequences and
cleave at the sugar-phosphate bond of the DNA backbone. The methylation of cytosine
typically occurs at CpG sequences within mammalian genomes. MspI, a type II
restriction endonuclease, recognizes CCGG sequences within DNA and cleaves between
the cytosine bases, regardless of whether the internal cytosine is modified by a methyl
group or a hydroxymethyl group [188, 191]. In 2011, Davis et al found that glucosylation
of the hydroxyl group of 5-hmC in DNA by another enzyme (beta glucose transerfase,
T4-βGT) would prevent digestion by MspI, therefore creating a technique to study 5hmC within DNA genomes [192].
While most Illumina workflows use a random DNA fragmentation process
(Bentley 2008), the RRHP technique uses enzymatic fragmentation to allow for
sequencing of cytosine bases modified with hydroxymethyl groups [188]. Using an initial
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digestion of DNA by MspI, cleavage at the phosphate backbone bond of all CCGG
sequences regardless of 5-mC or 5-hmC (blue circles) modification occurs (Figure 2.6).
After MspI fragmentation, adapters (shown in red and orange) are added to both ends of
the DNA fragments, followed by glucosylation of 5-hmC by T4-βGT. Now protected by
the glucosyl group, the second round of MspI digestion is inhibited at glucose modified
5-hmC (green circles) sites. Nonhydroxymethylated sequences with adapters are cleaved
during the second round of MspI digestions and will not undergo amplification during
Illumina workflow and further downstream analysis.
As the most widely used next generation sequencing technique, the Illumina
platform for deep sequencing is responsible for large advancements in mapping the
human genome, specifically in the identification of risk SNPs of complex diseases [193].
DNA sequences are fragmented and ligated with specific adapters at each end of the
fragment sequence. Ligated fragments are then bound to an Illumina flow cell where
complimentary adapter sequences were previously attached (Figure 2.7a). Utilizing a
bridge amplification technique (Figure 2.7b), template strands are formed on the flow
cell. Several rounds of bridge amplification form clusters of complimentary sequences
(Figure 2.7c). Once tens of thousands of clusters form on the flow cell (Figure 2.7d),
fluorescently labeled nucleotides with reversible termination sites on the sugar of each
nucleotide are added. In order to achieve high throughout sequencing, nucleotides are
elongated one at a time and measured using fluorescent imaging. An example of the
chemical structure of a reversible terminator nucleotide is shown in Figure 2.8, provided
in the Illumina product information.
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Figure 2.6 RRHP DNA fragmentation. Target DNA undergoes restriction enzyme
digestion using MspI to cleave all CCGG sequences, regardless of whether the internal
cytosine is hydroxymethylated (blue) or not. Fragmented DNA is ligated using Illumina
adapter sequences at 5’ and 3’ ends of the fragments. To protect 5-hmC sites,
glucosylation of hydroxyl groups (green) by T4-βGT prevents loss of ligated adapter
sequences from DNA fragments during second MspI digestion.
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Figure 2.7 Illumina Platform Workflow. Adapter ligated DNA fragments bound to an
Illumina flow cell (a) undergo bridge amplification (b) to form new template strands (c).
Many cycles of amplification produce clusters (d) of replicated DNA fragments. Addition
of primers, Polymerase, and reversible terminator fluorescent nucleotides are added to the
flow cell to initiate primer elongation and addition of a single nucleotide to template
strands. Excitation of fluorophores (e) followed by imaging of the flow cell (f) results in
base-by-base sequencing of DNA.
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Figure 2.8 Fluorescent Nucleotide with Reversible Terminator. Illumina sequencing
at single-base resolution occurs via the addition of a reversible terminator (-OCH2N3) to
the sugar molecule of a fluorescently labeled nucleotide, shown here with cytosine.
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Nucleotides, along with universal primers and specific polymerase enzymes, are
added to the flow cell to induce primer elongation. Upon laser excitation (using lasers
with 532 nm, 660 nm, and 700-840 nm wavelengths), each nucleotide emits a different
wavelength (Figure 2.7e) and images of the fluorescence are captured at each addition of
a nucleotide (Figure 2.7f). Enzymatic cleavage of the flurophore and loss of the
termination site allows for primer elongation and the next nucleotide is excited and the
flow cell imaged. Repeated cycles of nucleotide “extension – termination – fluorescence
– cleavage – extension” result in base-by-base recognition and genome-wide sequencing
of the DNA sample.
2.3.2 Summary of Project II
To quantify genome-wide levels of 5-hmC in HPG DNA of LOAD subjects
compared to NC, isolated nuclear DNA was sent to Zymo Research Corporation (CA,
USA) for their in-house hydroxymethylation sequencing technique (RRHP). Data files
were downloaded from Zymo and analyzed using a freely available PERL script termed
diffReps, initially coded for genome-wide analysis of chromatin immunoprecipitation
sequencing (ChIP-seq) data [194]. To determine regions of differential
hydroxymethylation in the hippocampus of LOAD subjects compared to NC, a negative
binomial distribution analysis was applied to our RRHP data in diffReps to determine 200
base pair regions of altered 5-hmC in the LOAD genome. Genes with significantly
altered levels of 5-hmC in LOAD compared to NC subjects were sorted based on
expression data in a previously published microarray [59], and the overlapping gene list
was analyzed using the Reactome Functional Interaction Network tool in CytoScape®.
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This tool determines significant relationships between the target gene list and known
interactions of genes within biologically relevant pathways.

2.4 Project III: Quantification of loci-specific 5-mC and 5-hmC levels in exons of PS1
and ABCA7 in SMTG throughout stages of AD progression
While genome-wide sequencing technologies have advanced greatly in the past
several years, the financial cost of analyzing multiple biological replicates is high. Until
the cost of novel sequencing techniques decrease, alternative methods applicable to
multiple samples to analyze specific genomic regions rather than genome-wide analyses
were developed. One such method pairs the specificity of target recognition by restriction
endonuclease mechanisms with the quantification ability of quantitative polymerase
chain reaction (qPCR) instrumentation. While the breadth of analysis is far smaller
compared to genome-wide studies such as RRHP, the benefit of analyzing multiple
biological replicates in various stages of AD progression at moderate cost could shed
light on the role cytosine modifications play in regulating protein levels in target genes
relevant to sporadic AD.
To analyze specific target sequences within exon of genes relevant to sporadic
AD, a quantification kit from New England Biolabs was used in which manipulation of
two specific restriction endonucleases target particular genomic sequences to quantify
levels of cytosine, 5-mC, and 5-hmC. Synthetic primers were designed flanking target
sequences within exons of genes relevant to sporadic AD, including PS1 and ABCA7.
These genes were implicated to play a possible role in the pathogenesis of AD, as well as
showed altered expression in sporadic AD subjects as discussed below.
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While mutations in PS1 were linked to the familial form of AD, deregulation of
PS1 was shown in post-mortem sporadic AD tissues and wild type PS1 was implicated in
leading to increased amyloid production with age in a mouse model of amyloid
depositions [195, 196]. ABCA7 (ATP Binding Cassette Subfamily A Member 7) is likely
a cholesterol transport protein and has been implicated as a possible risk gene in sporadic
AD SNP studies [71]. Loss of function in ABCA7 activity was shown in the AD variant
form [197], as well as a target in several AD methylation studies [183, 198]. These
alterations in expression in sporadic AD may be related to changes to the epigenetic
landscape of gene bodies, namely exons, within PS1 and ABCA7. To determine if
epigenetic alterations may play a role in these changes to transcription, DNA from SMTG
tissue specimens in various stages of AD progression was used to map epigenetic
landscapes within the exons of these two genes, and correlated to expression by analyzing
protein levels in the same tissue specimens.
2.4.1 qPCR and Specific Restriction Enzyme Digestion
The polymerase chain reaction (PCR) utilizes the biochemistry of DNA
replication mechanisms to amplify specific regions of genes of interest in vitro. The three
stages of PCR are denaturation, annealing, and elongation (Figure 2.9). Synthetic primers
designed to be identical to target gene DNA sequences bind to single stranded DNA after
denaturation. Primers anneal to the single stranded DNA and polymerase elongates the
primers by incorporating nucleotides, eventually replicating the DNA sequences of the
designed amplicon. The amplicon concentration doubles with each round of PCR during
the amplification phase, then as reagent concentrations diminish, the reaction plateaus
and amplicon production ceases. Analysis of product amplicons at the plateau phase, or
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Figure 2.9 Polymerase Chain Reaction. Double stranded DNA is denatured to allow for
synthetic primers to bind to single strands, termed annealing. Polymerase elongates the
primers to form template strands, recreating double stranded DNA. Each denatureanneal-elongate cycle results in doubling the amount of DNA from the previous cycle,
thus amplifying the target DNA sequence.
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the endpoint, typically occurs by separating DNA fragments on an agarose gel by
electrophoresis, and fluorescent intercalating dyes and UV excitation are used for
amplicon detection.
The use of PCR to amplify DNA fragments was used for decades in microbiology
and biochemistry, although, as an endpoint technique, it is inherently qualitative. The
development of real time quantitative PCR (qPCR), where fluorescent measurements are
obtained during product amplification rather than at the plateau phase, provides an
extremely accurate and quantitative technique [199]. Using qPCR, amplification of
products is measured in real time during the exponential phase of amplification where
accurate measurements are used to extrapolate initial starting amounts of target DNA
(Figure 2.10). SYBR Green, an intercalating fluorescent dye, binds to the minor groove
of double stranded DNA and fluoresces [200-202]. During the amplification phase of the
PCR mechanism, as amplicons are produced, bound SYBR green molecules increase
fluorescent intensity as more product amplicons are formed (Figure 2.11). Once this
fluorescence passes a threshold, typically 10x the standard deviation of the background
signal during early cycles, the cycle threshold number (Ct) value directly correlates to the
starting amount of DNA and accurate quantification of the target can be analyzed using
standard response curves.
MspI restriction enzyme digestion was described previously (Projects 2.3.2),
however pairing MspI with a second enzyme, the type II restriction endonuclease HpaII,
allows for one to distinguish between 5-mC and 5-hmC at the same CCGG sequence.
While MspI will cleave 5-hmC and 5-mC modifications, HpaII will only cleave
unmodified cytosine in the same CCGG sequences. Protection of the 5-hmC group by
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Figure 2.10 Real time qPCR Amplification Plot. While endpoint PCR utilizes the
plateau phase of the amplification curve, real time qPCR measures fluorescence
continuously, allowing for accurate measurement of initial starting amounts over a large
concentration range of input DNA. At a critical threshold, shown as ΔRn = 0.183036,
where fluorescence measures 10x above background signal, cycle threshold (Ct) values
correlate to initial starting amounts of DNA, measured during exponential phase of
amplification.
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Figure 2.11 SYBR Green reaction. As an intercalating dye, SYBR green (circle) binds
to double stranded DNA and fluoresces (sun). As the polymerase reaction forms new
double stranded template strands, the fluorescent signal increases relative to the amount
of product DNA amplified.

55

glucosylation and treatment with MspI allows for quantification of 5-hmC, while
treatment of HpaII will allow for quantification of 5-mC and 5-hmC. Thus, the difference
between the two treatments will allow for calculation of 5-mC levels (Figure 2.12).
Optimizing the interaction of restriction endonuclease enzymes with DNA also allows the
quantification of epigenetic modifications to cytosine at the single base level at sites
within genes of interest, but only at a fraction of the cost of global sequencing studies.
2.4.2 Summary of Project III
To quantify levels of cytosine, 5-mC, and 5-hmC in CCGG sequences within
exons of ABCA7 and PS1, glucosylation of 5-hmC by T4-βGT was paired with specific
restriction endonuclease digestion by MspI and HpaII, analyzed by real time qPCR.
Primers designed around specific CCGG sequences within the exons of each gene were
optimized and tested for specificity using endpoint PCR for single amplicon verification
as well as qPCR melt curves to ensure single product amplification. Levels of cytosine
modifications within the temporal lobe (SMTG) were analyzed at several stages of AD
progression, including PCAD, MCI, and LOAD, compared to NC subjects. To correlate
epigenetic modifications with protein expression, levels of protein were analyzed using
Western blot analysis.
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Figure 2.12 EpiMark kit reactions diagram. Glucosylation of the hydroxyl group of 5hmC (ghmC) protects the site from MspI cleavage, whereas HpaII cleaves unmodified
cytosine within CCGG sequences. By comparing the amount of undigested DNA (5-hmC
and 5-mC+5-hmC) with the total amount of DNA where no enzyme was added, levels of
5-hmC, 5-mC, and cytosine can be determined at loci-specific levels within genes.
Unprotected digestion by MspI (no reaction) is used to control for enzyme cleavage
efficiency.
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CHAPTER 3: MATERIALS AND METHODS
3.1 Materials
3.1.1 Reagents
Proteinase K, BioUltra Phenol, cholorform, 3-methyl-1-butanol, formic acid,
anhydrous pyridine, agarose gel, ethidium bromide, goTaq PCR colorless kit, betamercaptoethanol, Novex protein standards, and Teflon seals were purchased from Sigma
Aldrich, while BSTFA:TMCS, 99:1 was purchased from a Sigma Aldrich supplier
company, Supelco Inc. GC/MS auto-sampler vials, microvolume inserts, vial caps were
purchased from Agilent Technologies.
Synthetic primer pairs were designed and purchased from IDT, while the EpiMark
5-mC and 5-hmC quantification kit, as well as CutSmart buffer, were purchased from
New England Biolabs. From Invitrogen Life Technologies, the Fast SYBR Green Master
Mix, qPCR 96 well plates, adhesive film, and ultrapure DNAase free water were
purchased.
Polyclonal rabbit PS1 antibody and mouse GAPDH antibody were purchased
from Santa Cruz Biotechnology, while polyclonal rabbit ABCA7 antibody was purchased
from LifeSpan Bioscience. Fluorescently labeled secondary antibodies (anti-rabbit and
anti-mouse) were purchased from Licor.
3.1.2 GC/MS Standards
Labeled and unlabeled commercially available standards of cytosine, 5-mC, and
5-hmC were used to analyze epigenetic marks using GC/MS. Unlabeled standards of
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cytosine and 5-mC were purchased from Sigma Aldrich (St. Louis, MO), while unlabeled
5-hmC was purchased from MP Biomedical (Santa Ana, CA). Isotopically labeled
standards were purchased from three different vendors: [2-13C, 1, 3-15N] cytosine from
Cambridge Isotope Laboratories (Tewksbury, MA), [2-13C, 1, 3-15N] 5-hmC from
Moravek Biochemicals Inc. (Brea, CA), and 5-methyl-d3-cytosine-6-d1 from CDN
Isotopes (Pointe-Claire, QC, Canada).

3.2 Methods for global quantification of cytosine, 5-mC, and 5-hmC
3.2.1 Subject Data
Tissue specimens of short (< 4 h) post mortem interval (PMI) autopsies of agematched NC subjects, as well as PCAD, MCI, LOAD, FTLD and DLB subjects, were
obtained through the University of Kentucky Alzheimer’s Disease Center (UK-ADC)
Neuropathology Core. All specimens were obtained in compliance with Institutional
review board approved protocols and in agreement with The Code of Ethics of the World
Medical Association (Declaration of Helsinki). All participants or their legally authorized
representatives provided written informed consent. For all longitudinally followed
subjects in the UK-ADC, biannual physical examinations and annual neuropsychological
testing were completed.
All subject diagnoses were based on UK-ADC postmortem consensus
conferences between social workers, neurologists, neuropathologists, and
neuropsychologists. NC subjects had normal range scores for mental status test battery
exams, including 14 neuropsychological tests, and showed no evidence of memory
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decline [31]. Normal control subjects also showed low Braak staging scores (0-II) and
only age-associated histopathological changes. PCAD subjects, as described by the UKADC, met intermediate to high National Institute of Aging-Reagan Institute (NIA-RI)
criteria [203] for advanced AD pathologic changes at autopsy, as well as frequent to
moderate neuritic plaque burden by the Consortium to Establish a Registry for
Alzheimer’s disease (CERAD) guidelines [204]. PCAD subjects had normal range
psychometric test scores when corrected for age and education [31], but had Braak
staging scores between III-VI. Additionally, MCI subjects had Braak staging scores
between II-V, increased NFT density in the entorhinal cortex, hippocampus, and
amygdala, as well as increased neuritic plaque density in neocortical regions compared to
NC subjects. MCI subjects do not meet criteria for clinical diagnosis of dementia, but
showed increased memory impairment upon clinical cognition and memory exams,
specifically objective memory test impairment (based on word learning task exams) [35,
36]. Unlike MCI, LOAD subjects showed decreased cognition and memory impairment
for clinical diagnosis of dementia and probable AD [203, 205], as well as advanced
neuropathology (Braak stage scores V and VI), meeting CERAD and NIA-RI guidelines
for intermediate to high likelihood of AD.
Elevation of AD-related pathologic markers including Braak NFT stage scoring
[45] and counts of neuritic and diffuse plaques, as well as NFTs, were determined by the
UK-ADC Neuropathology Core. Mini Mental State Examination (MMSE) scores [206]
were used to determine global cognitive status for all subjects, provided by the UK-ADC.
At autopsy, tissues from the hippocampus/parahippocampal gyrus (HPG), superior and
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middle temporal gryus (SMTG), inferior parietal lobe (IPL), and cerebellum (CER) were
flash frozen in liquid nitrogen and stored at -80°C until processed for analysis.
3.2.2 DNA isolation
Frozen tissue specimens were homogenized in 1 mL of digestion buffer (0.05 M
Tris-HCl, 0.1 M Na2EDTA, 0.5% sodium dodecyl sulfate) and 0.5 mg/mL proteinase K
solution using a mechanical homogenizer and incubated overnight at 56°C as described
previously [185, 186]. Following tissue digestion, 5 M NaCl was added to the samples to
a final concentration of 0.08 M and vortexed. To extract DNA, three 1 mL phenol/ 8hydroxyquinoline extractions were followed by three 1 mL 24:1 chloroform: isoamyl
alcohol extractions. DNA was precipitated from supernatant with 5 M NaCl and 1.5 mL
of cold ethanol. The samples were hand mixed and precipitated overnight at -20°C. To
remove impurities and excess salt, the DNA pellet was washed three times with 60%
ethanol, dried, suspended in deionized water, and incubated for 15 min at 40°C. Purity of
DNA and concentration were measured using the ND1000 NanoDrop UV-Vis
Spectrophotometer (Fisher Scientific, NY).
3.2.3. Internal standard (IS) solutions
To prepare stock solutions of isotopically labeled standards, approximately 5 mg
of each standard was dissolved in 2.5 mL of sterile double distilled water. To determine
molar concentration of internal standard solutions, the absorbance was measured in
triplicate at 270 nm for cytosine and 5-mC [108] and 274 nm for 5-hmC [207] using a
Genesys 10uv Thermo Spectronic UV-Vis Spectrophotometer (Thermo Scientific). To
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compare retention times and fragmentation of labeled and unlabeled standards, solutions
of unlabeled standards of cytosine, 5-mC, and 5-hmC were prepared as described above.
3.2.4 Acid Hydrolysis
40 µg of DNA was added to 5 mL conical glass vials, frozen, and lyophilized. To
hydrolyze the bases, 250 µL of 90% formic acid was added to each sample. Air was
evacuated from samples using a Teflon seal and a 60 mL syringe with a 20 gauge needle.
Samples were heated for 30 min in a sand bath at 140°C. After cooling for 10 min at
-80°C, labeled standards were added to the vials and frozen at -80°C for at least two
hours. Samples were then lyophilized overnight.
3.2.5 Derivatization of DNA bases
To volatilize bases, 250 µL of a 50:50 solution of pyridine/BSTFA:TMCS was
added to each sample vial and evacuated as previously described [185]. To ensure the
reaction went to completion and all bases derivatized, samples were vortexed every 30
min for 2 h at 21°C. Vials were then dried under nitrogen gas for 2 h. To suspend DNA
bases, 20 µL BSTFA:TMCS was added to each vial, the vials were vortexed, and the
solution was transferred to a GC/MS autosampler insert and capped.
3.2.6 GC/MS Method
Separation of derivatized bases was accomplished using an Agilent 7890A GC on
an Agilent HP-5MSI ultra inert capillary column (0.25 mm diameter, 0.25 µm film
thickness, 30 m length). To analyze the sample, 1 µL was injected using splitless mode
with ultrapure helium as the carrier gas (99.999%), where the inlet pressure was set to
11.8 psi under constant flow. To obtain separation of cytosine, 5-mC, and 5-hmC elution
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peaks, a temperature program was developed: 100°C for 2 min hold, 5°C/min to 125°C,
0.75°C/min to 134.75°C, 0.3°C/min to 137.15°C, 10°C/min to 307.15°C, and held at
307.15°C for 2 min. Total run time was 47 min per sample. Retention times for the
standards were 17 min for cytosine, 19 min for 5-mC, and 36 min for 5-hmC.
From the GC column, samples were introduced into an Agilent 5975C inert XL
EI/CI MSD with Triple Axis Detector mass spectrometer with an injector temperature set
to 250°C and ion source at 230°C. Using selective ion monitoring (SIM) mode, data were
collected for specific m/z ratios of the base peak for IS and unlabeled cytosine
derivatives. IS m/z ratios monitored were 257 for [2-13C, 1, 3-15N] cytosine, 258 for 5methyl-d3-cytosine-6-d1, and 360 for [2-13C, 1, 3-15N] 5-hmC. The unlabeled cytosine
derivatives were monitored at m/z ratios of 254 for cytosine and 5-mC, and 357 for 5hmC at each respective retention time. To quantify levels of each base, the integrated area
of the signal for each analyte was normalized with respect to the IS signal and corrected
based on standard response curves for each labeled standard. Sample values were
calculated as pmol modification/mg DNA, taking into account 0.04 mg of DNA analyzed
for each sample and a 20:1 dilution factor (20 µL resuspended: 1 µL injection).
To develop standard curves for each labeled base, five replicate measures of 1:3
serial dilutions over a range of 1.5 pmol/µL – 375 pmol/µL were used to analyze
instrument response prior to tissue experiments. Concentration ranges were based on
average amounts of cytosine, 5-mC, and 5-hmC in 1 µL injections of DNA from
processed brain tissue specimens. Limit of detection and limit of quantification (LOQ)
were calculated based on the slope of the standard curve and standard deviation of blank
measurements.
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3.2.7 Spike Recovery
To determine if processing steps alter analyte recovery, a spike recovery analysis
was utilized. Samples included an IS blank using [2-13C, 1, 3-15N] cytosine, [2-13C, 1, 315

N] 5-hmC, and 5-methyl-d3-cytosine-6-d1 (IS mix), a spike blank with IS mix and

unlabeled standards mix, a DNA sample with IS mix, and a spiked sample with DNA, IS
mix, and unlabeled standards mix. Unlabeled cytosine standards were tested at two
concentrations. Commercially available labeled (IS) (125 pmol of each) and unlabeled
cytosine standards (168 pmol or 336 pmol of cytosine, 100 pmol or 200 pmol of 5-mC,
and 32 pmol or 64 pmol of 5-hmC) were added to normal control DNA extracted from
cerebellum tissue specimens. For DNA samples, 40 μg of DNA was used per vial, where
the sample and spiked sample came from the same stock DNA (80 μg total per set). The
unlabeled standards mix was added to 40 μg of DNA and underwent formic acid
treatment and derivatization to determine if processing steps altered the amount of
analyte recovered, i.e. if acid hydrolysis converted 5-mC standard to 5-hmC during
processing steps. Spiked samples were compared to blank samples to calculate percent
recoveries. Each type of sample (IS blank, spike blank, sample, and spiked sample) was
run in duplicate (blank vials) or triplicate (DNA vials) and the analysis repeated.
3.2.8 Statistical analysis
3.2.8.1 Power analysis and Randomization
To limit the potential for batch differences, DNA samples were randomized by
brain region and diagnosis and processed for acid hydrolysis and derivatization steps in
sets of 10. When quantifying results, data were recorded by subject case number with no
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indication of diagnosis to minimize subjective bias. No formal power analysis was
utilized and sample sizes were based on tissue specimen availability.
3.2.8.2 Subject demographic analysis
To determine statistical differences in subject demographic data between
diagnosis groups, ANOVA was used for parametric distributions (PMI and age), while
ANOVA on Ranks was used for non-parametric distributions within the data (MMSE
scores, Braak stage scores, and pathologic burden counts). In the event the ANOVA test
was significant (p < 0.05), Dunn’s post hoc analysis was performed. SigmaPlot version
13.0® (Systat Software Inc., San Jose, CA) was used to perform statistical analysis tests
on subject demographic data.
3.2.8.3 General Linear Regression Models
To test associations between epigenetic marks (5-mC and 5-hmC) in brain regions
(HPG, SMTG, IPL) with mean brain region-specific NP and NFT counts, general linear
regression models (GLM) were used. Six regression models were fitted to the data, one in
each brain region for each dependent variable (NP and NFT counts). Models
simultaneously estimated the association between NP/NFT counts and 5-mC and 5-hmC
while adjusting for age at death and gender. To test associations between MMSE scores
(global cognition measurement) near death and epigenetic marks (5-mC and 5-hmC),
GLMs were also used and adjusted for age at death and gender.
3.2.8.4 Repeated measures analysis
Due to the complexity of the data, a repeated measures analysis with brain region
as the repeated factor within subjects was used to analyze significant differences in levels
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of cytosine, 5-mC, and 5-hmC across four brain regions (HPG, SMTG, IPL, CER) from
five subject groups (NC, PCAD, MCI, LOAD, FTLD/DLB). Separate models were fitted
for cytosine, 5-mC, and 5-hmC. An unstructured covariance matrix was used to account
for correlations within the four measurements taken on each subject. Models tested the
main effect of brain region and subject group, as well as their two-way interaction
(adjusted for gender and age). GLMs and repeated measures analysis was performed in
SAS version 9.4®.

3.3 Methods for genome-wide profiling of 5-hmC
3.3.1 Subject Data
Tissue specimens of hippocampus/parahippocampal gyrus (HPG) from LOAD
(n=3) and NC (n=2) subjects were obtained as described previously (Methods 3.2.1).
3.3.2 DNA isolation
Nuclear DNA was extracted from HPG tissue specimens using dounce
homogenizer in 1 mL digestion buffer/ proteinase K solution as previously described
[176, 185]. Extraction of DNA using phenol:chloroform:isoamyl alcohol protocol was
performed as described above (Methods 3.2.2).
3.3.3 5-hmC whole genome profiling: RRHP
To analyze sites of 5-hmC modification in LOAD subjects, 1 µg of nDNA was
sent to Zymo Research Corporation (ZRC) (CA, USA) for analysis by their in-house
reduced representation hydroxymethylation profiling (RRHP) technique, where specific
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restriction endonuclease enzymes were used to analyze epigenetic modifications at the
internal cytosine of CCGG sequences [188]. Glucosylation of 5-hmC at the internal
cytosine (CCGG) protects it from cleavage by MspI, whereas without protection, MspI
cleaves between the CC bases within CCGG sequences. Library construction,
sequencing, alignment to the human genome (hg19), and count reads were performed by
ZRC. More than two million sites of possible 5-hmC modification were analyzed across
the genomes of three LOAD and two NC subjects. Data files (BAM files) were
downloaded from ZRC.
3.3.4 Data analysis: negative binomial distribution
To analyze genome data files, the free bedtools PERL script bamtobed [208] was
used to convert downloaded ZRC BAM files to BED format. BED files were analyzed
using an exact negative binomial test [209] with a sliding window approach in diffReps
v1.55.4 [194]. Window size was set to 200 base pairs (bp) with a slide of 20 bp. To
normalize data, raw read counts within 200 bp windows were linearly scaled by the
geometric mean of all the reads in the specified window for each sample. Only windows
that passed an initial cutoff (p < 1e-04) were retained. To correct for multiple comparisons,
p values were adjusted using Benjamini-Hochberg false discovery rate (FDR) [210].
Annotation of windows to genomic regions was performed using the freely available
regionanalysis PYTHON script, a now standalone script initially developed for diffReps.
All scripts were run using command line calling in Terminal v2.6.1 (Apple, Inc.,
Cupertino, CA, USA). A conservative cutoff was chosen (adj p ≤ 1e-04) for downstream
analysis due to the small samples size of subjects and to limit the potential of reporting
falsely significant windows. Gene annotations with significant windows aligning to
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promoter or genebody locations were filtered based on a published microarray of
differentially expressed genes in the hippocampus of sporadic AD subjects [59]. The
resulting list of genes was used for pathway enrichment analysis.
3.3.5 Functional Interaction Network Analysis
A network of functionally related genes was created using the Reactome
Functional Interaction (RFI) plugin app available win Cytoscape® v3.0. Using linker
genes provided by RFI, 322 of the 329 significant genes from our analysis were used to
create the gene network. Utilizing spectral partition clustering [211], the gene network
was divided into six related modules and enrichment scores for module pathways were
analyzed excluding linker genes to prevent bias and only report pathways relevant to the
322 gene targets. Using a binomial test [212] within RFI, statistical significance was
determined and multiple comparisons were corrected using a permutation test to give
FDR adjusted p values [213, 214]. Pathways with adjusted p < 0.05 were retained.
3.3.6 Subject Demographic analysis
All normally distributed values (age, PMI, NP and NFT burden) were analyzed
using Student’s t test, while nonparametric data were analyzed using Mann-Whitney U
tests (MMSE scores and Braak staging scores) to determine significant differences
between LOAD and NC subjects. All significance tests were performed in SigmaPlot
v.13 (Systat Software, Inc., CA, USA).
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3.4 Methods for qPCR analysis of cytosine, 5-mC, and 5-hmC
3.4.1 Subject Data
Tissue specimens of superior and middle temporal gyrus (SMTG) from PCAD
(n=7), MCI (n=10), LOAD (n=9), and NC (n=9) subjects were obtained as described
previously (Methods 3.2.1).
3.4.2 DNA isolation
DNA was extracted from frozen tissue specimens using the
phenol:chloroform:isoamyl alcohol protocol as described above (Methods 3.2.2).
3.4.3 Protein extraction
SMTG frozen tissue specimens were suspended in 350 µL of RIPA buffer (1mM
Na2EDTA, 1mM EGTA, 150mM NaCl, 1% NP40, 20mM Tris-HCl, 1mM Bglycerophosphate, 1% sodium deoxycholate, 1ug/mL leupeptin, 2.5mM sodium
pyrophosphate, 1mM sodium orthovanadate) with 1 mM PMSF dissolved in ethanol
added immediately before protein extraction. While on ice, samples were homogenized
using Heat Systems-Ultrasonics, Inc. W-380 Sonicator and centrifuged at 10k x g for 30
min at 4°C. Supernatant was collected and protein concentration measured using Pierce
BCA protein assay (Thermo Fisher) on UV-Vis plate reader (Thermo) for each sample.
3.4.4 Primer design
Gene sequences for primer design of target genes were obtained from the National
Center for Biotechnology Information (NCBI) reference database: ABCA7 (accession
number: NC000019.10), PS1 (accession number: NG007386.2). Exon primer pairs were
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designed using Integrated DNA Technologies (IDT) PrimerQuest software and
theoretical non-specificity was determined using PrimerBlast [215].
3.4.5 Primer sequences
Primer sequences for forward and reverse designed synthetic primers for PS1 and
ABCA7 are given in Table 3.1. Only primers specific to designed PS1 or ABCA7 target
sequences based on PrimerBlast results were purchased.
3.4.6 Endpoint PCR
To determine specificity of synthetic primer pairs, human DNA was amplified
using 5X GoTaq Flexi PCR reaction mix (Promega) on the Mastercycler Pro PCR
(Eppendorf). Product amplicon molecular weights were determined via SDS-PAGE gel
separation and NEB low molecular weight standard DNA ladder (New England Biolabs).
A 2% agarose gel was made using tris-acetate-EDTA buffer and loaded with 20 µL of
sample. Band separation was achieved with a 30 min run at 150V. Ethidium bromide, an
intercalating fluorescent dye, was used with UV excitation to image amplicon bands
within agarose gels.
3.4.7 Primer and DNA optimization
To optimize primer concentrations, solutions of 50, 100, 150, 200, and 250 nM
forward and reverse primers were run in triplicate using 100 ng of NC DNA. Using melt
curves and Ct values for each concentration of primer pairs, optimized primer
concentrations were determined for each exon. DNA concentration optimization was
determined using a 1:3 serial dilution beginning with 150 ng of DNA, run in triplicate
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Table 3.1 Primer sequences and target amplicon size for ABCA7 and PS1 exons.
Gene Location

Primer Sequence

Amplicon Size

ABCA7
FWD - CTTCTTGGGACCTGAGGA
Exon 12

108 bp
REV - CTCGTGACCACGTCAATG
FWD - GTTCCTGCGTGTGCTGAG
75 bp

Exon 14
REV - ACTCTCAGTGTCACGGAGT
FWD - TGCAGTGCTGGTAGAAGA

133 bp

Exon 18
REV - GATGTGGCCCTGGTAGAA
FWD - TCTATCCACAGGTCCATCTT
Exon 19

137 bp
REV - AACAGCACGTTGTACTGAG
FWD - CTTGAAACAGGTCTTCCTTATCTTC
100 bp

Exon 37
REV - CAAGCGCTCAAAGGCATC
PS1
FWD - AATGACGACAACGGTGAG
Exon 1

111 bp
REV - TAGCTCAGGTTCCTTCCA
FWD - GCCACCCTGAGCCATTATCT

Exon 4 Site 1

89 bp
REV - TGTCAGCTCCTCATCTTCTTCC
FWD - TATGGCGCCAAGCATGTGAT
154 bp

Exon 4 Site 2
REV - AGCCACACTGGCTTTGAGAAT
FWD - ATATGGCAGAAGGAGACCCG

113 bp

Exon 9
REV- ACAGCGACCCTGAAAAATCAAGATA
FWD - CTCGGTGCAGAAACTA

119 bp

Exon 12 Site 2
REV - GCAGTGTCAGTGAAATC
FWD - GAAGCAACAACTGAAGAG

107 bp

Exon 12 Site 3
REV - CTGTTTGGGCATCTATTG
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Reaction efficiencies were determined from response curves of DNA serial dilutions
using Life Technologies RT-PCR Handbook guidelines (Invitrogen, Inc).
3.4.8 Glucosylation of 5-hmC
To quantify cytosine, 5-mC, and 5-hmC at target CCGG exon sites, the EpiMark
5-mC and 5-hmC quantification kit (New England Biolabs) was used per manufacturer’s
instructions with the exception of replacing NEB Buffer 4 with CutSmart Buffer (NEB).
For each sample, 5 µg of DNA was added to CutSmart Buffer and UDP-Glucose. This
solution was split into two tubes, one reaction analysis, where T4-βGT was added to
glucosylate 5-hmC modifications, and one control analysis without the glucosylation
enzyme. Utilizing the specificity of MspI and HpaII endonuclease enzymes and q-PCR,
5-hmC and 5-mC were quantified.
3.4.9 Quantitative Polymerase Chain Reaction
To quantify levels of cytosine, 5-mC, and 5-hmC at target sites, Fast SYBR Green
Master Mix (Applied Biosystems) was used, where ROX reference dye within the master
mix corrects for instrument fluctuations in fluorescence. Forward and reverse primers,
master mix, water, and DNA were combined according to manufacturer’s specifications
(Applied Biosystems). For each reaction plate, a 1:3 DNA serial dilution curve was used
to determine reaction efficiency and quantification of analyte signal, where dilution curve
samples were run in triplicate. DNA, master mix, and primer pairs were added to 96 well
q-PCR plates (Applied Biosystems) in duplicate and total reaction volume per well was
20 µL.
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3.4.10 ViiA7 qPCR method
Plates were sealed with MicroAmp optical adhesive film (Applied Biosystems)
and centrifuged using RT-PCR plate MiniSpin (Applied Biosystems). Plates were loaded
into the Life Technologies ViiA7 Real Time PCR System. The run method included a
hold stage for 20 sec at 95°C, followed by a denaturation step for 3 sec at 95°C, and an
annealing step at 60°C for 30 sec for 40 cycles, followed by a melt curve analysis with
stage set to 95°C for 3 sec, 60°C for 1 min, and 95°C for 15 sec. Total run time was 57
min per plate.
3.4.11 Western blot
Protein samples (20 µg for PS1 blot and 33.75 µg for ABCA7 blot) were added to
2-mercaptoethanol loading buffer and PBS. Samples were denatured at 37°C for PS1 and
56°C for ABCA7 in a dry bath for 5 min and loaded onto premade gels. Novex protein
standards (Invitrogen) were used to identify molecular weights of protein bands. For PS1
blots, 16 µL of sample was separated using 4-12% Nupage Novex gels (Invitrogen) with
average runtimes of 40 min at 200V. Blots were transferred to nitrocellulose membranes
using iBlot dry transfer systems (Life Technologies). For ABCA7 blots, 25 µL of protein
samples were separated using 3-8% Nupage Tris-Acetate gels (Invitrogen) with runtimes
averaging 1 h at 115V. Proteins were transferred to 0.2 µm nitrocellulose membranes
using tank transfer at 70V for 4 h on ice. Blots were blocked for 1 h using 15 mL
Odyssey PBS blocking buffer solution (Licor). After three washes of TTBS, primary
antibody (1:1000) was reacted with membranes overnight at 4°C. Membranes were
washed again with TTBS three times and secondary antibody was added (1:10000) and
incubated at 21°C in the dark for 1 h. Excess secondary antibody was removed by three
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washes of TTBS and membranes suspended in PBS for analysis using LiCor Imaging
System (Odyssey Imaging, Licor). Band density measurements were compared using
Scion Imaging® software. A reference protein (GAPDH) was used to correct for possible
loading volume alterations.
3.4.12 Data Analysis
Reaction efficiencies were calculated for each plate using the DNA standard
curve slope. Quantification of cytosine, 5-mC, and 5-hmC levels at each target site were
calculated by using the average Ct value of the samples and the DNA standard curve.
Raw values were calculated as percentages of total DNA, determined from the reaction
tube without endonuclease restriction enzyme digestion. To normalize values across
multiple data sets, percentages were corrected for uncut DNA (unprotected MspI
digestion) for each reaction.
3.4.13 Statistical Analysis
3.4.13.1 Subject demographics
To determine if there were significant differences in subject demographic data
between the subject groups, a series of analyses of variance tests were performed using
SigmaPlot v13. While ANOVA was used to determine significant differences in mean
age and PMI values, the gender distribution between the subject groups was determined
using ANOVA on Ranks, where women were encoded as 0 while men were encoded as
1. All significant differences were reported as (p < 0.05).
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3.4.13.2 MANOVA models
Due to the multivariate nature of the analysis, where cytosine, 5-mC, and 5-hmC
were measured at single CCGG sequences, a multivariate statistical analysis was chosen.
To determine statistical significance between the subject groups at each target site, a
multivariate analysis of variance (MANOVA) test was used in SPSS v24. Models for
each exon were tested, including five models for exons of PS1 and four models for exons
of ABCA7. The main effects of the three dependent variables (cytosine, 5-mC, and 5hmC) within the subject groups (independent variable) were tested using a conservative
multivariate analysis (Pillai’s Trace test). In the event of an overall significant difference
among the subject groups, least square regression models were fit to the data and
pairwise comparisons were made using least significant difference analyses. All
significant differences were reported as (*p < 0.05) or trending toward significance as
(#p ≤ 0.1).
3.4.13.3 Protein level analysis
To determine significant differences in protein levels of PS1 and ABCA7 between
the subject groups, ANOVA was used. In the event the omnibus test was significant,
pairwise comparisons using Holmes-Sidak post-hoc analyses were used to compare
means against NC subjects. All significant differences were reported as (*p < 0.05).
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CHAPTER 4: RESULTS
[Some of these results were originally published in Journal of Neurochemistry.
EM Ellison, EL Abner, and MA Lovell. J Neurochem. (2017) 140: 383-394 © John
Wiley and Sons]

4.1 Global quantification of cytosine, 5-mC, and 5-hmC
4.1.1 GC/MS Standards Characterization
Commercially available standards were purchased and characterized using
GC/MS method described previously (Methods 3.2). Synthetic stable labeled cytosine
standards and unlabeled cytosine standards were characterized using chromatographic
separation retention times within the column and fragmentation patterns of m/z ratios
produced from electron ionization within the mass spectrometer. Based on fragmentation
pattern, the most abundant ion (m/z) was used for quantification (Table 4.1).
Chromatographic peak separation via the described temperature gradient resulted in three
well-separated peaks for cytosine (~17 min), 5-mC (~19 min), and 5-hmC (~37 min).
Retention time values listed in Table 4.1 reflect the elution time of each standard from a
single run. Overlay of chromatograms of stable labeled standards and of a mixture of
stable labeled and unlabeled standards showed agreement in retention times and well
separated peaks. Retention time agreement between stable labeled and unlabeled
standards was shown, as well as m/z shifts identical to number of isotopically labeled
atoms in each stable labeled cytosine standard, i.e. three mass units heavier for [2-13C, 1,
3-15N] cytosine compared to cytosine, as well as [2-13C, 1, 3-15N] 5-hmC compared to
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Table 4.1 Characterization of unlabeled and stable labeled cytosine bases using GC/MS.

Analyte

Retention
time
(min)

Molecular
Ion [M]+

Identification
Ions

Quantification
Ion

cytosine

16.97

255

254 and 240

254

C 15N
cytosine

16.96

258

257 and 243

257

5-mC

18.87

269

269 and 254

254

H 5-mC

18.75

273

273 and 258

258

5-hmC

36.53

357

357 and 342

357

36.52

360

360 and 345

360

13

2

13

C 15N 5-hmC
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5-hmC, corresponding to two 15N and a single 13C labels (Table 4.1). Likewise, 5-methyld3-cytosine-6-d1 compared to 5-mC showed four mass units difference, corresponding to
four 2H labels for the stable labeled standard (Table 4.1).
To ensure correct peak assignment, mass spectra were compared to database
references [216-218] for cytosine and 5-mC, however a 5-hmC spectrum was not
available in the MS database. In the absence of a database reference to confirm m/z ratios
for 5-hmC, a previously published 5-hmC analysis by GC/MS showed similar m/z ratios
to the current study [219]. Commercially available stable labeled cytosine standards
showed high percentage of labeling when compared to amount of unlabeled material
within each standard: [2-13C, 1, 3-15N] cytosine (99.8%), 5-methyl-d3-cytosine-6-d1
(99.3%), and [2-13C, 1, 3-15N] 5-hmC (99.8%).
To identify peaks within chromatograms, several m/z ratios characteristic to each
cytosine modification were used based on fragmentation patterns shown in the mass
spectra. Fragmentation of [2-13C, 1, 3-15N] cytosine produced two abundant ions, m/z 257
and 243 (Figure 4.1) in a ratio of 55:45, whereas unlabeled cytosine fragmentation
produced m/z ratios 254 and 240 in a similar ratio. For 5-methyl-d3-cytosine-6-d1, the
most abundant ions produced from EI fragmentation were m/z 273 and 258 (Figure 4.2)
where the ratio of ions is 25:75. Similarly, unlabeled 5-mC produced m/z ratios of 269
and 254 were observed at a ratio of 20:80. Finally, for [2-13C, 1, 3-15N] 5-hmC,
fragmentation of the molecular ion at m/z ratio of 360 produced an abundant daughter ion
at m/z 345 (Figure 4.3) where the ratio of ions was 70:30, while the unlabeled ions

78

Figure 4.1 Mass spectra of cytosine and [2-13C, 1,3-15N] cytosine. Mass spectra
obtained from GC/MS full scan of cytosine standard (a) and [2-13C, 1, 3-15N] cytosine (b).
Base ion [M-1]+ and several daughter ions ([M-15]+, [M-73]+) were labeled.
Derivatization groups (trimethylsilyl) are labeled as TMS in chemical structures.
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Figure 4.2 Mass spectra of 5-mC and 5-methyl-d3-cytosine-d1. Mass spectra obtained
from GC/MS full scan of 5-mC standard (a) and 5-methyl-d3-cytosine-d1 (b). Molecular
ion [M]+ and several daughter ions ([M-15]+, [M-73]+) were labeled. Derivatization
groups (trimethylsilyl) are labeled as TMS in chemical structures.

80

Figure 4.3 Mass spectra of 5-hmC and [2-13C, 1,3-15N] 5-hmC. Mass spectra obtained
from GC/MS full scan of 5-hmC (a) and [2-13C, 1, 3-15N] 5-hmC (b) standards. Molecular
ion [M]+ and several daughter ions ([M-15]+, [M-73]+, [M-89]+, [M-103]+) were labeled.
Derivatization groups (trimethylsilyl) are labeled as TMS in chemical structures.
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were m/z 357 and 342 at a comparable ratio. Although multiple m/z ratios were
monitored for peak identification and characterization SIM runs, the most abundant ion
(base ion) was used to quantify each analyte. The base ion m/z ratios were 257 for [213

C, 1, 3-15N] cytosine, which corresponds to the loss of one hydrogen from the

molecular ion ([M-1]+), 258 for 5-methyl-d3-cytosine-6-d1, corresponding to the loss of
one methyl group from the molecular ion ([M-15]+), and 360 for [2-13C, 1, 3-15N] 5-hmC,
corresponding to the molecular ion ([M]+).
Once characterized and separated, instrument response curves were analyzed over
a concentration range of 1.5 – 375 pmol/μL for each stable labeled standard. Five
replicate measures were taken at each concentration (1.5, 4.6, 13.9, 41.7, 125, and 375
pmol/μL) and averaged. Calibration curves showed a linear response based on linear
regression analysis in SigmaPlot for [2-13C, 1, 3-15N] cytosine (Figure 4.4), 5-methyl-d3cytosine-6-d1 (Figure 4.5), and [2-13C, 1, 3-15N] 5-hmC (Figure 4.6). All instrument
response curves showed a linear relationship throughout the concentrations analyzed for
[2-13C, 1, 3-15N] cytosine (Adj R2 = 0.993), 5-methyl-d3-cytosine-6-d1 (Adj R2 = 0.995),
and [2-13C, 1, 3-15N] 5-hmC (Adj R2 = 0.993). Limit of quantification (LOQ) values
were calculated for each standard based on slope of calibration curve and standard
deviation of blank measurements. The LOQ for [2-13C, 1, 3-15N] cytosine was calculated
as 3.4 pmol/ μL, which corresponds to 1709 pmol/ mg DNA. The LOQ 5-methyl-d3cytosine-6-d1 was calculated to be 0.4 pmol/ μL, corresponding to 201 pmol/mg DNA.
Finally, the LOQ for [2-13C, 1, 3-15N] 5-hmC was calculated to be 0.8 pmol/ μL,
corresponding to 402 pmol/mg DNA.
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Figure 4.4 Stable labeled cytosine standard curve. Linear instrument response curve
for [2-13C, 1, 3-15N] cytosine standard. Data points represent the mean ± SD (n = 5).
Linear regression (solid line) shown with 95% confidence interval (dashed line). Insert
shows 1.5 – 125 pmols of standard range.
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Figure 4.5 Stable labeled 5-mC standard curve. Linear instrument response curve for
5-methyl-d3-cytosine-6-d1 standard. Data points represent the mean ± SD (n = 5). Linear
regression (solid line) shown with 95% confidence interval (dashed line). Insert shows
1.5 – 125 pmols of standard range.
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Figure 4.6 Stable labeled 5-hmC standard curve. Linear instrument response curve for
[2-13C, 1, 3-15N] 5-hmC standard. Data points represent the mean ± SD (n = 5). Linear
regression (solid line) shown with 95% confidence interval (dashed line). Insert shows
1.5 – 125 pmols of standard range.
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4.1.2 Spike Recovery Analysis
To determine if processing steps alter analyte recovery, a spike recovery analysis
was carried out. Commercially available stable labeled and unlabeled cytosine standards
were added to 40 μg of DNA at two concentrations. Samples included an IS blank with
only stable labeled standards, a spike blank with IS mix and unlabeled standards mix, a
DNA sample with IS mix, and a spiked sample with DNA, IS mix, and unlabeled
standards mix. For each cytosine base, percent recoveries were calculated based on blank
measurements and reported as mean ± SD over three repeated experiments for a total of
n=8 measurements per base. The average recovery for all three cytosine bases fell within
the suggested 80-120% range according to current literature for both concentrations of
unlabeled (spiked) bases (cytosine, 94.2 ± 10.1%; 5-mC, 102.7 ± 4.5%; 5-hmC, 99.1 ±
19.8%).
4.1.3 Subject demographics analysis
Age is the most important risk factor for developing AD, therefore NC subjects
were age-matched to correct for potential age associated epigenetic modifications in brain
tissue specimens. To analyze the specificity of alterations in epigenetic marks to AD or
general neurodegenerative diseases, diseased control tissue specimens from FTLD and
DLB subjects were analyzed. As shown in Table 4.2, no statistically significant
differences were observed for age or PMI among the subject groups using ANOVA.
Table values for age and PMI reflect mean ± SD for each subject group.
Significant differences were observed in comparing pathology burden markers
between the subject groups. Braak staging scores were elevated in PCAD, MCI, and
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LOAD subjects compared to NC (p < 0.05), while no difference was observed between
FTLD/DLB and NC subjects. MMSE scores, a measure of global cognition, were
significantly decreased in dementia subjects (LOAD and FTLD/DLB) compared to NC (p
< 0.05) using ANOVA on Ranks and Dunn’s post hoc analysis (Table 4.2), while PCAD
and MCI showed no significant difference in MMSE scores compared to NC subjects.
Table values for MMSE scores reflect median and interquartile range for each subject
group (Table 4.2). In addition, the number of subjects with the Ԑ4 allele of APOE in each
subject group were also reported in Table 4.2.
Quantitative measures of neuropathologic burden, specifically regional NP and
NFT counts representing the arithmetic mean of plaques and tangles within most severely
affected brain regions, were provided by the UK-ADC. Counts of NP and NFT burden in
the HPG, SMTG, and IPL were compared among the subject groups using ANOVA on
Ranks with post-hoc analysis using Dunn’s analysis, reported as median with
interquartile range in Table 4.3. For all NP and NFT counts, the omnibus test was
significant (p < 0.05). For NP counts, all brain regions showed significant differences in
LOAD compared to NC subjects (HPG, p = 0.021; SMTG, p = 0.026; IPL, p = 0.024).
NFT counts were also elevated in LOAD subjects compared to NC in the SMTG (p <
0.001) and IPL (p < 0.001) brain regions (Table 4.3).
To analyze the role epigenetic modifications to cytosine play in the progression
of AD, three brain regions susceptible to AD pathologic markers (HPG, SMTG, and IPL)
and one brain region considered non-vulnerable (CER) to plaque and tangle pathology
were chosen. When available, complete sets of CER, IPL, SMTG, and HPG tissue
specimens were analyzed for NC, PCAD, MCI, LOAD, and FTLD/DLB subjects.
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Table 4.2 Demographic data for each subject group.

NC

PCAD

MCI

LOAD

FTLD/DLB

(N=10)

(N=8)

(N=11)

(N=10)

(N=11)

Age (years)

82.8 ± 8.9

85.4 ± 6.6

89.5 ± 6.4

82.5 ± 8.4

80.7 ± 12.8

Gender

5W / 5M

6W / 2M

8W / 3M

5W / 5M

3W / 8M

PMI (h)

2.7 ± 0.9

3.0 ± 0.5

2.6 ± 0.5

2.8 ± 0.8

3.6 ± 1.1

MMSE Score

29.5 [28 - 30]

30 [28.25 - 30]

28 [26 - 28]

16* [3 - 25.5]

17* [1.5 - 26.5]

APOE-Ԑ4 allele

1

2

5

6

3

Subject Demographics
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*p < 0.05

Table 4.3 Pathology burden data for each subject group.

NC

PCAD

MCI

LOAD

FTLD/DLB

Braak Stage

II [0-II]

IV* [III-V]

III* [II-V]

VI* [V-VI]

II [0-III]

NP – HPG

0

0 [0-1]

0.3 [0-5.0]

2.8* [0.9-4.1]

0 [0-0.8]

NP – SMTG

0 [0-5.0]

10.3 [7.5-19.5]

5.6 [2.3-12.4]

16.4* [6.1-30.8]

3.4 [0-17.8]

NP – IPL

0 [0-7.2]

13.1 [7.4-31.4]

6 [2-14.3]

19.8* [8.6-30.9]

5.8 [1.6-13.2]

NFT – HPG

3.2 [0.7-6.8]

2.6 [0.6-8.9]

24.3 [2.3-78.9]

20.7 [10.6-50.8]

1.8 [0-4]

NFT – SMTG

0

0.7 [0.1-1.5]

1.2 [0.5-9.4]

18.2* [11.0-24.6]

0 [0-0.8]

NFT – IPL

0

0.5 [0.2-1.3]

0 [0-5.8]

15.1* [9.6-25.6]

0 [0-0.4]

Pathology Burden
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*p < 0.05

Incomplete sets included MCI (HPG, n=5), PCAD (HPG, n=5), and FTLD/DLB (HPG,
n=6; SMTG, n=10) subject groups. The total number of subjects per group is reported in
(Table 4.2).
4.1.4 Raw levels of cytosine modifications
Levels of cytosine bases were quantified as pmols / mg DNA (Halliwell and
Dizdaroglu 1992) in HPG, SMTG, IPL, and CER brain regions for NC, PCAD, MCI,
LOAD, and FTLD/DLB subjects. A representative DNA sample with internal standards
is shown in Figure 4.7, where peaks contained DNA levels of respective cytosine base
and the stable labeled standard. Raw values were calculated from the signal intensity of
the sample compared to the internal standard, the instrument response of the standard
curve, a dilution factor of 20:1 (solution volume: injected volume), as well as the amount
of DNA analyzed. Raw calculated values were averaged for each subject group in each
analyzed brain region and reported in Table 4.4. Table values reflect mean ± SD (pmol
modification / mg DNA) and were rounded to whole numbers for simplicity.
4.1.5 Association of pathologic burden, MMSE scores, and epigenetic marks
Correlations of average NP and NFT counts, as well as MMSE scores, with 5-mC
and 5-hmC levels in AD pathology susceptible brain regions (HPG, SMTG, IPL) were
tested using general linear models. 5-mC was significantly associated with mean NP
counts in the SMTG (p = 0.021), although NFT counts showed no significant association.
For 5-hmC, there was no association with either measure in the HPG, SMTG, or IPL. In
HPG and IPL regions, 5-mC was not significantly associated with average NP or NFT
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Table 4.4. Mean ± SD of cytosine, 5-mC, and 5-hmC for each subject group by brain
region.
HPG

SMTG

IPL

CER

Cytosine (pmols / mg DNA)
NC

95056 ± 21963

84034 ± 13661

99634 ± 21729

91869 ± 16517

PCAD

81788 ± 25440

73660 ± 13319

94545 ± 25434

94247 ± 38731

MCI

74496 ± 14108

77930 ± 12408

87374 ± 18830

81711 ± 23190

LOAD

94926 ± 16336

96526 ± 20066

107957 ± 30112 85145 ± 16431

FTLD/DLB

94971 ± 27815

82071 ± 10903

74392 ± 10121

74896 ± 14954

5-methylcytosine (pmols / mg DNA)
NC

6139 ± 2037

7020 ± 1568

8088 ± 3852

9563 ± 2269

PCAD

7735 ± 3121

5486 ± 657

6799 ± 2556

8115 ± 3580

MCI

5386 ± 1288

6794 ± 1262

7256 ± 1738

7009 ± 2718

LOAD

6027 ± 1494

8787 ± 1958

8901 ± 4296

8950 ± 2651

FTLD/DLB

6336 ± 2131

5580 ± 1016

5512 ± 1503

5935 ± 1613

5-hydroxymethylcytosine (pmols / mg DNA)
NC

751 ± 135

915 ± 234

1135 ± 258

1302 ± 260

PCAD

1065 ± 136

1316 ± 321

1252 ± 193

1474 ± 257

MCI

828 ± 210

1345 ± 202

1280 ± 264

1474 ± 302

LOAD

787 ± 224

1111 ± 215

1082 ± 297

1251 ± 249

FTLD/DLB

1147 ± 226

1218 ± 167

1126 ± 327

1540 ± 217

91

Figure 4.7 Total Ion Chromatogram of representative DNA sample. Peaks of
cytosine (a), 5-mC (b), and 5-hmC (c) in a representative DNA sample combined with
stable labeled standards were well resolved using SIM GC/MS method.
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counts. Similarly, MMSE scores were not associated with 5-mC or 5-hmC in any of the
three brain regions analyzed.
4.1.6 Repeated Measures Analysis: Model Results
4.1.6.1 Cytosine
Using an unstructured covariance matrix, estimated means (EM) and standard
errors (SE) were calculated for each subject group across the brain regions analyzed (EM
± SE pmol / mg DNA). Average cytosine levels for NC subjects were 91,886 ± 3,004
pmols/ mg DNA, while PCAD subjects averaged 85,037 ± 3,618 pmol cytosine / mg
DNA, and MCI subjects showed 82,655 ± 3,242 pmol / mg DNA. LOAD subjects
average cytosine levels were 97,153 ± 3,006 pmol / mg DNA, while FTLD/DLB subjects
showed an average of 80,505 ± 3,215 pmol cytosine / mg DNA. Brain region specific
cytosine levels were calculated from the model, where average levels of cytosine were
determined for HPG (88,834 ± 3,548 pmol / mg DNA), SMTG (83,315 ± 2,148 pmol /
mg DNA), IPL (92,567 ± 3,188 pmol / mg DNA), and CER (85,037 ± 3,338 pmol / mg
DNA).
According to the repeated measures analysis, cytosine levels did not change
across brain regions (p = 0.133), although they were significantly altered between subject
groups (p = 0.0018). Compared to NC, MCI subjects showed significantly decreased
levels of cytosine (p = 0.042) as did FTLD/DLB subjects (p = 0.012). No significant
differences were detected between PCAD (p = 0.149) or LOAD (p = 0.218) subjects
compared to NC (Figure 4.8). Between group effects showed significant differences
between MCI and LOAD subjects (p = 0.002) as well as PCAD and LOAD subjects (p =
0.0128). Comparing dementia cases, FTLD/DLB subjects showed significantly decreased
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Figure 4.8 Global levels of cytosine throughout brain regions. Adjusted mean ± SE
(pmol / mg DNA) of cytosine were averaged across HPG, SMTG, IPL, and CER brain
regions for each subject group. Statistical significance is compared to NC based on
repeated measures analysis model (*p < 0.05).
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levels of cytosine across the brain regions studied compared to LOAD subjects (p =
0.0004).
4.1.6.2 5-mC
Average 5-mC levels for each subject group were calculated based on the
repeated measures analysis model, to give EM values in pmol 5-mC / mg DNA for NC
(7389 ± 360 pmol / mg DNA), PCAD (6543 ± 428 pmol / mg DNA), MCI (6857 ± 390
pmol / mg DNA), LOAD (8356 ± 356 pmol / mg DNA), and FTLD/DLB (5846 ± 388
pmol / mg DNA) subjects across analyzed brain regions. Brain region specific levels
were calculated by pooling all subjects to give mean 5-mC levels in HPG (6010 ± 387
pmol/mg DNA), SMTG (6785 ± 211 pmol / mg DNA), IPL (7307 ± 416 pmol / mg
DNA), and CER (7893 ± 381 pmol / mg DNA) brain regions.
For 5-mC levels, significant differences were detected by brain region (p =
0.0054) and by subject group (p = 0.0002) according to repeated measures analysis
model. For brain region differences, in the CER, 5-mC levels were significantly increased
compared to SMTG (p = 0.0079) and HPG (p = 0.0011). HPG levels of 5-mC were also
significantly decreased in HPG (p = 0.0265) compared to IPL, however no significant
difference was detected between levels of 5-mC in the HPG and SMTG (p = 0.1006)
regions. For subject group differences, FTLD/DLB levels of 5-mC were significantly
decreased compared with NC subjects (p = 0.0011), but PCAD (p = 0.1244), MCI (p =
0.3043), and LOAD (p = 0.0529) were not significantly different compared to NC
subjects (Figure 4.9). Between group effects showed significantly decreased levels of 5mC in PCAD (p = 0.0016), MCI (p = 0.0054), and FTLD/DLB cases (p < 0.0001)
compared to LOAD.
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Figure 4.9 Global levels of 5-mC throughout brain regions. Adjusted mean ± SE
(pmol / mg DNA) of 5-mC were averaged across HPG, SMTG, IPL, and CER brain
regions for each subject group. Statistical significance is compared to NC based on
repeated measures analysis model (#p < 0.1, *p < 0.05).
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4.1.6.3 5-hmC
Subject group and brain region specific levels of 5-hmC were estimated based on
the repeated measures analysis model to give EM ± SE pmol 5-hmC / mg DNA values.
Subjects group levels were estimated for NC (1028 ± 35 pmol / mg DNA), PCAD (1276
± 44 pmol / mg DNA), MCI (1243 ± 39 pmol / mg DNA), LOAD (1066 ± 36 pmol / mg
DNA), and FTLD/DLB (1244 ± 38 pmol / mg DNA) subjects across brain regions
analyzed. Brain region specific levels were estimated from pooled subjects to give
average 5-hmC levels in HPG (914 ± 33 pmol / mg DNA), SMTG (1185 ± 33 pmol / mg
DNA), IPL (1176 ± 41 pmol / mg DNA), and CER (1411 ± 36 pmol / mg DNA) brain
regions.
Similarly to the 5-mC model, levels of 5-hmC were significantly altered in both
brain region (p < 0.0001) and subject group (p < 0.0001) analyses. For brain region
comparisons, levels of 5-hmC were significantly higher in the CER compared to HPG (p
< 0.0001), SMTG (p < 0.0001), and IPL (p = 0.0001). HPG levels of 5-hmC were the
lowest of the four regions, showing significantly decreased levels compared to SMTG (p
< 0.0001) and IPL (p < 0.0001). For subject group differences, levels of 5-hmC were
significantly higher in PCAD (p < 0.0001), MCI (p = 0.0002), and FTLD/DLB (p =
0.0001) compared to NC, but not LOAD (p = 0.4286) subjects (Figure 4.10). Elevated
levels of 5-hmC were also shown in PCAD (p = 0.0006), MCI (p = 0.0019), and
FTLD/DLB (p = 0.0015) subjects compared to LOAD for between group effects.

97

Figure 4.10 Global levels of 5-hmC throughout brain regions. Adjusted mean ± SE
(pmol / mg DNA) of 5-hmC were averaged across HPG, SMTG, IPL, and CER brain
regions for each subject group. Statistical significance is compared to NC based on
repeated measures analysis model (*p < 0.05).
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4.1.6.4 Effects of AD specific epigenetic marks
To determine the relationship between 5-mC and 5-hmC levels in brain regions
susceptible to AD pathologic markers in relation to AD progression, FTLD/DLB cases
were excluded from the repeated measures analysis and significant differences between
brain regions of NC, PCAD, MCI, and LOAD subjects were tested. Cytosine levels were
not reported because statistically significant differences were not detected in the original
repeated measures model.
Brain region specific average levels of 5-mC and 5-hmC were calculated based on
repeated measures analysis model, pooling NC and AD subjects. Average 5-mC levels
were calculated for HPG (5969 ± 428 pmol / mg DNA), SMTG (7084 ± 250 pmol / mg
DNA), IPL (7840 ± 539 pmol / mg DNA), and CER (8429 ± 460 pmol / mg DNA).
Average 5-hmC levels were also calculated using repeated measures model to give values
for HPG (869 ± 33 pmol / mg DNA), SMTG (1176 ± 40 pmol / mg DNA), IPL (1195 ±
43 pmol / mg DNA), and CER (1380 ± 43 pmol / mg DNA).
For 5-mC, levels in the CER were significantly elevated compared to HPG (p =
0.0002) and SMTG (p = 0.0075). There was also a significant decrease in 5-mC levels in
HPG compared to IPL (p = 0.0057) and compared to SMTG (p = 0.0342) (Figure 4.11).
For 5-hmC, CER levels of 5-hmC were significantly increased compared to all other
brain regions (HPG, p < 0.0001; SMTG, p = 0.0003; IPL, p = 0.0079). Similarly, levels
of 5-hmC were significantly lower in the HPG compared to SMTG (p < 0.0001) and IPL
(p < 0.0001) (Figure 4.12).
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Figure 4.11 AD specific levels of 5-mC. Adjusted mean ± SE (pmol / mg DNA) of 5mC were averaged across NC, PCAD, MCI, and LOAD subjects groups and compared
between brain regions based on repeated measures analysis model (*p < 0.05).
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Figure 4.12 AD specific levels of 5-hmC. Adjusted mean ± SE (pmol / mg DNA) of 5hmC were averaged across NC, PCAD, MCI, and LOAD subjects groups and compared
between brain regions based on repeated measures analysis model (*p < 0.05).
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[Some of these results were originally submitted to Journal of Molecular
Neuroscience. EM Ellison, MA Bradley-Whitman, and MA Lovell. J Mol Neuro.
(2017) Submitted.]

4.2 Genome-wide analysis of 5-hmC
4.2.1 Subject demographics analysis
To analyze genome-wide levels of 5-hmC modifications in HPG of LOAD
subjects, an initial study of LOAD (n = 3) and NC (n = 2) subjects were compared (Table
4.5). Significant differences were not detected in PMI or age between the subject groups
using Student’s t test. For pathologic markers, NFT burden in the subiculum (Sub) was
significantly higher in LOAD compared to NC subjects (p = 0.02), although NFT burden
in CA1 was not significantly different between the groups. While there is a clear
difference between the median Braak staging scores as well as the MMSE scores of
LOAD and NC subjects, the small sample sizes lacked sufficient power to test differences
using Mann-Whitney U tests (p = 0.2).
4.2.2 RRHP analysis
Genome-wide RRHP analysis of 5-hmC modifications in hippocampal DNA of
LOAD (n = 3) and NC (n = 2) subjects identified more than 2 million sites of CCGG
sequences throughout the genome. BAM (binary version of sequence alignment map)
files were downloaded from Zymo Research Corporation for each subject, which
included annotated counts of 5-hmC identifications. The total number of unique CpG
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Table 4.5 Subject demographic data for RRHP analysis.

Demographics
Gender
Age (y)
PMI (h)
MMSE
Braak Stage
NFT (CA1)
NFT (Sub)

NC

LOAD

2F
84.5 ± 0.7
2.5
29
0
0
0

2F/1M
85.3 ± 4.0
3.0 ± 0.7
5
VI
66.5 ± 38.9
109.5 ± 30.6*

*p < 0.05
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Table 4.6 Genomic distribution of sites of 5-hmC modifications determined by RRHP analysis.
NC1

NC2

LOAD1

LOAD2

LOAD3

2,001,592

1,836,178

2,122,829

1,650,574

1,571,910

CpG Island

192470

226829

177154

196115

192180

Promoter

151942

177465

143138

151640

147500

5UTR

214435

204048

223353

184042

174395

Exon

121968

119666

123193

113473

104889

Intron

896143

822705

949917

749531

709913

3UTR

98460

96829

100528

86442

82564

H3k4me3

283204

292654

284383

263598

248927

H3k27me3

520180

467504

554629

419013

394663

High CpG Promoter

113764

142706

103664

118508

118072

Intermediate CpG Promoter

25316

23605

25690

22354

19841

Low CpG Promoter

13832

12154

14735

11723

10433

Bivalent Site

60195

58735

61643

53572

49919

7X Regulatory Potential

56693

66134

52718

56906

56312

Total Unique CpG sites

104

sites for each subject is reported in Table 4.6, as well as CpGs annotated to specific
genomic elements, provided by Zymo Research Corporation. As described by Petterson
et al. [188], analyzed sites included CCGG sequences within 5’UTR (untranslated
region), 3’UTR, promoter, exon, and intron genomic regions for known genes, as well as
CpG islands. The promoter sites, defined as ± 1 kb from the transcription start site of a
known reference gene, were further characterized as sites within high, intermediate, and
low CpG content promoters. Utilizing histone-binding site sequencing data, CCGG sites
within regions of the genome assigned to H3K4me3 and H3K27me3 binding sites were
reported, as well as sites common to both H3K4me3 and H3K27me3, termed bivalent
regions. Finally, CCGG sites within regions conserved across multiple species, termed 7x
regulatory potential regions, were also reported (Table 4.6).
4.2.3 Negative binomial analysis of DhmRs
A negative binomial distribution was applied to the RRHP data files using a
sliding window approach in the diffReps program [194]. Window size was set to 200
base pairs, with a slide of 20 bases, resulting in 3.29e08 windows analyzed. DiffReps
utilizes an initial uncorrected statistical cutoff of p < 1e-04 to define differential sites, that
resulted in 1.65e06 windows in our analysis. These windows were then corrected for
multiple comparisons using false discovery rate to produce adjusted p values.
Overlapping windows were combined and the best-adjusted p value assigned to the
combined window [194], resulting in 1.26e05 windows in our analysis. These windows
were then annotated to the hg19 genome using PERL script regionanlaysis.
Using the initial predefined cutoff, the estimated false positive rate for the
negative binomial test was reported as 0.2% by Shen et al. [194]. However, due to the
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small sample size in our analysis, a conservative adjusted p value (p ≤ 1e-04) was chosen
to further limit the risk of identifying potentially falsely identified significant windows.
This cutoff resulted in 43,112 windows or differentially hydroxymethylated regions
(DhmRs). Annotation of these windows using Ensembl gene IDs and Ensembl transcript
IDs by regionanalysis, including known splice variants of each gene, resulted in
duplication of some windows. To correct for this, repeated windows based on splice
variants were removed, resulting in 15,158 unique DhmRs. The 15,158 DhmRs were
sorted into increased or decreased levels of 5-hmC in LOAD compared to NC subjects.
For clarity, a schematic of the data processing involved in this analysis is shown in Figure
4.13.
4.2.4 Distribution of 5-hmC in DhmRs
Of the 15,158 DhmRs in LOAD subjects, the majority of these regions showed
increased levels of 5-hmC (64% overall) confined to intragenic locations, including
promoter, intron, and exon genomic regions, and intergenic regions (Figure 4.14).
Promoter regions included sites ± 3 kbp (kilobase pair) from the transcription start site of
a specified gene, while genebody regions included all sites between the promoter and 1
kbp from the transcription end site for the gene. Significantly increased DhmRs included
9,629 windows, while decreased levels of 5-hmC resulted in 5,529 windows passing the
conservative adjusted p value cutoff (FDR p ≤ 1e-04). Considering all sites with
significantly altered 5-hmC, 85% of sites were located in genomic regions assigned to
known genes (promoter and genebody regions). The genomic distribution of significant
DhmRs is shown in Figure 4.14. Intragenic DhmRs were assigned to annotated genes,
resulting in 5999 genes with altered hydroxymethylomes in the hippocampus of LOAD
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Figure 4.13 Workflow of RRHP data processing using diffReps. More than 3e08
windows were analyzed using a negative binomial distribution analysis and a sliding
window approach in the diffReps program to analyze RRHP count data. Using a
predefined uncorrected p value cutoff, windows were reduced to 1.65e06 and p values
were corrected using FDR. Overlapping windows were combined to reduce the total
window count to 1.26e05. A conservative adjusted p value (FDR p ≤ 1e-04) resulted in
43,112 windows retained. Duplicated windows based on splice variants were removed,
resulting in 15,158 unique windows or differentially hydroxymethylated regions
(DhmRs).
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Figure 4.14 Distribution of DhmRs. Distribution of the 15,158 DhmRs showed 64%
overall increased (white) levels of 5-hmC in LOAD compared to NC, while the
remaining 36% were decreased (gray). These sites were further characterized by genomic
locations of promoter, genebody (exons and introns), and intergenic regions, where 85%
of altered DhmRs were associated with known genes (promoter and genebody).
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compared to NC subjects using regionanalysis PERL script. Intergenic DhmRs were not
annotated with a gene name but location of site was labeled as “OtherIntergenic”,
“GeneDesert”, “Pericentromere”, or “Subtelomere” in diffReps output file. For
simplicity, all intergenic windows with significant adjusted p values were grouped as
“Increased Intergenic” or “Decreased Intergenic” in Figure 4.14.
4.2.5 Reactome FI Gene Network analysis
To correlate epigenetic modifications with altered expression, genes with DhmRs
were sorted according to a published microarray of altered hippocampal gene expression
in sporadic AD [59]. This filtered our initial list of 5999 to 329 genes with altered gene
expression and altered levels of 5-hmC. To determine the biological significance of this
list of genes in AD, Reactome FI was used to create a gene network of likely interactions
utilizing linker genes provided by Reactome FI [220, 221]. The curated network, using
322 of the 329 genes (Table 4.7), was organized into six clusters, or modules, and
pathway enrichment analysis was performed on each module excluding linker genes to
prevent bias and only report pathways relevant to list of target genes (Figure 4.15). The
322 target genes were shown as circles in Figure 4.15a, while linker genes were depicted
as diamonds.
Statistical significance was determined in RFI using a binomial test and p values
assigned to each enriched pathway. Only significant pathways with adjusted p values
(FDR p < 0.05) were retained. The six modules included in the curated network
contained genes relevant to signaling (blue), energy metabolism (red), cell cycle (purple),
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Table 4.7 Modules and genes from Reactome FI network analysis.

RFI Network Module

Gene List

Module 0: Signaling

ABL1, ABLIM1, ACTR2, ADCY2, APBA2, ARHGEF10, ARHGEF16,
C4B, CACNA1A, CDH10, CDH13, CDH4, CLIC2, CNTNAP2, CR1, CSK,
DGKG, DIAPH2, DLGAP1, ENAH, F2R, GAK, GNA12, GNA14, GNAL,
GNAO1, GNAS, GNAZ, GPR4, GRIA3, GRIN2A, GRM6, HTR2A,
IQGAP1, ITPK1, JPH3, KCNA6, KCNAB1, KCNAB2, KCNJ14, LRP1B,
LRP6, MADCAM1, MAP2K3, MYO1C, MYO1F, MYO9B, NFATC1,
NMB, PDE4C, PLCB1, PLCE1, PLCG2, PLCL2, PRKAR1B, PRKAR2B,
PTN, RAB22A, RALBP1, RALGDS, RAMP1, RANBP3, RTN1, SH3BP2,
SHANK2, STK11, TRPV1, ULK2, WNT7B

Module 1: Energy
Metabolism

AATK, ACAT1, ANK3, AP2B1, APC2, ATP1A2, ATP2B2, ATP5B, ATP5J,
ATP5J2, BAIAP3, BGN, CADPS, CAP2, CEPT1, CHST3, CSNK1E,
EDAR, EHD1, ELF2, EPS15, FEZ2, FOLH1, FRAT1, FYCO1, G6PD,
GHITM, GOSR2, GPM6B, HADHA, INSR, IRS2, ITPR1, KIF13B,
L1CAM, MGA, MKNK2, NDUFA10, NDUFA3, NDUFB3, NME4,
OGDH, PLXNA1, PLXNB2, POLRMT, QARS, RPS6KA1, SCAMP3,
SDHD, SEMA3B, SEMA3F, SLC12A7, SLC1A7, SLC25A12, SLC25A6,
SLC7A5, STK10, TCEAL1, TPD52, TUBG2, TYK2, UQCRC2, USP3,
UST, WFS1, ZNF142

Module 2: Cell Function

AK5, AKAP12, AMPD3, BIN1, BRD4, CAMKK2, CCND3, CEBPD,
CHD2, CLU, CPT1B, CREBBP, DAPK2, DAPK3, DRAP1, FADS1,
FGFR3, GDF1, HBA1, IL6R, IRF7, JUND, KCNN3, KLF1, LDLR,
LPIN1, LTBP2, MAGED1, MAPRE3, MTF1, NCOR2, NFIC, NOTCH4,
NPAS2, NPAS3, NR2F6, OGG1, OSBPL10, PKNOX2, PPP1R15A, RBL1,
RREB1, SH3GLB2, SPIB, SREBF1, SREBF2, SSBP1, STK24, TCF3,
TDG, TGFB1, THRA, TRIM26, UNG, WFDC1

Module 3: Gene
Expression

BANP, BCL7A, CCNA1, CDC5L, CDK7, COMT, CPSF1, CTBP1,
CTBP2, DDX27, DGCR6, FSTL1, GPI, H2AFX, HDAC4, LMNA, LZTS1,
MBD3, MPST, MTA1, MUC3A, MYT1L, NELL1, PAX6, PML, PRPF8,
PTBP1, PTRF, REC8, SIRT6, SIRT7, SLC19A1, SMARCA2, SNRPD2,
STAG2, SYN2, TCF7, TFAP2A, TLE3, VARS2

Module 4: Protein
degradation

AGPAT2, AMFR, ARIH2, BTRC, CDC34, CUL5, ENSA, FBXL2, FZR1,
GLI2, GMEB2, MGLL, NME3, ODC1, PER1, PLOD3, PPP2R2B,
PRDX3, PRL, PRPF4B, PSMA1, PSMD14, RNF11, SPTLC2, TIMM44,
TTC3, UBE3B, WWOX, ZIC1

Module 5: Cell Structure
and Stabilization

ACTN1, COL21A1, COL4A1, COL4A3, COL6A2, DAG1, DMD, FLNA,
FLNC, GPC5, GPR56, ITGB4, ITGB5, ITGB8, LIMK2, LRP8, MAFF,
MAFG, MAP2K7, MAP3K11, NDST1, NRXN1, PACSIN2, PAK4, RGS12,
SNTA1, SORBS1, TNXB, VWF
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Figure 4.15 Reactome FI network and significantly enriched pathways. Of the 329
genes with significantly altered gene expression [59] and DhmRs from RRHP analysis,
322 target genes (circles) and linker genes (diamonds) were used to curate a gene
network of likely interaction in the Reactome Functional Interaction (RFI) plugin app
from CytoScape (a). The network was clustered into six modules and pathway
enrichment within the modules was determined by a binomial test, excluding linker
genes, and p values were corrected for multiple comparisons using a permutation test to
calculate FDR p values (p < 0.05) (b). As described in the text, similar pathways were
grouped, including synapse signaling and neurodegenerative diseases, and the least
significant adjusted p value was retained (╪).
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gene expression (green), protein degradation (yellow), and cell structure and stabilization
(orange) pathways (Figure 4.15). Enriched pathways relevant to neurodegeneration,
specifically AD, are discussed below. For a complete list of significantly enriched
pathways and the full gene names of the 329 genes with altered 5-hmC and altered
expression in HPG of LOAD compared to NC subjects, please refer to Appendices B and
C.
The signaling module included enriched pathways of calcium signaling (adj. p =
2.23e-06), long-term depression (adj. p = 1.15e-05), Wnt signaling (adj. p = 3.89e-03), and
synapse signaling (adj. p = 7.59e-03). Pathways within the energy metabolism module
were TCA cycle and electron transport (adj. p = 1.53e-05), neurodegenerative diseases
(adj. p = 1.15e-04), cGMP-PKG signaling (adj. p = 7.72e-03) and axon guidance (adj. p =
1.19e-02). For the cell cycle module, enriched pathways included base excision repair, AP
site formation (adj. p = 5.56e-04), generic transcription (adj. p = 1.01e-02), NOTCH
signaling (adj. p = 2.26e-02), and endocytosis (adj. p = 4.92e-02). The gene expression
module contained significant pathways related to RNA Polymerase I and III and
mitochondrial transcription (adj. p = 7.4e-03) as well as processing of pre-mRNA (adj. p =
7.4e-03). Module 4, containing genes relevant to protein degradation, highlighted
pathways related to ubiquitin mediated proteolysis (adj. p = 9.68e-04) and degradation of
cell cycle proteins (adj. p = 2.50e-02). Finally, the cell structure and stabilization module
contained enriched pathways of focal adhesion (adj. p = 8.18e-12), extracellular matrix
organization (adj. p = 6.77e-10), regulation of actin cytoskeleton (adj. p = 2.4e-04) and
NCAM signaling for neurite outgrowth (adj. p = 1.43e-02).
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Similar genes were highlighted in several enriched pathways, including signaling
pathways for four types of neurons (serotonergic, dopaminergic, cholinergic, and
glutamatergic neurons) and three neurodegenerative diseases (Alzheimer’s disease,
Huntington’s disease, and Parkinson’s disease). These pathways were combined and the
least significant adjusted p value reported (denoted with ╪ in Figure 4.15).

4.3 Loci-specific levels of cytosine, 5-mC, and 5-hmC
4.3.1 Primer specificity and method validation
4.3.1.1 PS1 primers
Synthetic PS1 primers (Table 3.1) purchased from IDT were tested for specificity
using the PrimerBlast tool from NCBI. No hits for known products matching primer
sequences except for the designed targets were discovered. To test for the specificity of
primers against unknown products, each primer set was amplified using GoTaq Flexi
PCR master mix with human DNA and separated via SDS-PAGE gels using endpoint
PCR. Primer sets for exon 4, 9, and 12 showed no nonspecific product amplification
(Figure 4.16). As highlighted in Figure 4.16, the primer set for exon 1 showed
nonspecific amplification of a large amplicon near 700 bp and was excluded from
downstream analysis. While endpoint PCR showed no indication of primer-dimer
formation, a qPCR melt curve analysis was utilized to determine specificity of primer
pairs throughout the 0.2 – 150 ng DNA linear range (Figure 4.17). As depicted in melt
curves, no nonspecific product amplification was observed throughout the 0.2 – 150 ng
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Figure 4.16 PS1 primer specificity via endpoint PCR. PS1 exon primer pairs showed
amplification of target amplicon in expected bp range with no nonspecific amplification
and no primer-dimer formation in negative control lanes (left of labeled product) for
exons 4 site 1 (4_1), 4 site 2 (4_2), 9, 12 site 2 (12_2), and 12 site 3 (12_3). Exon 1,
however, showed non-specific amplification of large product near 450 bp.
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Figure 4.17 Melt curves of PS1 in qPCR optimization. Specificity of target
amplification was determined using melt curve analysis for exon 4 site 1 (A), exon 4 site
2 (B), exon 9 (C), exon 12 site 2 (D), and exon 12 site 3 (E) for PS1. As shown above, a
single peak for each analysis indicated specific amplification of target amplicon with no
primer-dimer formation. A shoulder peak was shown in the exon 4 site 2 melt curve (B),
likely indicating a low complexity region causing non-uniform melting.
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DNA curve. Over a concentration range of 0.2 – 150 ng of input DNA, a linear response
was observed for all primer pairs (Figure 4.18, 4.19, and 4.20). Endpoint PCR and melt
curve analyses showed specific target recognition for all PS1 primers, while response
curves showed linearity across a wide DNA range and acceptable reaction efficiencies for
all primer sets.
4.3.1.2 ABCA7 primers
ABCA7 synthetic primers (Table 3.1) were tested for specificity by analyzing
forward and reverse primer sequences in NCBI’s website tool PrimerBlast. Besides
intended target amplicon, no other product matched designed primer pairs. Endpoint PCR
was used to validate PrimerBlast results, showing no nonspecific amplification of
products other than targeted amplicons for ABCA7 exons 12, 18, 19, and 37 (Figure
4.21). Similar to PS1 primers, ABCA7 primers show specific amplification of target
sequence with the exception of primers for exon 14, where nonspecific amplification of a
large amplicon excluded exon 14 from further analysis. As described above, melt curves
were analyzed for ABCA7 primers to ensure specificity of primers for intended target
sequence (Figure 4.22). Response curves were analyzed over the same concentration
range (0.2 – 150 ng DNA) and showed linear responses and acceptable reaction
efficiencies for optimized primer concentrations (Figure 4.23, 4.24, 4.25, and 4.26).
Primer pair and DNA optimization using SYBR Green Fast Master mix and qPCR
resulted in linear response curves, reaction efficiencies between accepted 90-110% range,
and no primer-dimer formation in product melt curves or endpoint PCR analysis.
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Figure 4.18 PS1 exon 4 qPCR response curves. Over a concentration range of 0.2 –
150 ng of DNA, response curves for PS1 primers of exon 4 site 1 (a) and exon 4 site 2 (b)
showed linear responses (R2 < 0.9) and reaction efficiencies within acceptable range (90110%) at optimized primer pair concentrations. Data points represent mean ± SD (n=3).
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Figure 4.19 PS1 exon 9 qPCR response curve. Over a concentration range of 0.2 – 150
ng of DNA, the response curve for PS1 primers of exon 9 showed a linear response (R2 <
0.9) and reaction efficiency within acceptable range (90-110%) at optimized primer pair
concentrations. Data points represent mean ± SD (n=3).
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Figure 4.20 PS1 exon 12 qPCR response curves. Over a concentration range of 0.2 –
150 ng of DNA, response curves for PS1 primers of exon 12 site 2 (a) and exon 12 site 3
(b) showed linear responses (R2 < 0.9) and reaction efficiencies within acceptable range
(90-110%) at optimized primer pair concentrations. Data points represent mean ± SD
(n=3).
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Figure 4.21 ABCA7 primer specificity via endpoint PCR. ABCA7 exon primer pairs
showed amplification of target amplicon in expected bp range with no nonspecific
amplification and no primer-dimer formation in negative control lanes (left of labeled
product) for exons 12, 18, 19, and 37. Exon 14, however, showed non-specific
amplification of large product near 600 bp.
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Figure 4.22 Melt curves of ABCA7 in qPCR optimization. Specificity of target
amplification was determined using melt curve analysis for exon 12 (A), exon 18 (B),
exon 19 (C), and exon 37 (D) for ABCA7. As shown above, a single peak for each
analysis indicated specific amplification of target amplicon with no primer-dimer
formation.
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Figure 4.23 ABCA7 exon 12 qPCR response curve. Over a concentration range of 0.2
– 150 ng of DNA, the response curves for ABCA7 primers of exon 12 showed a linear
response and reaction efficiency within acceptable range (90-110%) at optimized primer
pair concentrations. Data points represent mean ± SD (n=3).
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Figure 4.24 ABCA7 exon 18 qPCR response curve. Over a concentration range of 0.2
– 150 ng of DNA, the response curves for ABCA7 primers of exon 18 showed a linear
response and reaction efficiency within acceptable range (90-110%) at optimized primer
pair concentrations. Data points represent mean ± SD (n=3).
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Figure 4.25 ABCA7 exon 19 qPCR response curve. Over a concentration range of 0.2
– 150 ng of DNA, the response curves for ABCA7 primers of exon 19 showed a linear
response and reaction efficiency within acceptable range (90-110%) at optimized primer
pair concentrations. Data points represent mean ± SD (n=3).
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Figure 4.26 ABCA7 exon 37 qPCR response curve. Over a concentration range of 0.2
– 150 ng of DNA, the response curves for ABCA7 primers of exon 37 showed a linear
response and reaction efficiency within acceptable range (90-110%) at optimized primer
pair concentrations. Data points represent mean ± SD (n=3).
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4.3.2 EpiMark kit validation
To determine efficiency of enzymes in the EpiMark 5-hmC and 5-mC Analysis
kit, characterized mouse DNA and primer sequences from NEB were requested and
tested against kit enzymes MspI and HpaII. NEB primer sequences (Forward primer:
TGTTTCCTTACCCTGAATGACTCCC, Reverse primer:
TTGCAACCCACACTATTCCCTTG) were specific for the mouse gene alpha-2macroglobulin receptor-associated protein precursor. Enzyme reactions were carried out
using NEB4 (New England Biolabs buffer 4), the buffer supplied in the EpiMark
quantification kit, as well as NEB’s new CutSmart® buffer. The use of CutSmart buffer
compared to NEB4 lead to enzyme stability and reproducible results (Figure 4.27) and
was used in place of NEB4.
4.3.3 Subject demographics analysis
To compare loci-specific levels of 5-mC and 5-hmC in SMTG throughout the
progression of AD, tissue specimens from NC, PCAD, MCI, and LOAD subjects were
obtained from the UK-ADC (Table 4.8). Statistical analysis of subject demographic
information showed no significant difference in age (p = 0.274, ANOVA), gender
distribution (p = 0.788, ANOVA on Ranks), or PMI (p = 0.655, ANOVA) between the
subject groups. Significant differences were detected in MMSE scores and Braak staging
scores compared to NC subjects using ANOVA on Ranks analyses. Braak staging scores
were significantly increased in PCAD and LOAD subjects compared to NC, as well as a
significant decrease in MMSE scores for LOAD compared to NC subjects according to
Dunn’s post-hot analyses (*p < 0.05).

127

Table 4.8 Subject demographic data for gene-specific qPCR study.
NC
(n=9)

PCAD
(n=7)

MCI
(n=10)

LOAD
(n=9)

Gender

4M / 5F

2M / 5F

3M / 8F

4M / 5F

Age (y)

84.1 ± 8.3

85.1 ± 7.1

89.5 ± 6.4

83.2 ± 8.5

PMI (h)

2.7 ± 1.0

3.0 ± 0.5

2.6 ± 0.5

2.6 ± 0.6

MMSE

29.5 [28 - 30]

30 [28 – 30]

28 [26 – 28]

16* [3 – 25]

Braak
Staging Score

II [I – II]

IV* [IV – V]

III [II – IV]

VI* [V – VI]

*p < 0.05
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Figure 4.27 EpiMark reaction buffer comparison. To determine the most effective
reaction buffer for restriction enzyme digestion experiments, NEB4 and CutSmart buffers
supplied by New England Biolabs were compared. Characterized mouse DNA was
supplied from New England Biolabs as well as forward and reverse primer sequences
used in EpiMark kit product development. Light blue bars indicate cleavage of CCGG
site (MspI) and 5-hmC modifications (MspI+T4βGT). Green bars indicate combined 5mC and 5-hmC modifications (HpaII and HpaII+T4βGT). Purple bars indicate total DNA
(no enzyme and only T4βGT). As shown above, CutSmart buffer yields better
reproducibility and stability of enzymes compared to NEB4.
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4.3.4 Quantification of SMTG levels
Extracted DNA samples from SMTG of NC, PCAD, MCI, and LOAD subjects
were treated with EpiMark kit restriction enzymes to analyze levels of cytosine, 5-mC,
and 5-hmC at target CCGG sequences within exons 4, 9, and 12 of PS1 and exons 12, 18,
19, and 37 of ABCA7. Initial DNA concentrations were determined from response curves
over an input range of 0.2 – 150 ng of DNA. A representative qPCR amplification plot
was shown in Figure 4.28, where Ct values for treated DNA, including MspI digested
DNA, glucose protected MspI digested DNA, and HpaII treated DNA, as well as
untreated DNA, were used to determine the percent of cytosine, 5-mC, and 5-hmC at
specific CCGG sequences within PS1 and ABCA7 exons. Percentages of each
modification were calculated based on total amount of DNA (no enzyme) and normalized
to MspI cutting efficiency (unprotected Msp1 digestion).
4.3.5 Statistical analysis - MANOVA
At each CCGG target sequence within the analyzed exons of PS1, three
dependent variables were measured; cytosine, 5-mC, and 5-hmC. For this reason, a
multivariate analysis was chosen, specifically, a multivariate analysis of variance
(MANOVA). The data met assumptions for MANOVA, including continuous data with
independent observations for dependent variables, included more than two independent
variables, showed no evidence of multicollinearity of the dependent variables via
regression analyses, contained no multivariate outliers based on Mahalanobis distances
and data showed homogeneity of covariance as tested by Levene’s test [222]. However,
multivariate normality criteria were not met, thus the more
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Figure 4.28 qPCR amplification plot of representative treated DNA sample. Utilizing
EpiMark restriction enzymes digestion protocol, cycle threshold values were used to
determine levels of 5-mC and 5-hmC at CCGG sequences of AD and NC subjects. One
untreated sample (a) and three treated DNA samples, including HpaII digested DNA (b),
glucose protected MspI digested DNA (c), and unprotected MspI digested DNA (d), were
used to determine total DNA (a), methylated and hydroxymethylated DNA (b), only
hydroxymethylated DNA (c), and MspI digestion efficiency (d) for each sample (blue
curves). Initial concentration of modifications in each reaction and qPCR reaction
efficiencies were determined using DNA response curves (red and yellow curves) over a
concentration range of 0.2 – 150 ng of DNA. Response curve concentrations were run in
triplicate, while treated and untreated DNA samples were run in duplicate.
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conservative multivariate test, Pillai-Trace, was used. Four MANOVA models were
tested for the exons of ABCA7 and five models for the exons of PS1.
To determine significant differences of cytosine, 5-mC, and 5-hmC percentages at
target sequences in exons of PS1 and ABCA7, MANOVA models were used to calculate
mean ± SE (% modification of CCGG) values for 5-hmC, 5-mC, and cytosine for each
subject group. In the event the multivariate analysis was significant, a test of between
subject effects was performed for each dependent variable using least square regression.
In the event the subject groups made a significant difference for each dependent variable
within the model, a pairwise comparison of least square differences between the subject
groups was performed.
4.3.5.1 PS1 Exon 4: Site 1
To determine levels of cytosine, 5-mC, and 5-hmC at site 1 of exon 4, mean ± SE
(% modification of CCGG) were compared using multivariate analysis model. The
MANOVA model was significant for the omnibus multivariate test (p < 0.001, Pillai’s
Trace) and a significant subject group effect within the model was shown for all three
dependent variables (5-hmC, p < 0.001; 5-mC, p < 0.001; cytosine, p < 0.05). However,
pairwise comparison of between subject effects did not produce a significant result for
cytosine, 5-mC, or 5-hmC. Mean cytosine levels of NC subjects were 4.31 ± 2.89 % and
were not statistically different from levels of 3.64 ± 3.19 % for PCAD, 7.19 ± 2.63 % for
MCI, or 4.70 ± 2.82 % for LOAD subjects according to pairwise comparison within
MANOVA model. Likewise, 5-mC levels were 33.64 ± 4.31 % for NC, and no
statistically significant difference was found for levels of 33.94 ± 4.77 % for PCAD,
31.65 ± 3.94 % for MCI, and 36.06 ± 4.21 % for LOAD subjects. Levels of 5-hmC were
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62.06 ± 3.71 % for NC subjects, 62.42 ± 4.11 % for PCAD, 61.16 ± 3.38 % for MCI, and
59.24 ± 3.62 % for LOAD and no significant differences were detected between levels of
5-hmC for any of the subject groups (Figure 4.29).
4.3.5.2 PS1 Exon 4: Site 2
To determine levels of cytosine, 5-mC, and 5-hmC at site 2 of exon 4, mean ± SE
(% modification of CCGG) were compared using multivariate analysis model. The
MANOVA model for exon 4: site two of PS1 was significant for the omnibus
multivariate test (p < 0.001, Pillai’s Trace) and a significant subject group effect within
the model was shown for all three dependent variables (p < 0.001). Pairwise comparison
of between subject effects for cytosine model yielded no significant differences between
the mean levels of 5.42 ± 2.38 % for NC, 7.81 ± 2.64 % for PCAD, 4.04 ± 2.17 % for
MCI, and 6.17 ± 2.33 % for LOAD subjects. However, trending towards significant
differences in mean levels of 5-mC of MCI compared to NC subjects was detected, where
decreased levels of 5-mC in MCI (33.76 ± 4.80 %) compared to 42.22 ± 5.26 % for NC
subjects (#p ≤ 0.1). Mean 5-mC levels of 29.91 ± 5.82 % for PCAD and 35.53 ± 5.13 %
for LOAD subjects, however, were not significantly different from NC subjects. Lastly,
5-hmC levels were 53.83 ± 4.58 % for NC subjects, 62.28 ± 5.07 % for PCAD, 62.20 ±
4.18 % for MCI, and 59.59 ± 4.47 % for LOAD subjects, but pairwise comparison
analyses showed no significant differences between 5-hmC levels of the subject groups
(Figure 4.30).
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Figure 4.29 SMTG cytosine modification levels in exon 4 site 1 of PS1. Estimated
mean ± SE (% modification) for 5-hmC, 5-mC, and cytosine levels via qPCR analysis.
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Figure 4.30 SMTG cytosine modification levels in exon 4 site 2 of PS1. Estimated
mean ± SE (% modification) for 5-hmC, 5-mC, and cytosine levels via qPCR analysis.
Trending towards significance shown compared to NC subjects (#p ≤ 0.1).
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4.3.5.3 PS1 Exon 9
To determine levels of cytosine, 5-mC, and 5-hmC of target sequence of exon 9,
mean ± SE (% modification of CCGG) were compared using multivariate analysis model.
The MANOVA model for exon 9 of PS1 was significant for the omnibus multivariate test
(p < 0.001, Pillai’s Trace) and a significant subject group effect within the model was
shown for all three dependent variables (p < 0.001). Pairwise comparison of cytosine
levels of 9.56 ± 2.72 % for NC, 9.96 ± 3.01 % for PCAD, 5.34 ± 2.48% for MCI, and
6.86 ± 2.65 % for LOAD subjects showed no statistically significant difference between
the subject groups. Likewise, analysis of 5-mC levels of 27.01 ± 5.64 % for NC, 30.76 ±
6.24 % for PCAD, 30.74 ± 5.15 % for MCI, and 34.44 ± 5.50 % for LOAD subjects in
the MANOVA pairwise comparison produced no significant difference between the
subject groups. Mean levels of 5-hmC were 63.87 ± 4.41 % for NC subjects, 59.29 ± 4.88
% for PCAD, 63.92 ± 4.02 % for MCI, and 59.71 ± 4.30 % for LOAD subjects and no
statistically significant difference was detected during pairwise comparison (Figure 4.31).
4.3.5.4 PS1 Exon 12: Site 2
To determine levels of cytosine, 5-mC, and 5-hmC at site 2 of exon 12, mean ±
SE (% modification of CCGG) were compared using multivariate analysis model. The
MANOVA model for exon 9 of PS1 was significant for the omnibus multivariate test (p
< 0.001, Pillai’s Trace) and a significant subject group effect within the model was
shown for all three dependent variables (p < 0.001). Mean ± SE cytosine levels were
21.42 ± 7.14 % for NC, 17.63 ± 7.90 % for PCAD, 23.94 ± 6.51 % for MCI, and 27.47 ±
6.96 % for LOAD subjects and were not significantly different from pairwise comparison
analysis. Likewise, 5-mC levels were 40.58 ± 6.56 % for NC, 44.54 ± 7.26 % for PCAD,
136

Figure 4.31 SMTG cytosine modification levels in exon 9 of PS1. Estimated mean ±
SE (% modification) for 5-hmC, 5-mC, and cytosine levels via qPCR analysis.
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36.24 ± 5.98 % for MCI, and 38.24 ± 6.40 % for LOAD subjects, while levels of 5-hmC
were 38.00 ± 7.57 % for NC subjects, 37.84 ± 8.37 % for PCAD, 39.82 ± 6.90 % for
MCI, and 34.30 ± 7.38 % for LOAD subjects. Pairwise comparison of 5-mC and 5-hmC
levels showed no statistically significant difference between groups for either dependent
variable at target sequence site 2 of exon 12 (Figure 4.32).
4.3.5.5 PS1 Exon 12: Site 3
To determine levels of cytosine, 5-mC, and 5-hmC at site 3 of exon 12, mean ±
SE (% modification of CCGG) were compared using multivariate analysis model. The
MANOVA model for exon 9 of PS1 was significant for the omnibus multivariate test (p
< 0.001, Pillai’s Trace) and a significant subject group effect within the model was
shown for all three dependent variables (p < 0.001). Pairwise comparison analysis of
each dependent variable showed no statistically significant difference in mean levels of
cytosine, 5-mC, or 5-hmC between the sets of subject groups. Mean levels of cytosine of
52.14 ± 5.81 % for NC, 53.73 ± 6.43 % for PCAD, 49.06 ± 5.30 % for MCI, and 57.54 ±
5.67 % for LOAD subjects were compared, yet no difference was detected between the
subject groups. Likewise, 5-mC levels were 27.88 ± 5.35 % for NC, 32.59 ± 5.92 % for
PCAD, 34.95 ± 4.88 % for MCI, and 25.94 ± 5.22 % for LOAD subjects, while levels of
5-hmC were 19.99 ± 3.90 % for NC subjects, 13.68 ± 4.32 % for PCAD, 15.99 ± 3.56 %
for MCI, and 16.53 ± 3.81 % for LOAD subjects and no difference between the means of
each subject groups were statistically significant for either 5-mC or 5-hmC models
(Figure 4.33).
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Figure 4.32 SMTG cytosine modification levels in exon 12 site 2 of PS1. Estimated
mean ± SE (% modification) for 5-hmC, 5-mC, and cytosine levels via qPCR analysis.
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Figure 4.33 SMTG cytosine modification levels in exon 12 site 3 of PS1. Estimated
mean ± SE (% modification) for 5-hmC, 5-mC, and cytosine levels via qPCR analysis.
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4.3.5.6 ABCA7 Exon 12
Similar to analyses of PS1 exons, levels of cytosine, 5-mC, and 5-hmC in exons
of ABCA7, mean ± SE (% modification of CCGG) were compared using multivariate
analysis model. The MANOVA model for exon 12 of ABCA7 was significant for the
omnibus multivariate test (p < 0.001, Pillai’s Trace) and a significant subject group effect
within the model was shown for all three dependent variables (5-hmC, p < 0.001; 5-mC,
p < 0.001; cytosine, p < 0.05). Pairwise comparison of cytosine levels of 2.28 ± 1.79 %
for NC, 1.35 ± 1.98 % for PCAD, 3.24 ± 1.56 % for MCI, and 4.18 ± 1.75 % for LOAD
subjects showed no significant difference between the subject groups. However,
statistically significant differences were detected in 5-mC levels of 56.20 ± 3.69 % for
MCI compared to 68.64 ± 4.14 % for LOAD subjects (*p < 0.05), while trending towards
significant differences were detected in 5-mC levels of MCI compared to mean levels of
65.25 ± 4.24 % for NC subjects (#p ≤ 0.1), but 5-mC levels of 64.10 ± 4.92 % for PCAD
subjects were not statistically significant between the subject groups. Lastly, levels of 5hmC of 34.55 ± 3.53 % for PCAD, 40.56 ± 2.78 % for MCI, or 30.98 ± 3.11 % for
LOAD compared to levels of 34.21 ± 2.98 % for NC subjects were not statistically
significant (Figure 4.34). Interestingly, there was a statistically significant increase in
MCI levels of 5-hmC compared to LOAD subjects in exon 12 of ABCA7 (*p < 0.05).
4.3.5.7 ABCA7 Exon 18
Levels of cytosine, 5-mC, and 5-hmC were analyzed in exon 18 of ABCA7 using
a multivariate analysis of variance statistical analysis. The MANOVA model for exon 18
was significant for the omnibus multivariate test (p < 0.001, Pillai’s Trace) and a
significant subject group effect within the model was shown for all three dependent
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Figure 4.34 SMTG cytosine modification levels in exon 12 of ABCA7. Estimated
mean ± SE (% modification) for 5-hmC, 5-mC, and cytosine levels via qPCR analysis.
Trending towards significance shown compared to NC subjects (#p ≤ 0.1).

142

variables (p < 0.001). Pairwise comparison of cytosine levels of 16.99 ± 3.90 % for NC,
7.80 ± 4.33 % for PCAD, 9.03 ± 3.40 % for MCI, and 13.19 ± 3.81 % for LOAD subjects
gave trending towards significant differences in MCI and PCAD levels compared to NC
(#p ≤ 0.1) (Figure 4.35). However, neither the 5-mC nor 5-hmC models gave statistically
significant pairwise comparisons between the subject groups. 5-mC levels were 60.72 ±
4.71 % for NC, 70.71 ± 5.22 % for PCAD, 64.89 ± 4.11 % for MCI, and 65.27 ± 4.60 %
for LOAD subjects, while levels of 5-hmC were 22.29 ± 3.00 % for NC subjects, 21.48 ±
3.32 % for PCAD, 26.09 ± 2.61% for MCI, and 21.54 ± 2.93 % for LOAD subjects
according to pairwise comparisons of multivariate analysis.
4.3.5.8 ABCA7 Exon 19
Levels of cytosine, 5-mC, and 5-hmC from qPCR analyses were analyzed using a
multivariate analysis. The MANOVA model for exon 19 of ABCA7 was significant for
the omnibus multivariate test (p < 0.001, Pillai’s Trace) and a significant subject group
effect within the model was shown for all three dependent variables (5-hmC, p < 0.001;
5-mC, p < 0.001; cytosine, p < 0.01). Pairwise comparisons of each dependent variable,
however, did not produce statistically significant results (Figure 4.31). Mean levels of
cytosine were 7.34 ± 2.16 % for NC, 4.92 ± 2.39 % for PCAD, 3.38 ± 1.88 % for MCI,
and 4.54 ± 2.11 % for LOAD subjects. Additionally, 5-mC levels were 46.28 ± 4.43 %
for NC, 50.57 ± 4.91% for PCAD, 44.19 ± 3.86 % for MCI, and 48.71 ± 4.33 % for
LOAD subjects, while levels of 5-hmC were 46.38 ± 4.09 % for NC subjects, 44.51 ±
4.53 % for PCAD, 52.52 ± 3.56 % for MCI, and 46.75 ± 3.99 % for LOAD subjects.
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Figure 4.35 SMTG cytosine modification levels in exon 18 of ABCA7. Estimated
mean ± SE (% modification) for 5-hmC, 5-mC, and cytosine levels via qPCR analysis.
Trending towards significance shown compared to NC subjects (#p ≤ 0.1).
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Figure 4.36 SMTG cytosine modification levels in exon 19 of ABCA7. Estimated
mean ± SE (% modification) for 5-hmC, 5-mC, and cytosine levels via qPCR analysis.
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4.3.5.9 ABCA7 Exon 37
Finally, levels of cytosine, 5-mC, and 5-hmC within target sequence of ABCA7
exon 37 were analyzed using a multivariate analysis. The MANOVA model for exon 37
of ABCA7 was significant for the omnibus multivariate test (p < 0.001, Pillai’s Trace)
and a significant subject group effect within the model was shown for all three dependent
variables (p < 0.001). Pairwise comparisons of cytosine levels of 20.02 ± 3.43 % for NC,
19.50 ± 3.80 % for PCAD, 14.73 ± 2.99 % for MCI, and 15.09 ± 3.35 % for LOAD
subjects produced no statistically significant differences between mean values of subject
groups. Likewise, no significant differences were shown between 5-mC levels of 67.01 ±
3.43 % for NC, 65.28 ± 3.80 % for PCAD, 67.72 ± 3.36 % for MCI, and 70.72 ± 3.35 %
for LOAD subjects. Pairwise comparison of 5-hmC levels gave trending towards
significant values for MCI compared to NC subjects, where an increase in 5-hmC was
shown between mean levels of 17.55 ± 1.54 % for MCI subjects compared to 12.98 ±
1.77 % for NC (#p ≤ 0.1) (Figure 4.37). Mean 5-hmC of 15.23 ± 1.96 % for PCAD and
14.20 ± 1.73 % for LOAD subjects were not significantly different from NC subjects.
4.3.6 Protein Expression
4.3.6.1 PS1 protein
To determine whether significant alterations of epigenetic changes within exons
correlated to fluctuations in gene expression, SMTG levels of PS1 protein from NC,
PCAD, MCI, and LOAD subjects were analyzed via band density measurements of
protein bands separated via electrophoresis and polyacrylamide gel separation of Western
blot protocol. Normalized to the reference protein GAPDH, PS1 expression was
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Figure 4.37 SMTG cytosine modification levels in exon 37 of ABCA7. Estimated
mean ± SE (% modification) for 5-hmC, 5-mC, and cytosine levels via qPCR analysis.
Trending towards significance shown compared to NC subjects (#p ≤ 0.1).
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calculated as percent of NC were mean ± SE was 100.00 ± 6.19 % for NC, 107.47 ± 8.56
% for PCAD, 119.50 ± 5.50 % for MCI, and 97.44 ± 3.34 % for LOAD. To determine
statistically significant differences between the subject groups compared to NC subjects,
ANOVA was utilized. The omnibus test was significant (p < 0.05) and a Holm-Sidak
post-hoc analysis was performed. Statistically significant differences were observed for
MCI compared to NC subjects, were PS1 protein levels were elevated in MCI subjects
(*p < 0.05) (Figure 4.38).
4.3.6.2 ABCA7 protein
To determine whether significant alterations of epigenetic changes within exons
correlated to fluctuations in gene expression, SMTG levels of ABCA7 protein from NC,
PCAD, MCI, and LOAD subjects were analyzed via band density measurements.
Normalized to a the reference protein GAPDH, ABCA7 expression was calculated as
percent of NC to give values of 100.00 ± 6.18 % for NC, 110.35 ± 7.16 % for PCAD,
97.29 ± 8.18 % for MCI, and 60.59 ± 10.60 % for LOAD. To determine statistically
significant differences between the subject groups compared to NC subjects, ANOVA
was used and significant across the subject groups (*p < 0.05). Protein levels of ABCA7
were significantly decreased in LOAD subjects compared to NC via post-hoc HolmSidak test (*p < 0.05) (Figure 4.39).
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Figure 4.38 PS1 protein expression in SMTG. Representative Western blot of PS1 (Nterminal fragment) and GAPDH (a). Mean ± SE (% NC) of PS1 protein in SMTG of NC,
PCAD, MCI, and LOAD subjects (b). PS1 expression was normalized to GAPDH protein
and reported as percent of NC. Statistical significance was determined using ANOVA
and Holm-Sidak post-hoc analysis (*p < 0.05).
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Figure 4.39 SMTG protein expression of ABCA7. Representative Western blot of
ABCA7 and GAPDH proteins (a). Mean ± SE (% of NC) of ABCA7 protein in SMTG of
NC, PCAD, MCI, and LOAD subjects (b). ABCA7 expression was normalized to
GAPDH and reported as percent of NC. Statistical significance was determined using
ANOVA and Holm-Sidak post-hoc analysis (*p < 0.05).
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CHAPTER 5: DISCUSSION
Alzheimer’s disease is the sixth leading cause of death in the United States, and
the only disease in the list of top ten causes of death with no therapeutic option or means
of halting or slowing progression of the disease [13]. While the discovery of inherited
genetic mutations in the rare familial form have advanced the understanding of how
characteristic pathologic lesions, including amyloid-beta plaques, form in susceptible
brain regions [9, 14, 15], decades of research have yet to lead to a therapeutic treatment
option for AD patients [46]. Development of the disease in the sporadic form may be
causal to micro-environmental influences, where deregulation of gene expression
mechanisms within brain cells lead to lesion development and disease progression [55].
Analysis of post-mortem tissue of sporadic AD subjects showed alterations in
transcription in brain regions susceptible to pathologic lesion development, even in
preclinical stages of AD [58-60, 62, 68].
Epigenetic regulation of gene expression by cytosine methylation has been
associated with gene silencing mechanisms in normal cellular function and disease
studies [134, 144, 145] as shown through bisulfite conversion sequencing techniques
[123, 124]. However, with the recent discovery of oxidized derivatives of 5-mC in
mammalian genomes [113, 114, 117], particularly 5-hmC, the role of cytosine
modification in regulating transcription again became unclear, partially due to the
seemingly opposing roles 5-mC and 5-hmC in regulating transcription [121, 144, 145].
Another complication in elucidating the role 5-mC and 5-hmC may play in regulating
gene expression comes from the discovery that bisulfite conversion does not distinguish
between these two modifications [125], where previously reported levels of 5-mC were
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better described as cytosine modifications. Levels of 5-hmC, the most abundant 5-mC
derivative, remain relatively low throughout tissue and cell types, although some studies
reported as high as 40% of all 5-mC in the brain as hydroxymethylated [149, 153].
Interest in DNA methylation and derivatives of 5-mC as a possible means of
transcription regulation in neurodegenerative diseases, specifically AD, seems probable
for several reasons. In blood and tissue samples of AD patients, increased levels of
homocysteine and deregulation of SAM/SAH ratios in the methionine cycle (Figure 1.4)
were detected [161-163], likely altering DNA methylation states in AD subjects.
Furthermore, mammalian levels of 5-hmC were the most abundant in brain cells
compared to other organs and cell types [149, 153]. Finally, due to the non-replicative
nature of neurons, means of quickly responding to influences of the microenvironment
surrounding neurons via regulating gene expression gives credence to the suggested role
cytosine modifications play in the brain, particularly in neurodegenerative diseases.
In order to determine whether epigenetic modifications to cytosine are
deregulated in AD, it was the aim of this dissertation to quantify levels of cytosine, 5-mC,
and 5-hmC in post-mortem brain tissues of AD subjects compared to normal controls at
the global and gene-specific levels. The global study of cytosine, 5-mC, and 5-hmC in
multiple brain regions at early and late stages of AD progression would confirm
differences in epigenetic landscapes in AD compared to NC, as well as provide
epigenetically altered brain regions for further study. The genome-wide study of 5-hmC
levels in the hippocampus of late stage AD compared to NC subjects would identify
biological pathways with gene-specific altered hydroxymethylomes relevant to AD and
neurodegeneration. Additionally, the loci-specific quantification of cytosine
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modifications within exons of target genes in the temporal lobe would show site specific
alterations in cytosine, 5-mC, and 5-hmC in early and late stages of AD progression.

5.1 Global levels of 5-mC and 5-hmC are altered in early stages of disease
progression in AD
Initial findings regarding the role global levels of epigenetic modifications play in
sporadic AD were controversial [173-176, 178]. Some studies showed an increase in 5mC and/or 5-hmC [175-177], others showed an overall decrease of modifications [173,
178], while one study showed no changes in AD compared to NC subjects. Variations in
immunochemical techniques, tissue processing procedures, and semi-quantitative
analyses across the studies, as well as the use of a single brain region in several of the
studies, likely led to the inconsistent findings and leave the question unanswered: are
epigenetic modifications to DNA altered in sporadic AD? To answer this question, a
specific quantitative study was essential to determine whether 5-mC and 5-hmC levels
were altered in brain regions relevant to AD.
Pairing GC/MS and stable isotope labeled cytosine bases, a sensitive and selective
method to analyze cytosine, 5-mC, and 5-hmC was validated using temperature
programmed peak separation (Figure 2.3), linear standard curve analyses (Figure 4.4, 4.5,
and 4.6), and limit of quantification calculations (Results 4.1.1). Quantification of
cytosine, 5-mC, and 5-hmC from four brain regions (HPG, SMTG, IPL, and CER) in
early (PCAD and MCI) and late (LOAD) stages of AD progression were compared to
age-matched NC subjects, as well as disease control subjects (FTLD/DLB). To determine
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statistically significant differences between mean levels of each epigenetic mark,
repeated measures analyses were used.
As this study verified, epigenetic modifications to cytosine were globally altered
in early stages of disease progression throughout the brain, as well as in other forms of
neurodegenerative diseases, including FTLD and DLB. While both PCAD and MCI
subjects showed a statistically significant increase in global levels of 5-hmC compared to
NC subjects (Figure 4.10), this also correlated to a significant decrease in cytosine levels
for MCI subjects compared to NC (Figure 4.8). While no statistically significant
differences were observed for LOAD subjects in the cytosine, 5-mC, or 5-hmC models
compared to NC levels, a marginally significant increase in 5-mC (p = 0.053) was
observed (Figure 4.9). All models showed significant differences for FTLD/DLB
subjects, where both cytosine and 5-mC were significantly decreased and global 5-hmC
levels were significantly increased compared to NC subjects. These findings were in
agreement with current literature suggesting alterations of epigenetic mechanisms are
relevant to dementia, neurological psychosis, and genetic diseases leading to neurological
disorders [223-228].
Compared to LOAD, epigenetic marks in PCAD and MCI subjects showed
increased levels of 5-hmC and decreased global levels of cytosine and 5-mC. This
suggests that alterations to epigenetic mechanisms affect early stages of AD progression
and return to basal conditions in the later stage of disease. While 5-mC and 5-hmC may
play a role in the earliest stages of disease progression, alterations in epigenetic marks
seem to have less of a global impact on the brain after rampant cell death and
neurodegeneration observed in late stage disease.
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As Figure 4.11 and Figure 4.12 showed, levels of 5-mC and 5-hmC varied across
brain regions for NC, PCAD, MCI, and LOAD subjects. Interestingly, brain regions
susceptible to AD pathology later in disease progression (SMTG and IPL) showed
increased levels of 5-mC and 5-hmC compared to one of the earliest affected brain
regions (HPG). In brain regions susceptible to deposition of pathologic lesions (HPG,
SMTG, and IPL), levels of 5-mC and 5-hmC were significantly decreased compared to a
typically non-vulnerable region (CER). In agreement with current studies [180, 229],
human cerebellum levels of 5-mC and 5-hmC were elevated compared to other brain
regions. However, these alterations may reflect variations in cell type distributions
between the brain regions analyzed. While levels of 5-mC and 5-hmC varied across brain
regions and were significantly decreased in AD-pathologic susceptible regions compared
to a non-vulnerable region, the biological significance of these results is unclear.
Typically, an overall increase in 5-mC was associated with gene silencing, while
hydroxymethylation was shown to have the opposite effect, where increases in 5-hmC
were associated with gene activation. However, it has been suggested that regulation of
transcription may depend more on site-specific alterations rather than global measures
[144, 146, 147, 151, 230]. Several studies showed rampant deregulation of transcription
in post-mortem tissue analyses of AD compared to NC subjects, as well as in AD animal
models [59-61, 63-68]. In a microarray study of expression profiles in the medial frontal
gyrus of subjects with varying degrees of AD pathology (Braak staging scores 0-VI), an
increase in expression of synaptic activity and plasticity genes were associated with early
stages of NFT development (i.e. low Braak staging scores), although as pathology burden
increased, expression levels of these genes decreased [58]. While the regulation of genes
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at various stages of disease progression in AD could be linked to the deregulation of
epigenetic marks described in our study, more research is needed to understand these
multifaceted mechanisms.
As age is the most significant risk factor for development of AD, it is no surprise
that genes relevant to aging mechanisms have altered transcription [231-234]. While it
was argued that epigenetic alterations in neurodegenerative diseases were likely due to
aging or epigenetic drift, our data clearly demonstrated that epigenetic alterations were
specific to neurodegeneration, including AD and FTLD/DLB dementias, as data were
controlled for age in repeated measures analyses and NC subjects were age-matched with
no significant difference detected between mean ages of subject groups (Table 4.2).
While age associated epigenetic changes are likely more relevant to individual subject
variability, this would only be detectable in longitudinal studies of living patients, where
analytes could be measured in the same subject across the time-span of the study.
However, this type of analysis would be impossible for brain tissue studies and limited to
bodily fluid samples (i.e. blood, urine, or CSF).
As described above, our data confirmed significant alterations in global levels of
epigenetic modifications to cytosine in post-mortem tissue of several types of
neurodegenerative diseases, including AD. These changes were more associated with
early stages of AD development rather than late stage AD. This study also describes an
overall decrease in levels of 5-mC and 5-hmC in brain regions susceptible to AD
pathologic lesions, including the hippocampus and temporal lobe, compared to a brain
region typically considered non-vulnerable to the development of pathologic lesions, the
cerebellum. In addition, while age associated epigenetic drift may play a role in
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alterations to 5-mC and 5-hmC, significant differences shown in our study were corrected
for age, and were neurodegenerative disease specific, including AD and FTLD/DLB
subjects. While previous literature showed epigenetic marks varied across cell types and
brain regions, to our knowledge, no study has used a selective and quantitative technique
to analyze levels of 5-mC and 5-hmC in multiple brain regions of PCAD, MCI, and
LOAD compared to NC subjects.
While this study determined alterations in global levels of 5-mC and 5-hmC in
neurodegenerative diseases compared to normal control subjects, it provided no
information as to biological pathways or genes epigenetically altered in
neurodegeneration, specifically pathways and genes that may be relevant to the
pathogenesis of AD. In the following sections, however, two gene-specific studies will
discuss pathways and loci-specific alterations of epigenetic marks in AD.

5.2 Genome-wide levels of 5-hmC are altered in hippocampus of LOAD
subjects
While bisulfite sequencing techniques allowed researchers to study 5-mC over the
past several decades, the discovery of oxidized derivatives of 5-mC, namely 5-hmC, have
again clouded the role epigenetic modifications play in regulating gene expression in
normal cellular function and in disease, specifically in the brain. In AD, three studies
using bisulfite conversion of 5-mC to sequence regions of altered methylation within
genomes of AD subjects compared to NC provided gene targets that may be
epigenetically regulated in AD within the prefrontal cortex [175, 182, 183]. As discussed
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previously, bisulfite conversion does not distinguish between 5-mC and 5-hmC [125], so
the term “methylation” should be considered as “cytosine modification” to incorporate
the underrepresentation of 5-hmC in these studies. Given the high concentrations of 5hmC in mammalian brain cells and the opposing roles 5-mC and 5-hmC have in
regulating transcription, specific analysis of genome-wide hydroxymethylation is
essential to elucidating biologically relevant pathways epigenetically regulated in AD.
With the advancement of sequencing techniques able to distinguish 5-mC from 5hmC, a sensitive single-base resolution mapping of hydroxymethylation modifications
was utilized to evaluate sites of altered 5-hmC in the hippocampus of LOAD subjects
compared to NC. Fragmentation of DNA using 5-hmC specific restriction endonuclease
enzymes paired with the deep sequencing capability of the Illumina platform allowed for
more than 2 million sites of potential 5-hmC modifications to be identified. Statistically
significant sites of hydroxymethylation were mapped to a gene interaction network using
freely available software to determine biologically relevant pathways with altered
hippocampal levels of 5-hmC in late stage AD.
Using a negative binomial distribution analysis, differentially hydroxymethylated
genomic regions were analyzed and annotated to the human genome. Of the sites
analyzed by the RRHP analysis, more than 15,000 regions were significantly altered in
LOAD subjects compared to NC, mapping to more than five thousand genes. Distribution
of the statistically significant sites, or differentially hydroxymethylated regions (DhmRs),
showed an overall increase (64 %) in 5-hmC in LOAD subjects, including 9,629 DhmRs,
where the remaining 5,529 sites showed decreased levels of 5-hmC in the hippocampus
of LOAD compared to NC subjects (Figure 4.14).
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Interestingly, eighty-five percent of the altered sites were confined to genomic
regions associated with known reference genes, including sites assigned to promoter and
genebody locations. Since alterations in hydroxymethylation within gene-associated
genomic locations correlated to altered transcription and gene expression [230], sites
were filtered based on a previously published microarray of hippocampal gene expression
in AD [59]. This study in particular was used due to the similarities in diagnosis criteria
of late stage AD and NC subjects as well as similar PMI time frames used by the UKADC. After filtering the statistically significant DhmRs with Blalock et al.’s list of
differentially expressed genes, 329 genes with significantly altered levels of 5-hmC and
changes in gene expression in the hippocampus of LOAD compared to NC subjects
remained.
To determine biologically meaningful pathways that may be relevant to AD
progression, the 329 target genes were used to curate a gene network of likely
interactions using Reactome’s Functional Interaction (RFI) network builder from
Cytoscape®. Of the 329 genes from our analysis, 322 genes were used to create the gene
network while the remaining seven genes were unrecognized by RFI and excluded from
the network build. Network genes involved in similar pathways were grouped into six
modules (Figure 4.15a) and pathway enrichment showed modules were related to
signaling, energy metabolism, cell cycle, gene expression, protein degradation, and cell
structure and stabilization pathways (Figure 4.15b). Relevance to AD and
neurodegeneration of significantly enriched pathways within these modules, as well
specific genes identified in our analysis within the pathways, will be discussed below.
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Several genes within significantly enriched pathways in the signaling and cell
cycle modules were also implicated as genes of interest that may play a role in the
pathophysiology of sporadic AD. These genes included bridging integrator 1 (BIN1),
clusterin (CLU), and compliment receptor 1 (CR1). These genes, involved in immune
function, lipid processing, endocytosis, and clearances mechanisms [73], were also
reported as target genes in genome-wide methylation mapping studies [183, 235, 236] as
well as in genome-wide association studies of single nucleotide polymorphisms (SNPs)
relevant to sporadic AD [71, 237]. Additionally, DLGAP1 (discs large associated protein
1), a postsynaptic density regulator, was also suggested as a gene of interest in a smaller
genome-wide association study of SNPs relevant to sporadic AD, although not as
strongly associated as BIN1, CLU, and CR1 [238].
Common to most neurodegenerative diseases and neuropsychological disorders,
the deregulation of cellular signaling, predominantly at the synapse, leads to adverse
effects. Alterations in levels of adenylate cyclase (ADCY2, ADCY3, ADCY7, ADCY9),
G proteins (GNAO1, GNA14, GNAL, GNAS, GNAZ, GNB1), and phospholipase C
(PLCB1, PLCE1, PLCG2) protein families within synaptic and calcium signaling
cascades alters mechanisms of exocytosis, long-term depression, and gene expression in
neurons according to curated KEGG pathways. Specific ion channel regulators, including
genes regulating calcium (CACNA1), potassium (KCNJ14, KCNQ2, KCNA6), and
sodium (GRIA3) ion channels, fell within significantly enriched signaling pathways
according to our analysis. Of these genes, KCNA6, the potassium voltage-gated channel
subfamily A member 6 gene, was identified as a hub gene in a recent 5-hmC mapping
study of the prefrontal cortex of AD subjects [239], and was suggested to play a role in
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neurotransmitter release and insulin secretion [240]. Additionally, several genes
highlighted in the synaptic signaling pathway (including cholinergic, dopaminergic,
glutamatergic, and serotonergic neurons) of our enrichment analysis were also gene
targets in other neurodegenerative and neuropsychological disorder studies, including
SH3 and multiple ankyrin repeat domains 2 (SHANK2) and 5-hydroxytryptamine
receptor 2A (HTR2A). SHANK2 levels were elevated in AD subjects, likely from
destruction of the Shank-postsynaptic platform enhanced by glutamate receptor
dysfunction, ultimately contributing to synapse loss in AD [241]. Loss of HTR2A
receptors in AD brain correlated to decreased cognitive performance [242], while
epigenetic dysregulation of HTR2A was associated with early onset schizophrenia and
bipolar disorder [243].
Critical cellular processes, including adhesion, survival, proliferation,
differentiation, and apoptotic pathways utilize Wnt signaling genes [244, 245]. Due to the
crucial role Wnt pathways play in healthy cellular homeostasis, it is not surprising that
many genes involved in this pathway were implicated in AD. Alterations to Wnt
signaling pathways deregulated synaptic development and were suggested to play a role
in the progression of AD [246]. As one of the susceptibility gene identified for sporadic
AD from SNP studies discussed previously, CLU was shown to regulate Aβ toxicity via
the non-canonical Wnt/phospholipase C pathway, as well as contributed to tau
phosphorylation and cognitive decline [247]. Downregulation of WNT7B in an APP/PS1
transgenic mouse model of AD was associated with synapse organization [248, 249], as
well as altered expression of hippocampal WNT7B in AD subjects [250]. Finally, genetic
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variations in LRP6 (LDL receptor related protein 6) were associated with APOE-ε4 allele
and increased risk of developing sporadic AD [251].
Properly regulated energy mechanisms are essential to cellular function which is
why deregulation of energy metabolism processing and mitochondrial function are major
hallmarks of neurodegenerative diseases, including AD, Huntington’s disease, and
Parkinson’s disease [252]. Key mechanisms, including electron transport chain processes,
regulation of insulin signaling pathways, as well as the TCA cycle, are essential to the
production of energy needed for healthy cellular function and maintaining homeostasis.
Decreased expression of OGDH (oxoglutarate dehydrogenase), a TCA cycle regulator,
was observed in brain regions of AD subjects as well as in a mouse model of AD
pathology [253, 254]. Genes heavily involved in the electron transport chain, i.e.
mitochondrial complexes I-V, had altered gene expression across several neurological
dysfunction disorders, including NADH dehydrogenases (NDUFA3, NDUFA10,
NDUFB3), ATP synthases (ATP5J and ATP5B), succinate dehydrogenase (SDSH), and
ubiquinol-cytochrome c reductase (UQCRC2) [68, 255, 256]. Several insulin regulator
genes, including INSR (insulin receptor) and IRS2 (insulin receptor substrate 2),
necessary for synaptic plasticity and learning [257], also recruited GABA receptors to
postsynaptic sites and controlled neurotransmitter release/uptake in glutamate receptors
[258]. Although no conclusive studies have provided a link between AD and diabetes,
insulin regulated pathways overlapping between the two diseases suggests a potential role
in energy metabolism dysfunction and neurodegeneration [259].
In addition to providing energy for cellular processes, energy metabolism
pathways regulate axon guidance and development, as well as neuron stabilization where
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deregulation of energy mechanisms adversely affects neuronal function. Several axon
guidance regulators, including a family of axon guidance cues termed plexins and
semaphorins, are upstream of tau phosphorylation pathways, and when deregulated, led
to microtubule destabilization [260]. As an activator of Rho-GTPase pathways, PLXNB2
was suggested to deregulate dendrite formation and maintenance [261], while genes of
the SEMA3 family, including SEMA3B and SEMA3F, facilitated repulsive and attractive
guidance mechanisms [262]. In a mouse model of AD, Aβ plaques disrupted the
formation of axon initial segments, which require the scaffolding protein ANK3 (ankryin
3 or ankryin G), ultimately reducing axon lengths and overall excitability of neurons
[263].
Cell cycle mechanisms ensure proper timing of cellular events and processes
through a series of checkpoints to maintain healthy cellular function. Alterations to these
mechanisms and cell function pathways are key characteristics of many diseases,
including neurodegeneration and cancer [264, 265]. Some of these deregulated pathways
include endocytosis, base excision repair (BER), NOTCH signaling, gene expression, and
transcription. Oxidative damage to DNA and deregulated BER mechanisms are
established features of neurodegeneration, including early stages in the progression of
AD [52-54, 266]. Genes involved in BER processes, including OGG1 (8-oxoguanine
glycosylase), TDG (thyamine dehydrogenase), and UNG (uracil-DNA glycosylase),
showed decreased expression throughout the progression of AD [54, 267], as well as
regulated epigenetic modifications to cytosine in the TET demethylation pathway [268].
Genes involved in endocytosis processes, a mechanism of active transport of extracellular
substances brought into the cell, including TGFB1 and FGFR3, showed altered levels of
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expression in an AD mouse model [248, 249, 269], while levels of TGFB1 were also
elevated in CSF samples of clinically diagnosed probable AD patients [270]. As
discussed previously, BIN1 was recently identified as a possible risk gene of sporadic
AD, but studies also showed elevated expression of BIN1 [271] which may play a role in
tau pathology development in AD [73].
Along with DNA damage repair and trafficking mechanisms, cell cycle pathways
also play a role in signaling and gene expression. Signaling cascades involving NOTCH
regulate presenilin proteins and likely contribute to amyloid production and plaque
formation. In a northern Israeli population, where an atypically high prevalence of
sporadic AD occurs, SNPs in NOTCH4 were associated with sporadic AD [272].
Alterations in transcriptional regulatory genes, including NCOR2, TCF3, CREBBP, and
NR2F6, showed adverse effects in neurodegenerative disease studies. In AD brain,
NCOR2 affected memory formation [273], while hippocampal levels of TCF3 expression
were increased [250]. Deficits in early memory and learning were associated with altered
expression of CREBBP and NR2F6 in an animal model of AD [274], as well as lead to
neuronal apoptosis [275]. While CDK7 is a component of the transcription factor
complex activating RNA polymerase II as well as a cell cycle regulator, expression was
increased in the hippocampus of AD subjects [276]. Mechanisms involving RNA
polymerase also affect splicing pathway genes, including PTBP1, PRPF8, and CDC5L,
where deregulation of these genes altered cell proliferation, neuron differentiation
pathways, and repressed pre-mRNA splicing mechanisms [277, 278].
Disruption of clearance mechanisms and pathways involved in protein
degradation, including the ubiquitin-proteasome system, lead to accumulation of
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aggregate-prone proteins within the cell, ultimately contributing to cell loss and
neurodegeneration, however the exact mechanism is not well understood [279, 280].
While ubiquitination of proteins was associated with protein degradation, it was also
shown to be an essential pathway for DNA repair, endocytosis, signaling, and trafficking
mechanisms [281-283]. Compared to cognitively normal subjects, the proteasome protein
PSMA1 was decreased in serum of mild cognitive impairment and probable AD subjects
[284]. In addition, regulatory genes BTRC and FZR1, involved in ubiquitination
mechanisms, also regulate Wnt signaling pathways. Levels of phosphorylated β-catenin
were regulated by BTRC [285] and increased phosphorylated β-catenein lead to
proteasome dysfunction [286].
Lastly, the sixth module highlighted by enrichment analysis of epigenetically and
transcriptionally deregulated genes in sporadic AD was related to cell structure and
stabilization. Focal adhesions form between the actin cytoskeleton and membrane
receptors within cells. By utilizing signaling mechanisms, focal adhesions reorganize the
actin cytoskeleton as well as regulate gene expression by growth factor mediated
signaling [287]. Upstream of actin polymerization and Wnt pathways, collagen proteins
(COL4A1, COL4A3, COL6A2) and integrin receptors (ITGB4, ITGB5, ITGB8) also
regulate extracellular matrix organization mechanisms. The phosphorylation of p21
activated protein kinase 4 (PAK4) resulted in the dephosphorylation of slingshot protein,
which led to the activation of cofilin, an actin severing protein, ultimately causing actin
filament turnover [288]. In contrast, phosphorylation of LIM domain kinase proteins,
including LIMK2, inactivated cofilin via phosphorylation and allowed for actin
cytoskeleton reorganization [289]. In AD, current studies showed deregulation of cofilin
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led to alterations in cytoskeleton maintenance and organization [290]. In addition to actin
regulatory mechanisms, deregulation of neurexins and neuroligins led to alterations in
dendritic spine morphology and NRXN1, a presynaptic ligand and component of the
synaptic regulatory pathway, was linked to autism in a recent study [291-293].
While this study was the first, to our knowledge, to analyze genome-wide 5-hmC
levels in the hippocampus of sporadic AD subjects compared to NC, similar genomewide studies of AD post-mortem tissue showed related trends, where the majority of
alterations showed increased levels of 5-hmC, although analysis techniques (single-base
resolution mapping and 5-hmC enrichment analyses) and brain regions (hippocampus and
prefrontal cortex) differed between the studies [239, 294]. Common to all three analyses,
MYT1L (myelin transcription factor 1-like) showed altered 5-hmC levels in AD
compared to NC subjects. While the function of MYT1L in AD has yet to be determined,
one study used MYT1L to produce induced neuronal cells and described the gene as a
neuronal fate-inducing factor [295].
While global levels of epigenetic modifications were altered in neurodegenerative
disease subjects compared to NC using the GC/MS quantitative analysis described
previously, no information about potential pathways specifically relevant to AD could be
inferred. However, using a sensitive and selective 5-hmC mapping technique, altered
hydroxymethylomes of LOAD subjects compared to NC were analyzed, and significantly
altered levels of 5-hmC within genes with altered expression levels were mapped to
pathways involved in signaling, energy metabolism, cell cycle mechanisms, gene
expression, protein degradation, and cell structure and stabilization. Many target genes
within these pathways were previously reported as genes of interest in neurodegenerative
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disease studies as well as in studies of neuropsychological disorders. Epigenetic
modifications to cytosine likely alter transcriptional states in these pathways in AD,
leading to deregulated gene expression and may play a role in the pathogenesis of the
disease.
While small sample sizes were a limitation of this study, it did provide gene
targets to further characterize epigenetic modifications in AD using larger sample sizes.
In the final section of this chapter, results of the qPCR and restriction endonuclease
digestion study analyzing levels of 5-mC and 5-hmC at specific sequences within the
exons of two genes relevant to sporadic AD will be discussed.

5.3 Altered sites of 5-mC and 5-hmC in exons of PS1 and ABCA7 in early
stages of AD
While sequencing technologies have advanced steadily, especially in analyses
able to distinguish 5-mC from 5-hmC like RRHP previously described, costs remain
high. Since studies of human diseases require biological replicates for statistical analyses
to draw meaningful conclusions, the use of currently available deep sequencing analyses
are not ideal for larger subject group studies. In order to analyze gene-specific epigenetic
modifications to DNA using multiple replicates, qPCR paired with specific restriction
endonuclease digestion was used to analyze levels of cytosine, 5-mC, and 5-hmC within
exons of two genes relevant to sporadic AD, PS1 and ABCA7. Both genes were shown to
have altered expression in AD studies, as discussed below. While qPCR analyses were
limited to one target amplicon for each reaction, analysis of single sites at several stages
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of AD progression compared to NC subjects allowed for identification of possible targets
of epigenetic regulation that may play role in the deregulation of transcription in AD.
Mutations in PS1 are linked to the development of familial AD [14, 15], however
various studies suggested alteration in this gene may play a role in the sporadic form of
the disease as well. In a study of sporadic AD subjects compared to NC, mRNA and
protein levels of PS1 and γ-secretase activity were elevated in the frontal cortex of AD
cases, likely contributing to an overproduction of Aβ in sporadic AD brain [195]. A
neuroblastoma cell culture study that manipulated the methionine pathway showed
decreased levels of SAM deregulated the methylation status of the promoter of PS1,
causing an increase in the expression of PS1 to increase production of Aβ [296], whereas
another study found hypermethylation of the promoter of PS1 decreased expression and
subsequently decreased Aβ production in neuroblastoma cells [297]. It should be noted
that “methylation” in these studies would be better described as “modification” since the
restriction enzyme used for methylation analyses, HpaII, is not specific for 5-mC, but
rather modified (5-mC and 5-hmC) cytosine bases. Additionally, PS1 showed
significantly altered (FDR p < 0.05) 5-hmC levels in our RRHP analysis of DhmRs
within the hippocampus of LOAD subjects compared to NC (ellisonRRHPEDT.pdf),
however did not meet criteria for the conservative adjusted p value cutoff used for
network analysis. Collectively, these studies suggest a role of epigenetic modification in
the regulation of PS1 in sporadic AD.
While not as widely characterized as PS1, recent studies suggested a role of
ABCA7 in sporadic AD, through genome-wide association studies as well as epigenetic
modification analyses. ABCA7 is a transporter protein that may play a role in cholesterol
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transport and phagocytosis mechanisms [73, 74]. In a mouse model of AD, deletion of
ABCA7 led to an increase in Aβ accumulation, suggesting a possible role for ABCA7 in
Aβ clearance in the brain [298]. Several genome-wide association studies found SNPs in
ABCA7 associated with sporadic AD [71, 299, 300]. Several of these SNPs were
associated with loss of function of ABCA7 in sporadic AD as well as altered mRNA
expression [63, 197, 301]. Although increased and decreased mRNA expression levels of
ABCA7 were reported in sporadic AD, loss of function variants likely lead to a decrease
in overall protein expression [300]. In a recent bisulfite sequencing analysis of genomewide epigenetic modifications in the prefrontal cortex, ABCA7 was found as a target
gene associated with sporadic AD [183]. In addition, a 5-mC enrichment study found
ABCA7 to be hypermethylated in prefrontal cortex of AD subjects [235]. Similar to PS1,
sites within ABCA7 were significantly altered (FDR p < 0.05) according to our RRHP
study of LOAD compared to NC subjects, however did not meet criteria for the
conservative adjusted p value cutoff used for network analysis.
Single target recognition via specific primer sequence design is an essential
component of qPCR analyses. Therefore, synthetic primers designed to target exon
sequences within PS1 and ABCA7 genes were tested for specificity using endpoint PCR.
As shown in Figure 4.16, nonspecific amplification was not detected for primer pairs
targeting exon 4, 9, or 12 of PS1. Similarly, primer pairs designed to target sequences
within exon 12, 18, 19, and 37 for ABCA7 showed no nonspecific amplification as
depicted in Figure 4.21. Melt curve analyses were also conducted during qPCR
experiments to test for specificity of primer pairs, but also to account for primer-dimer
formations that may alter fluorescent detection of target amplification. Much like the
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endpoint PCR analyses, melt curves for PS1 primers (Figure 4.17) and ABCA7 primers
(Figure 4.22) showed no non-specific target amplification and no primer-dimer
formation.
Multivariate analyses of epigenetic modifications within exon target sequences of
NC, PCAD, MCI, and LOAD subject groups were conducted to determine statistically
significant relationships between cytosine, 5-mC, and 5-hmC and the subject groups. To
account for non-normal data distributions within the three dependent variables, Pillai’s
Trace, the most robust multivariate test for MANOVA assumption violations [302], was
used to determine statistically significant relationships. For all target sequences in exons
of PS1 and ABCA7, the effect of subject group showed a statistically significant
relationship to the multiple dependent variables (Pillai’s Trace, p < 0.001). Taking into
account each dependent variable from the models, alterations among the subject groups
were also detected for cytosine, 5-mC, and 5-hmC (Least Squares Regression, p < 0.05).
To determine statistically significant differences between the subject groups, a least
square difference (LSD) analysis was used. Results from these analyses are discussed
below.
While significant relationships were shown between the subject groups and
combined modifications (Pillai’s Trace) as well as between subject groups and each
dependent variable (Least Squares Regression), significant differences of mean levels of
each subject group were not detected for cytosine, 5-mC, or 5-hmC at target sequences of
PS1, including either site of exon 4, exon 9, as well as both sites of exon 12. However, a
trending towards significant difference was detected at the second site of exon 4, were
levels of 5-mC were seemingly decreased in PCAD subjects compared to NC (p ≤ 0.1)
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(Figure 4.30). To determine whether this difference may correlate to SMTG protein
expression of PS1, isolated proteins were measured using Western blot analysis. As
shown in Figure 4.38, no significant difference was shown between protein levels of
PCAD compared to NC subjects, although elevated levels of PS1 were shown in MCI
subjects compared to NC.
Epigenetic modifications within exons of ABCA7 showed similar results. While
the multivariate analyses showed significant relationships between the subject groups and
combined modifications (Pillai’s Trace), as well as for each cytosine base and subject
groups (Least Squares Regression), statistically significant relationships were not
observed between AD compared to NC subjects for cytosine, 5-mC, and 5-hmC levels in
ABCA7 exons, including exon 12, 18, 19, and 37. However, multiple trending towards
significant (p ≤ 0.1) relationships were discovered between PCAD and MCI subjects
compared to NC. Levels of 5-mC were decreased in exon 12 of ABCA7 for MCI subjects
compared to NC (Figure 4.34). In addition, levels of cytosine were also decreased in exon
18 for both PCAD and MCI subjects compared to NC (Figure 4.35). Finally, levels of 5hmC were elevated for MCI subjects compared to NC in exon 37 of ABCA7 (Figure
4.37). Interestingly, significant differences were detected between MCI and LOAD
subjects in exon 12 of ABCA7, where elevation of 5-hmC was shown with a decrease in
5-mC levels in MCI subjects compared to LOAD (p < 0.05). To determine whether these
suggested alterations were associated with altered SMTG levels of protein for each
subject group, Western blot analysis was used. As shown in Figure 4.39, no significant
differences were detected in protein levels of PCAD or MCI compared to NC subjects,
but significantly decreased levels of ABCA7 were shown in LOAD subjects.
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While statistically significant differences in mean levels of cytosine, 5-mC, and 5hmC were not shown between stages of AD progression compared to NC subjects, this
study does highlight subtle alterations in each epigenetic mark at various stages of AD,
mainly confined to PCAD and MCI stages. Another interesting finding of this study was
the variation in ratios of cytosine, 5-mC, and 5-hmC within exons of the same gene.
While levels of each mark in ABCA7 showed little fluctuation between ratios in exons
12, 18, and 37, where levels were 10% cytosine, 70% 5-mC, and 20% 5-hmC (Figure
4.34, 4.35, and 4.37), levels of each mark in exon 19 shifted to 45% 5-mC and 45% 5hmC (Figure 4.36). In comparison, levels of each epigenetic mark remained relatively
stable at both sites within exon 4 as well as exon 9, where levels were about 10%
cytosine, 30% 5-mC, and 60% 5-hmC (Figure 4.29, 4.30, and 4.31). However, within
exon 12, at site 2, levels shifted to 20% cytosine, 40% 5-mC, and 40% 5-hmC (Figure
4.32), while at site 3, a large shift in epigenetic marks were observed compared to earlier
exon levels, shifting to 50% cytosine, 35% 5-mC, and 15% 5-hmC (Figure 4.33). Not
only do epigenetic patterns change within similar genomic elements of single genes (i.e.
between exons of the same gene), but also patterns change within single exons, as shown
in the shift in ratios of each mark within exon 12 of PS1. This shifting pattern may
explain the discrepancy observed in previous studies attempting to correlate location
specific 5-mC and 5-hmC modifications with gene expression data [144, 146, 147].
While SMTG protein levels of PS1 (Figure 4.33) and ABCA7 (Figure 4.34) were
significantly altered compared to NC for some of the AD subject groups, these changes
did not correlate to statistically significant epigenetic changes within exons of various
stages of AD progression according to the MANOVA analyses. However, this study did
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show that interrogation of specific target sites within genes of interest was possible and
future analysis of site-specific alterations may lead to a better understanding of the role
epigenetic modifications to cytosine play throughout the stages of AD progression.
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CHAPTER SIX: CONCLUSIONS
Alzheimer’s disease currently affects more than 5 million patients, is the most
common form of dementia and the sixth leading cause of death in the United States [13].
Accumulation of pathologic lesions of plaques and tangles within brain regions of AD
patients leads to synapse and cell loss, eventually causing memory impairment and
cognitive decline. With the baby boom generation approaching or at the age of onset of
clinical indications of the disease, the effect on the healthcare system is projected to reach
more than $250 billion by 2050 [13]. Although decades of research provided insight into
facets of the disease mechanism, a lack of understanding of the etiology and aspects of
pathogenesis have resulted in no viable therapeutic option to slow or halt
neurodegeneration in AD [46].
While development of plaques in rare cases of familial AD were linked to gene
mutations in amyloid processing genes, the same pathologic features occur in the brains
of sporadic AD patients who lack these causal mutations. Efforts to find a genetic
component of sporadic AD led to numerous genome-wide association studies of single
nucleotide polymorphisms in post-mortem brain tissues and blood samples of AD
subjects [71, 299, 300]. While several risk genes were discovered, including APOE-ε4,
variations in these genes account for only 30 % of sporadic AD cases [13, 70]. Clearly,
additional non-genetic factors must play a role in the deregulation of gene expression and
transcription mechanisms found to be altered in early and late stages of AD progression.
Associated with gene silencing, 5-mC was thought to be passively removed from
DNA, allowing for gene expression mechanisms to be activated [106]. In 2009, with the
discovery of enzymatic oxidization of 5-mC in mammalian genomes, oxidized
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derivatives of 5-mC, including 5-hmC, were thought to be intermediates in an active
TET-assisted demethylation pathway [113, 117]. However, current studies suggest 5hmC as a stable epigenetic mark within mammalian genomes, adding another layer of
complexity to the role cytosine modifications assume in regulating transcription. While 5mC remains associated with gene repression, 5-hmC was suggested to activate genes,
although regulation of either mark to gene expression likely depends on genomic location
of modifications [147, 151]. The majority of studies analyzing 5-mC used bisulfite
conversion to determine methylation states, but it was revealed this technique does not
distinguish between 5-mC and 5-hmC [125], thus findings are more accurately described
as cytosine modification rather than methylation. This is especially problematic in
neurodegenerative disease studies of post-mortem brain tissues as levels of 5-hmC were
found to be highly concentrated within mammalian brain and CNS samples.
Previously reported analyses of 5-mC and 5-hmC levels in sporadic AD showed
inconclusive findings, likely due to the semi-quantitative nature of immunochemical
analyses. This dissertation, using a quantitative method pairing GC/MS and stable labeled
cytosine standards, validates the suggested interaction between epigenetic modification
and AD. Global alterations of cytosine, 5-mC, and 5-hmC were shown in early and late
stages of AD compared to NC subjects. While significantly decreased levels of global
cytosine in MCI subjects compared to NC were found, significantly elevated levels of 5hmC were quantified in PCAD and MCI subjects, and 5-mC levels were suggested to be
elevated in LOAD subjects. This study also confirms neurodegenerative disease-specific
alterations to cytosine modifications, in contrast to epigenetic changes explained by age-
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related epigenetic drift, where NC subjects were age-matched for AD subject groups, in
addition to controlling for age and gender in the repeated measures analysis.
Global alterations in cytosine modifications in FTLD and DLB subjects compared
to NC show epigenetic modifications were not specific to AD but were common to
several forms of neurodegeneration. Levels of cytosine and 5-mC were significantly
decreased in FTLD/DLB subjects compared to NC, while global levels of 5-hmC were
elevated. It should be noted that analyzed brain regions were chosen based on pathologic
lesion susceptibility in AD progression, however AD affected brain regions may not be
relevant to other types of neurodegeneration. Finally, as this dissertation shows, levels of
5-mC and 5-hmC varied across brain regions, where compared to CER, regions
susceptible to plaque and tangle pathology exhibited decreased levels of 5-mC and 5hmC, especially in the HPG and SMTG. Whether these findings reflect altered cell type
distributions between brain regions or suggest epigenetic regulation plays more of a role
in one brain region compared to another has yet to be determined.
While global analyses were used to confirm relevance of epigenetic modifications
to neurodegenerative diseases, including but not specific to AD, global levels give no
indication of possible pathways of interest that may be epigenetically regulated in
neurodegeneration. While global alterations were shown to be common to
neurodegenerative diseases, it is likely that pathways and genes are altered specifically
related to AD. Several studies have shown genome-wide alterations in cytosine
modifications in AD, however through bisulfite sequencing studies of the prefrontal
cortex providing no information of whether sites were methylated or hydroxymethylated
[175, 182, 183]. This dissertation shows an overall increase in significantly altered
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genomic levels of hippocampal 5-hmC in LOAD compared to NC subjects, mainly
confined to gene-associated regions. Interestingly, 85% of significantly altered regions of
hydroxymethylation in LOAD compared to NC subjects were associated with promoter
and genebody locations. This finding suggests a regulatory role of hydroxymethylation in
altering gene expression and transcription mechanisms in the brain, although the exact
function of 5-hmC within genomic elements remains poorly understood.
A network analysis of interactions between the identified genes provided
significantly altered pathways, both epigenetically and transcriptionally altered, relevant
to AD mechanisms. Altered pathways were related to signaling cascades, energy
metabolism and consumption, cell cycle mechanisms, gene expression and transcription,
protein degradation and clearance pathways, as well as cell structure and stabilization
mechanisms. Several of the genes identified in the aforementioned bisulfite studies, as
well as genes identified in genome-wide association studies of sporadic AD, were
significantly altered in our analysis, providing further evidence of altered
hydroxymethylation in AD. In addition, similar mechanisms and pathways overlapped
between two other hydroxymethylation mapping studies of sporadic AD subjects [239,
294], even though mapping techniques and brain regions analyzed varied. To our
knowledge, this is the first study to analyze genome-wide hydroxymethylation at singlebase resolution within the hippocampus of LOAD compared to NC subjects. This study
also provided pathways and specific genes to target in future analyses, particularly in
early stages of AD progression, including PCAD and MCI, to determine how 5-hmC
affects pathogenesis mechanisms in AD and potentially lead to therapeutic discoveries.
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To better understand gene specific roles epigenetic modifications may play
throughout stages of AD progression, a quantitative method pairing qPCR and specific
restriction enzyme digestion was used to determine levels of cytosine, 5-mC, and 5-hmC
at specific target sequences within exons of two epigenetically regulated genes relevant to
sporadic AD. As described previously, this study suggested subtle alterations in SMTG
levels of cytosine, 5-mC, and 5-hmC in early stages of AD progression, including PCAD
and MCI, compared to NC subjects. Although statistically significant differences between
subject groups compared to NC were not shown according to the MANOVA analyses,
suggested alterations warrant further analysis in future studies, particularly of epigenetic
modifications within PCAD and MCI subjects. This study did highlight interesting
aspects of the epigenetic landscape within exons of PS1 and ABCA7. Within similar
genomic elements (i.e. exons) of one gene, epigenetic patterns shifted and ratios of
cytosine/ 5-mC/ 5-hmC were altered depending on the exon analyzed for PS1 and
ABCA7. In addition, epigenetic patterns changed within exons, as shown by two sites
within exon 12 of PS1 with very different ratios of cytosine modifications. These findings
indicate site-specific alterations within genes not only vary across exons of a single gene,
but also within a single exon of the same gene. Whereas previous studies have used
single locations to determine methylation or hydroxymethylation levels within genomic
locations, i.e. one site to determine methylation of a promoter [296, 297], caution should
be taken in extrapolating epigenetic patterns from a single CpG sequence.
In conclusion, this dissertation provides evidence of altered epigenetic
modifications in AD on global and gene specific scales, particularly in early stages of
disease progression, including PCAD and MCI, compared to NC subjects. It also
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indicates probable involvement of epigenetic mechanisms regulating gene expression of
deregulated pathways implicated in the pathogenesis of AD. Future analyses of gene
targets within these epigenetically regulated pathways, including signaling cascades,
energy metabolism and consumption, cell cycle functions, and cytoskeletal structures and
stabilization, may aid in the advancement of elucidating the disease mechanism,
potentially contributing to the identification of a therapeutic option for combatting AD.
Looking to the future, the role cytosine modifications play in regulating gene
expression within specific cell types, including neurons and glia, needs to be further
elucidated, particularly with respect to AD pathology. To clarify a cell specific role of
cytosine modification and development of AD pathology, cultures of pure neurons and
glia could be treated with toxic oligomeric Aβ to induce an epigenetic response. To
determine the response of Aβ-treatment in mixed cell types, a combined culture of
neurons and glia could be used. Quantification of global levels of 5-mC and 5-hmC in
Aβ-treated and untreated cells would be analyzed by mass spectrometry. In addition, gene
specific alterations of cytosine modifications could be mapped throughout the genome
using bisulfite conversion of cytosine modifications (5-mC + 5-hmC) by Zymo Research
Corporations’ Methyl-MidiSeq technique, as well as 5-hmC specific modifications using
the RRHP protocol. Epigenetic alterations could then be correlated with mRNA
expression data and protein levels to distinguish between neuron-specific and gliaspecific fluctuations of 5-mC and 5-hmC, providing cell-type specific gene targets and
biological pathways deregulated by toxic Aβ exposure. Analysis of induced epigenetic
responses within each cell type would identify genes and pathways deregulated
epigenetically as well as at the transcription and protein level during a key stage of AD
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pathologic lesion development. Comparison with gene targets and pathways identified
previously by RRHP in this dissertation, including pathways related to signaling, energy
metabolism, cellular homeostasis, expression and cell structure, insight of neuron-specific
alterations in LOAD subjects compared to NC could be elucidated. Together, these data
would clarify the effect of early AD pathology development in deregulating the
epigenetic machinery of brain cells, likely leading to targetable biological mechanisms
for future AD prevention and/or treatment therapies.
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APPENDIX A: ABBREVIATIONS
[M]+ – molecular ion
5-caC – 5-carboxylcytosine
5-fC – 5-formylcytosine
5-ghmC – glucosylated 5-hydroxymethylcytosine
5-hmC – 5-hydroxymethylcytosine
5-mC – 5-methylcytosine
ABCA7 – ATP binding cassette subfamily A member 7
AD – Alzheimer’s disease
AICD – amyloid precursor protein intracellular domain
ANOVA – analysis of variance
APOE-Ԑ4 – apolipoprotein E allele Ԑ4
APP – amyloid precursor protein
Aβ – amyloid beta
BAM – binary version of sequence alignment map
BED – binary version of pedigree data
BER – base excision repair
bp – base pair
BSTFA:TMCS – N,O-Bis(trimethylsilyl)trifluoroacetamide:Trimethylchlorosilane
CCGG – cytosine cytosine guanine guanine sequence
CER – cerebellum
CERAD – Consortium to Establish a Registry for Alzheimer’s disease
ChIP-seq – chromatin immunoprecipitation sequencing
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CNS – central nervous system
CpG – cytosine phosphate guanine sequence
CSF – cerebral spinal fluid
Ct – cycle threshold number
DhmR – differentially hydroxymethylated region
DLB – dementia with Lewy bodies
DNA – deoxyribonucleic acid
DNMT – DNA methyltransferase
EC – entorhinal cortex
ELISA – enzyme-linked immunosorbent assay
EM – estimated mean
FDA – Federal Drug Administration
FDR – false discovery rate
FTLD – frontal temporal lobar degeneration
GAPDH - Glyceraldehyde 3-phosphate dehydrogenase
GC/MS – gas chromatography mass spectrometry
GLM – general linear regression model
H3K27me1 – histone 3 lysine 27 single methylation
H3K27me3 – histone 3 lysine 27 triple methylation
HpaII - Haemophilus parainfluenzae type II restriction endonuclease
HPG – hippocampus/parahippocampal gyrus
IDH – isocitrate dehydrogenase
IDT – Integrated DNA Technologies
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IPL – inferior parietal lobe
IS – internal standard
LOAD – late onset Alzheimer’s disease
LOQ – limit of quantification
m/z – mass to charge ratio
MANOVA – multivariate analysis of variance
MCI – mild cognitive impairment
MeCP2 – methyl CpG binding protein-2
miRNA – micro ribonucleic acid
MMSE – Mini Mental State Examination
mRNA – messenger ribonucleic acid
MspI - Moraxella species 1 type II restriction endonuclease
NC – normal control
ncRNA – noncoding ribonucleic acid
NEB – New England Biolabs
NFT – neurofibrillary tangle
NIA-RI – National Institure of Aging-Reagan Institute
nm – nanometer
NMDA - N-methyl-D-aspartate
oxBS-Seq – oxidative bisulfite sequencing
PCAD – preclinical Alzheimer’s disease
PD – Parkinson’s disease
PERL – Practical Extraction and Reporting Language
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PMI – post-mortem interval
PS1 – presenilin-1
PS2 – presenilin-2
qPCR – quantitative polymerase chain reaction
RFI – Reactome functional interaction
ROS – reactive oxygen species
RRHP – reduced representation hydroxymethylation profiling
RT-PCR – real time polymerase chain reaction
SAH – S-adenosyl homocysteine
SAM – S-adenosyl methionine
SD – standard deviation
SDS-PAGE – sodium dodecyl sulfate polyacrylamide gel electrophoresis
SE – standard error
SIM – single ion monitoring
siRNA – short interfering ribonucleic acid
SMTG – superior and middle temporal gyrus
SNP – single nucleotide polymorphism
SP – senile plaque
SYBR green – N’,N'-dimethyl-N-[4-[(E)-(3-methyl-1,3-benzothiazol-2ylidene)methyl]-1-phenylquinolin-1-ium-2-yl]-N-propylpropane-1,3-diamine
T4-βGT – T4 Phage beta glucose transferase
TAB-Seq – TET assisted bisulfite sequencing
TDG – thymine DNA-glycosylase
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TET – ten eleven translocase
TF – transcription factor
UDP - Uridine diphosphate
UHP – ultra high purity
UK-ADC – University of Kentucky Alzheimer’s disease Center
UTR – untranslated region
UV – ultraviolet
ZRC – Zymo Research Corporation
αKG – alpha keto-glutarate
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APPENDIX B: GENE SYMBOL AND NAME
Symbol
AATK
ABL1
ABLIM1
ACAT1
ACTN1
ACTR2
ADCY2
ADGRB3
ADGRG1
AGPAT2
AK5
AKAP12
AMFR
AMPD3
ANK3
AP2B1
APBA2
APC2
ARHGEF10
ARHGEF16
ARIH2
ASMTL
ATP1A2
ATP2B2
ATP5B
ATP5J
ATP5J2
BAIAP3
BANP
BCL11B
BCL7A
BGN
BIN1
BRD1
BRD4
BTRC
C4B
CA11
CACNA1A
CADPS
CALM3
CAMKK2
CAP2
CCNA1
CCND3
CDC34
CDC5L
CDH10
CDH13
CDH4
CDK7
CEBPD
CEPT1
CHD2
CHST3
CLIC2
CLU
CNTNAP2
COL21A1
COL4A1
COL4A3
COL6A2
COMT
CPSF1
CPT1B
CR1

Gene Name
apoptosis associated tyrosine kinase(AATK)
ABL proto-oncogene 1, non-receptor tyrosine kinase(ABL1)
actin binding LIM protein 1(ABLIM1)
acetyl-CoA acetyltransferase 1(ACAT1)
actinin alpha 1(ACTN1)
ARP2 actin related protein 2 homolog(ACTR2)
adenylate cyclase 2(ADCY2)
Adhesion G Protein-Coupled Receptor B(ADGRB3)
Adhesion G Protein-Coupled Receptor G1
1-acylglycerol-3-phosphate O-acyltransferase 2(AGPAT2)
adenylate kinase 5(AK5)
A-kinase anchoring protein 12(AKAP12)
autocrine motility factor receptor(AMFR)
adenosine monophosphate deaminase 3(AMPD3)
ankyrin 3(ANK3)
adaptor related protein complex 2 beta 1 subunit(AP2B1)
amyloid beta precursor protein binding family A member 2(APBA2)
APC2, WNT signaling pathway regulator(APC2)
Rho guanine nucleotide exchange factor 10(ARHGEF10)
Rho guanine nucleotide exchange factor 16(ARHGEF16)
ariadne RBR E3 ubiquitin protein ligase 2(ARIH2)
acetylserotonin O-methyltransferase-like(ASMTL)
ATPase Na+/K+ transporting subunit alpha 2(ATP1A2)
ATPase plasma membrane Ca2+ transporting 2(ATP2B2)
ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide(ATP5B)
ATP synthase, H+ transporting, mitochondrial Fo complex subunit F6(ATP5J)
ATP synthase, H+ transporting, mitochondrial Fo complex subunit F2(ATP5J2)
BAI1 associated protein 3(BAIAP3)
BTG3 associated nuclear protein(BANP)
B-cell CLL/lymphoma 11B(BCL11B)
BCL tumor suppressor 7A(BCL7A)
biglycan(BGN)
bridging integrator 1(BIN1)
bromodomain containing 1(BRD1)
bromodomain containing 4(BRD4)
beta-transducin repeat containing E3 ubiquitin protein ligase(BTRC)
complement C4B (Chido blood group)(C4B)
carbonic anhydrase 11(CA11)
calcium voltage-gated channel subunit alpha1 A(CACNA1A)
calcium dependent secretion activator(CADPS)
calmodulin 3(CALM3)
calcium/calmodulin dependent protein kinase kinase 2(CAMKK2)
CAP, adenylate cyclase-associated protein, 2 (yeast)(CAP2)
cyclin A1(CCNA1)
cyclin D3(CCND3)
cell division cycle 34(CDC34)
cell division cycle 5 like(CDC5L)
cadherin 10(CDH10)
cadherin 13(CDH13)
cadherin 4(CDH4)
cyclin dependent kinase 7(CDK7)
CCAAT/enhancer binding protein delta(CEBPD)
choline/ethanolamine phosphotransferase 1(CEPT1)
chromodomain helicase DNA binding protein 2(CHD2)
carbohydrate sulfotransferase 3(CHST3)
chloride intracellular channel 2(CLIC2)
clusterin(CLU)
contactin associated protein-like 2(CNTNAP2)
collagen type XXI alpha 1 chain(COL21A1)
collagen type IV alpha 1 chain(COL4A1)
collagen type IV alpha 3 chain(COL4A3)
collagen type VI alpha 2 chain(COL6A2)
catechol-O-methyltransferase(COMT)
cleavage and polyadenylation specific factor 1(CPSF1)
carnitine palmitoyltransferase 1B(CPT1B)
complement C3b/C4b receptor 1 (Knops blood group)(CR1)
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CREBBP
CRIM1
CSK
CSNK1E
CTBP1
CTBP2
CTPS2
CUL5
DAG1
DAPK2
DAPK3
DDX27
DGCR6
DGKG
DIAPH2
DLEU1
DLGAP1
DLGAP2
DMD
DRAP1
EDAR
EHD1
ELF2
EML2
ENAH
ENSA
ENTPD3
EPS15
F2R
FADS1
FBXL2
FEZ2
FGFR3
FGL1
FLNA
FLNC
FOLH1
FRAT1
FSTL1
FYCO1
FZR1
G6PD
GAK
GBAS
GDF1
GHITM
GLI2
GLTSCR2
GMEB2
GNA12
GNA14
GNAL
GNAO1
GNAS
GNAZ
GOSR2
GPC5
GPI
GPM6B
GPR4
GRIA3
GRIN2A
GRM6
GUK1
H2AFX
HADHA
HBA1
HDAC4
HTR2A

CREB binding protein(CREBBP)
cysteine rich transmembrane BMP regulator 1(CRIM1)
c-src tyrosine kinase(CSK)
casein kinase 1 epsilon(CSNK1E)
C-terminal binding protein 1(CTBP1)
C-terminal binding protein 2(CTBP2)
CTP synthase 2(CTPS2)
cullin 5(CUL5)
dystroglycan 1(DAG1)
death associated protein kinase 2(DAPK2)
death associated protein kinase 3(DAPK3)
DEAD-box helicase 27(DDX27)
DiGeorge syndrome critical region gene 6(DGCR6)
diacylglycerol kinase gamma(DGKG)
diaphanous related formin 2(DIAPH2)
deleted in lymphocytic leukemia 1(DLEU1)
DLG associated protein 1(DLGAP1)
DLG associated protein 2(DLGAP2)
dystrophin(DMD)
DR1 associated protein 1(DRAP1)
ectodysplasin A receptor(EDAR)
EH domain containing 1(EHD1)
E74 like ETS transcription factor 2(ELF2)
echinoderm microtubule associated protein like 2(EML2)
enabled homolog (Drosophila)(ENAH)
endosulfine alpha(ENSA)
ectonucleoside triphosphate diphosphohydrolase 3(ENTPD3)
epidermal growth factor receptor pathway substrate 15(EPS15)
coagulation factor II thrombin receptor(F2R)
fatty acid desaturase 1(FADS1)
F-box and leucine rich repeat protein 2(FBXL2)
fasciculation and elongation protein zeta 2(FEZ2)
fibroblast growth factor receptor 3(FGFR3)
fibrinogen like 1(FGL1)
filamin A(FLNA)
filamin C(FLNC)
folate hydrolase 1(FOLH1)
frequently rearranged in advanced T-cell lymphomas 1(FRAT1)
follistatin like 1(FSTL1)
FYVE and coiled-coil domain containing 1(FYCO1)
fizzy/cell division cycle 20 related 1(FZR1)
glucose-6-phosphate dehydrogenase(G6PD)
cyclin G associated kinase(GAK)
glioblastoma amplified sequence(GBAS)
growth differentiation factor 1(GDF1)
growth hormone inducible transmembrane protein(GHITM)
GLI family zinc finger 2(GLI2)
glioma tumor suppressor candidate region gene 2(GLTSCR2)
glucocorticoid modulatory element binding protein 2(GMEB2)
G protein subunit alpha 12(GNA12)
G protein subunit alpha 14(GNA14)
G protein subunit alpha L(GNAL)
G protein subunit alpha o1(GNAO1)
GNAS complex locus(GNAS)
G protein subunit alpha z(GNAZ)
golgi SNAP receptor complex member 2(GOSR2)
glypican 5(GPC5)
glucose-6-phosphate isomerase(GPI)
glycoprotein M6B(GPM6B)
G protein-coupled receptor 4(GPR4)
glutamate ionotropic receptor AMPA type subunit 3(GRIA3)
glutamate ionotropic receptor NMDA type subunit 2A(GRIN2A)
glutamate metabotropic receptor 6(GRM6)
guanylate kinase 1(GUK1)
H2A histone family member X(H2AFX)
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha
subunit(HADHA)
hemoglobin subunit alpha 1(HBA1)
histone deacetylase 4(HDAC4)
5-hydroxytryptamine receptor 2A(HTR2A)
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IL6R
INSR
IQGAP1
IRF7
IRS2
ITGB4
ITGB5
ITGB8
ITPK1
ITPR1
JPH3
JRK
JUND
KCNA6
KCNAB1
KCNAB2
KCNJ14
KCNN3
KIF13B
KLF1
L1CAM
LARGE1
LDLR
LILRA2
LIMK2
LMNA
LPIN1
LRP1B
LRP6
LRP8
LTBP2
LZTS1
MADCAM1
MAFF
MAFG
MAGED1
MAN2B1
MAP2K3
MAP2K7
MAP3K11
MAPRE3
MATN2
MBD3
MGA
MGLL
MKNK2
MLC1
MPST
MT1L
MTA1
MTF1
MUC3A
MYO1C
MYO1F
MYO9B
MYT1L
NAV2
NCOR2
NDRG4
NDST1
NDUFA10
NDUFA3
NDUFB3
NELL1
NFATC1
NFIC
NMB
NME3
NME4
NOTCH4

interleukin 6 receptor(IL6R)
insulin receptor(INSR)
IQ motif containing GTPase activating protein 1(IQGAP1)
interferon regulatory factor 7(IRF7)
insulin receptor substrate 2(IRS2)
integrin subunit beta 4(ITGB4)
integrin subunit beta 5(ITGB5)
integrin subunit beta 8(ITGB8)
inositol-tetrakisphosphate 1-kinase(ITPK1)
inositol 1,4,5-trisphosphate receptor type 1(ITPR1)
junctophilin 3(JPH3)
Jrk helix-turn-helix protein(JRK)
JunD proto-oncogene, AP-1 transcription factor subunit(JUND)
potassium voltage-gated channel subfamily A member 6(KCNA6)
potassium voltage-gated channel subfamily A member regulatory beta subunit 1(KCNAB1)
potassium voltage-gated channel subfamily A regulatory beta subunit 2(KCNAB2)
potassium voltage-gated channel subfamily J member 14(KCNJ14)
potassium calcium-activated channel subfamily N member 3(KCNN3)
kinesin family member 13B(KIF13B)
Kruppel like factor 1(KLF1)
L1 cell adhesion molecule(L1CAM)
LARGE Xylosyl- And Glucuronyltransferase 1
low density lipoprotein receptor(LDLR)
leukocyte immunoglobulin like receptor A2(LILRA2)
LIM domain kinase 2(LIMK2)
lamin A/C(LMNA)
lipin 1(LPIN1)
LDL receptor related protein 1B(LRP1B)
LDL receptor related protein 6(LRP6)
LDL receptor related protein 8(LRP8)
latent transforming growth factor beta binding protein 2(LTBP2)
leucine zipper tumor suppressor 1(LZTS1)
mucosal vascular addressin cell adhesion molecule 1(MADCAM1)
MAF bZIP transcription factor F(MAFF)
MAF bZIP transcription factor G(MAFG)
MAGE family member D1(MAGED1)
mannosidase alpha class 2B member 1(MAN2B1)
mitogen-activated protein kinase kinase 3(MAP2K3)
mitogen-activated protein kinase kinase 7(MAP2K7)
mitogen-activated protein kinase kinase kinase 11(MAP3K11)
microtubule associated protein RP/EB family member 3(MAPRE3)
matrilin 2(MATN2)
methyl-CpG binding domain protein 3(MBD3)
MGA, MAX dimerization protein(MGA)
monoglyceride lipase(MGLL)
MAP kinase interacting serine/threonine kinase 2(MKNK2)
megalencephalic leukoencephalopathy with subcortical cysts 1(MLC1)
mercaptopyruvate sulfurtransferase(MPST)
metallothionein 1L (gene/pseudogene)(MT1L)
metastasis associated 1(MTA1)
metal regulatory transcription factor 1(MTF1)
mucin 3A, cell surface associated(MUC3A)
myosin IC(MYO1C)
myosin IF(MYO1F)
myosin IXB(MYO9B)
myelin transcription factor 1 like(MYT1L)
neuron navigator 2(NAV2)
nuclear receptor corepressor 2(NCOR2)
NDRG family member 4(NDRG4)
N-deacetylase and N-sulfotransferase 1(NDST1)
NADH:ubiquinone oxidoreductase subunit A10(NDUFA10)
NADH:ubiquinone oxidoreductase subunit A3(NDUFA3)
NADH:ubiquinone oxidoreductase subunit B3(NDUFB3)
neural EGFL like 1(NELL1)
nuclear factor of activated T-cells 1(NFATC1)
nuclear factor I C(NFIC)
neuromedin B(NMB)
NME/NM23 nucleoside diphosphate kinase 3(NME3)
NME/NM23 nucleoside diphosphate kinase 4(NME4)
notch 4(NOTCH4)
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NPAS2
NPAS3
NR2F6
NRN1
NRXN1
ODC1
OGDH
OGG1
OSBPL10
PACSIN2
PAK4
PAX6
PDE4C
PER1
PEX10
PKNOX2
PLCB1
PLCE1
PLCG2
PLCL2
PLOD3
PLXNA1
PLXNB2
PML
POLRMT
PPP1R15A
PPP2R2B
PRDX3
PRKAR1B
PRKAR2B
PRL
PRPF4B
PRPF8
PSMA1
PTBP1
PTN
PTRF
QARS
RAB22A
RALBP1
RALGDS
RAMP1
RANBP3
RBL1
REC8
RGS12
RNF11
RPS6KA1
RREB1
RTN1
SCAMP3
SCLY
SDHD
SEC14L1
SEMA3B
SEMA3F
SH3BP2
SH3GLB2
SHANK2
SIRT6
SIRT7
SLC12A7
SLC19A1
SLC1A7
SLC25A12
SLC25A6
SLC2A9
SLC6A8
SLC7A5

neuronal PAS domain protein 2(NPAS2)
neuronal PAS domain protein 3(NPAS3)
nuclear receptor subfamily 2 group F member 6(NR2F6)
neuritin 1(NRN1)
neurexin 1(NRXN1)
ornithine decarboxylase 1(ODC1)
oxoglutarate dehydrogenase(OGDH)
8-oxoguanine DNA glycosylase(OGG1)
oxysterol binding protein like 10(OSBPL10)
protein kinase C and casein kinase substrate in neurons 2(PACSIN2)
p21 (RAC1) activated kinase 4(PAK4)
paired box 6(PAX6)
phosphodiesterase 4C(PDE4C)
period circadian clock 1(PER1)
peroxisomal biogenesis factor 10(PEX10)
PBX/knotted 1 homeobox 2(PKNOX2)
phospholipase C beta 1(PLCB1)
phospholipase C epsilon 1(PLCE1)
phospholipase C gamma 2(PLCG2)
phospholipase C like 2(PLCL2)
procollagen-lysine,2-oxoglutarate 5-dioxygenase 3(PLOD3)
plexin A1(PLXNA1)
plexin B2(PLXNB2)
promyelocytic leukemia(PML)
RNA polymerase mitochondrial(POLRMT)
protein phosphatase 1 regulatory subunit 15A(PPP1R15A)
protein phosphatase 2 regulatory subunit Bbeta(PPP2R2B)
peroxiredoxin 3(PRDX3)
protein kinase cAMP-dependent type I regulatory subunit beta(PRKAR1B)
protein kinase cAMP-dependent type II regulatory subunit beta(PRKAR2B)
prolactin(PRL)
pre-mRNA processing factor 4B(PRPF4B)
pre-mRNA processing factor 8(PRPF8)
proteasome subunit alpha 1(PSMA1)
polypyrimidine tract binding protein 1(PTBP1)
pleiotrophin(PTN)
polymerase I and transcript release factor(PTRF)
glutaminyl-tRNA synthetase(QARS)
RAB22A, member RAS oncogene family(RAB22A)
ralA binding protein 1(RALBP1)
ral guanine nucleotide dissociation stimulator(RALGDS)
receptor activity modifying protein 1(RAMP1)
RAN binding protein 3(RANBP3)
RB transcriptional corepressor like 1(RBL1)
REC8 meiotic recombination protein(REC8)
regulator of G-protein signaling 12(RGS12)
ring finger protein 11(RNF11)
ribosomal protein S6 kinase A1(RPS6KA1)
ras responsive element binding protein 1(RREB1)
reticulon 1(RTN1)
secretory carrier membrane protein 3(SCAMP3)
selenocysteine lyase(SCLY)
succinate dehydrogenase complex subunit D(SDHD)
SEC14 like lipid binding 1(SEC14L1)
semaphorin 3B(SEMA3B)
semaphorin 3F(SEMA3F)
SH3 domain binding protein 2(SH3BP2)
SH3 domain containing GRB2 like endophilin B2(SH3GLB2)
SH3 and multiple ankyrin repeat domains 2(SHANK2)
sirtuin 6(SIRT6)
sirtuin 7(SIRT7)
solute carrier family 12 member 7(SLC12A7)
solute carrier family 19 member 1(SLC19A1)
solute carrier family 1 member 7(SLC1A7)
solute carrier family 25 member 12(SLC25A12)
solute carrier family 25 member 6(SLC25A6)
solute carrier family 2 member 9(SLC2A9)
solute carrier family 6 member 8(SLC6A8)
solute carrier family 7 member 5(SLC7A5)
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SMARCA2
SNRPD2
SNTA1
SNTG1
SORBS1
SPIB
SPTLC2
SREBF1
SREBF2
SSBP1
STAG2
STK10
STK11
STK24
SYN2
SYNGR3
TBC1D2
TCEAL1
TCF3
TCF7
TCOF1
TDG
TFAP2A
TGFB1
THRA
TIGAR
TIMM44
TLE3
TNXB
TPD52
TREX2
TRIM14
TRIM26
TRIM36
TRPV1
TTC3
TUBG2
TYK2
UBE3B
ULK2
UNG
UQCRC2
USP3
UST
VARS2
VWF
WFDC1
WFDC2
WFS1
WNT7B
WRB
WWOX
ZDHHC11
ZIC1
ZNF142

SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member
2(SMARCA2)
small nuclear ribonucleoprotein D2 polypeptide(SNRPD2)
syntrophin alpha 1(SNTA1)
syntrophin gamma 1(SNTG1)
sorbin and SH3 domain containing 1(SORBS1)
Spi-B transcription factor(SPIB)
serine palmitoyltransferase long chain base subunit 2(SPTLC2)
sterol regulatory element binding transcription factor 1(SREBF1)
sterol regulatory element binding transcription factor 2(SREBF2)
single stranded DNA binding protein 1(SSBP1)
stromal antigen 2(STAG2)
serine/threonine kinase 10(STK10)
serine/threonine kinase 11(STK11)
serine/threonine kinase 24(STK24)
synapsin II(SYN2)
synaptogyrin 3(SYNGR3)
TBC1 domain family member 2(TBC1D2)
transcription elongation factor A like 1(TCEAL1)
transcription factor 3(TCF3)
transcription factor 7 (T-cell specific, HMG-box)(TCF7)
treacle ribosome biogenesis factor 1(TCOF1)
thymine DNA glycosylase(TDG)
transcription factor AP-2 alpha(TFAP2A)
transforming growth factor beta 1(TGFB1)
thyroid hormone receptor, alpha(THRA)
TP53 Induced Glycolysis Regulatory Phosphatase
translocase of inner mitochondrial membrane 44(TIMM44)
transducin like enhancer of split 3(TLE3)
tenascin XB(TNXB)
tumor protein D52(TPD52)
three prime repair exonuclease 2(TREX2)
tripartite motif containing 14(TRIM14)
tripartite motif containing 26(TRIM26)
tripartite motif containing 36(TRIM36)
transient receptor potential cation channel subfamily V member 1(TRPV1)
tetratricopeptide repeat domain 3(TTC3)
tubulin gamma 2(TUBG2)
tyrosine kinase 2(TYK2)
ubiquitin protein ligase E3B(UBE3B)
unc-51 like autophagy activating kinase 2(ULK2)
uracil DNA glycosylase(UNG)
ubiquinol-cytochrome c reductase core protein II(UQCRC2)
ubiquitin specific peptidase 3(USP3)
uronyl 2-sulfotransferase(UST)
valyl-tRNA synthetase 2, mitochondrial(VARS2)
von Willebrand factor(VWF)
WAP four-disulfide core domain 1(WFDC1)
WAP four-disulfide core domain 2(WFDC2)
wolframin ER transmembrane glycoprotein(WFS1)
Wnt family member 7B(WNT7B)
tryptophan rich basic protein(WRB)
WW domain containing oxidoreductase(WWOX)
zinc finger DHHC-type containing 11(ZDHHC11)
Zic family member 1(ZIC1)
zinc finger protein 142(ZNF142)
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APPENDIX C: RFI SIGNIFICANTLY ENRICHED PATHWAYS

Module

Pathway

FDR

0

Glutamatergic synapse(K)

1.14E-06

0

Opioid Signalling(R)

1.27E-06

0

Calcium signaling
pathway(K)

2.23E-06

0

Long-term depression(K)

1.15E-05

0

Endothelins(N)

1.15E-05

0
0
0
0
0
0
0

Phospholipase D signaling
pathway(K)
PAR1-mediated thrombin
signaling events(N)
Integration of energy
metabolism(R)
Inflammatory mediator
regulation of TRP channels(K)
Rap1 signaling pathway(K)
Plasma membrane estrogen
receptor signaling(N)
Sphingosine 1-phosphate (S1P)
pathway(N)

1.97E-05
1.97E-05
7.85E-05
1.31E-04
2.61E-04

Target Genes
ADCY2,PLCB1,GRIN2A,GRM6,GNAS,DLGAP1,
GNAO1,GRIA3,SHANK2,CACNA1A
GNAZ,ADCY2,PRKAR2B,PLCB1,PDE4C,GNAL,
GNAO1,PRKAR1B
GNA14,ADCY2,PLCB1,GRIN2A,GNAL,PLCE1,
GNAS,PLCG2,CACNA1A,F2R,HTR2A
GNAZ,GNA12,PLCB1,GNAS,GNAO1,GRIA3,
CACNA1A
GNAZ,GNA14,ADCY2,GNA12,PLCB1,GNAL,
GNAO1
ADCY2,GNA12,PLCB1,GRM6,GNAS,DGKG,
RALGDS,PLCG2,F2R
GNAZ,GNA14,GNA12,PLCB1,GNAO1,F2R
ADCY2,IQGAP1,PRKAR2B,GNAS,STK11,
PRKAR1B,CACNA1A
ADCY2,TRPV1,PLCB1,GNAS,MAP2K3,PLCG2,
HTR2A
ADCY2,PLCB1,GRIN2A,PLCE1,GNAS,GNAO1,
MAP2K3,RALGDS,F2R

2.61E-04

GNAZ,GNA14,PLCB1,GNAL,GNAO1

3.39E-04

GNAZ,GNA14,GNA12,GNAO1

0

Dopaminergic synapse(K)

5.18E-04

0
0

5.18E-04
5.18E-04
5.28E-04

ADCY2,PRKAR2B,GNAS,PRKAR1B

0
0

S1P5 pathway(N)
S1P3 pathway(N)
Vasopressin regulates renal
water homeostasis via
Aquaporins(R)
S1P2 pathway(N)
Circadian entrainment(K)

PLCB1,GRIN2A,GNAL,GNAS,GNAO1,GRIA3,
CACNA1A
GNAZ,GNA12,GNAO1
GNAZ,GNA14,GNA12,GNAO1

5.28E-04
6.69E-04

0

cAMP signaling pathway(K)

7.41E-04

GNAZ,GNA14,GNA12,GNAO1
ADCY2,PLCB1,GRIN2A,GNAS,GNAO1,GRIA3
ADCY2,GRIN2A,PDE4C,PLCE1,GNAS,NFATC1,
GRIA3,F2R

0

0
0
0
0
0

LPA receptor mediated
events(N)
S1P4 pathway(N)
GPCR downstream
signaling(R)
Inositol phosphate
metabolism(R)
Thrombin signalling through
proteinase activated receptors
(PARs)(R)

9.76E-04

GNAZ,GNA14,ADCY2,GNA12,GNAO1

1.79E-03

GNAZ,GNA12,GNAO1
GNAZ,GNA14,ADCY2,GNA12,PLCB1,RAMP1,
ARHGEF16,PDE4C,GNAL,GRM6,GNAS,
NMB,GPR4,DGKG,F2R,HTR2A

2.08E-03
2.54E-03

PLCB1,ITPK1,PLCE1,PLCG2

2.78E-03

GNA14,GNA12,F2R

0

Pathways in cancer(K)

2.78E-03

0

Morphine addiction(K)

3.89E-03

0

Wnt signaling pathway(P)

3.89E-03

0

0

Muscarinic acetylcholine
receptor 2 and 4 signaling
pathway(P)
Heterotrimeric G-protein
signaling pathway-Gi alpha and
Gs alpha mediated pathway(P)

ADCY2,GNA12,PLCB1,RALBP1,GNAS,RALGDS,
WNT7B,PLCG2,ABL1,F2R
ADCY2,PDE4C,GNAS,GNAO1,CACNA1A
GNA14,PLCB1,CDH4,NFATC1,CDH13,WNT7B,
LRP6,CDH10

4.08E-03

PRKAR2B,PRKAR1B

4.26E-03

ADCY2,PRKAR2B,GNAL,GRM6,PRKAR1B,HTR2A
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0

Phosphatidylinositol signaling
system(K)
Melanogenesis(K)
Retrograde endocannabinoid
signaling(K)
Oxytocin signaling pathway(K)
Chagas disease (American
trypanosomiasis)(K)
Cholinergic synapse(K)
Serotonergic synapse(K)
Vascular smooth muscle
contraction(K)
CDC42 signaling events(N)
Inositol phosphate
metabolism(K)
DAG and IP3 signaling(R)
Inflammation mediated by
chemokine and cytokine
signaling pathway(P)
Platelet activation(K)
CXCR3-mediated signaling
events(N)
Metabotropic glutamate
receptor group II pathway(P)
Neurotransmitter Receptor
Binding And Downstream
Transmission In The
Postsynaptic Cell(R)
CXCR4-mediated signaling
events(N)
Hedgehog signaling
pathway(P)
Gastrin-CREB signalling
pathway via PKC and
MAPK(R)
Nicotine addiction(K)
Gap junction(K)
Potassium Channels(R)
GnRH signaling pathway(K)
Ras signaling pathway(K)
Posttranslational regulation of
adherens junction stability and
dissassembly(N)
Estrogen signaling pathway(K)

0

Signaling by Rho GTPases(R)

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

0

0
0
0
0
0
0
0
0
0

0
0
0
0
0

0
0

LPA4-mediated signaling
events(N)
aspirin blocks signaling
pathway involved in platelet
activation(B)
RAC1 signaling pathway(N)
Amoebiasis(K)
Heterotrimeric G-protein
signaling pathway-Gq alpha
and Go alpha mediated
pathway(P)
Endothelin signaling
pathway(P)
nitric oxide signaling
pathway(B)

5.00E-03

PLCB1,ITPK1,PLCE1,DGKG,PLCG2

5.25E-03

ADCY2,PLCB1,GNAS,GNAO1,WNT7B

5.25E-03

ADCY2,PLCB1,GNAO1,GRIA3,CACNA1A

5.44E-03

ADCY2,KCNJ14,PLCB1,GNAS,NFATC1,GNAO1

5.44E-03

GNA14,PLCB1,GNAL,GNAS,GNAO1

7.29E-03
7.59E-03

ADCY2,KCNJ14,PLCB1,GNAO1,CACNA1A
PLCB1,GNAS,GNAO1,CACNA1A,HTR2A

9.64E-03

ADCY2,GNA12,PLCB1,RAMP1,GNAS

9.64E-03

ENAH,IQGAP1,ACTR2,MAP2K3

0.0102

PLCB1,ITPK1,PLCE1,PLCG2

0.0105

ADCY2,PRKAR2B,PRKAR1B

0.0112

PLCB1,PLCE1,PLCL2,PLCG2

0.0117

ADCY2,PLCB1,GNAS,PLCG2,F2R

0.012

GNAZ,GNAO1,MAP2K3

0.0125

PRKAR2B,PRKAR1B

0.0125

ADCY2,PLCB1,GRIN2A,GNAL,GRIA3

0.0134

GNAZ,PLCB1,CSK,GNAO1

0.0134

PRKAR2B,PRKAR1B

0.0145

GNA14,PLCB1,GRIN2A,NMB,GPR4,DGKG,F2R,
HTR2A

0.0153
0.0172
0.0186
0.0194
0.0219

GRIN2A,GRIA3,CACNA1A
ADCY2,PLCB1,GNAS,HTR2A
KCNAB2,KCNAB1,KCNJ14,KCNA6
ADCY2,PLCB1,GNAS,MAP2K3
RALBP1,GRIN2A,PLCE1,RALGDS,PLCG2,ABL1

0.0219

GNA12,IQGAP1,ABL1

0.0224

ADCY2,PLCB1,GNAS,GNAO1
IQGAP1,ACTR2,RALBP1,ARHGEF16,DIAPH2,
MYO9B,ABL1

0.0266
0.0269

ADCY2,GNAL

0.0269

PLCB1,F2R

0.0269
0.0269

IQGAP1,ACTR2,MAP2K3
GNA14,PLCB1,GNAL,GNAS

0.0269

PLCB1,GRM6,GNAO1,CACNA1A

0.0269

ADCY2,PRKAR2B,PRKAR1B

0.0269

PRKAR2B,GRIN2A

192

0

Alzheimer disease-presenilin
pathway(P)
Factors involved in
megakaryocyte development
and platelet production(R)
gata3 participate in activating
the th2 cytokine genes
expression(B)
S1P1 pathway(N)
PDGFR-beta signaling
pathway(N)
Canonical Wnt signaling
pathway(N)
pkc-catalyzed phosphorylation
of inhibitory phosphoprotein of
myosin phosphatase(B)
Neuroactive ligand-receptor
interaction(K)
BCR signaling pathway(N)
regulation of ck1/cdk5 by type
1 glutamate receptors(B)
Amphetamine addiction(K)
signaling pathway from gprotein families(B)
Signaling by Robo receptor(R)
Complement and coagulation
cascades(K)
Cell junction organization(R)
Thyroid hormone synthesis(K)
fmlp induced chemokine gene
expression in hmc-1 cells(B)
Nongenotropic Androgen
signaling(N)
links between pyk2 and map
kinases(B)
Cortocotropin releasing factor
receptor signaling pathway(P)
GPCR ligand binding(R)
Regulation of actin
cytoskeleton(K)
Gastric acid secretion(K)

1

Huntington's disease(K)

1.28E-05

1

The citric acid (TCA) cycle
and respiratory electron
transport(R)

1.53E-05

1

Oxidative phosphorylation(K)

3.44E-05

1

Parkinson's disease(K)

4.18E-05

1

Alzheimer's disease(K)

1.15E-04

0
0

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

1

Non-alcoholic fatty liver
disease (NAFLD)(K)
cGMP-PKG signaling
pathway(K)
Carbon metabolism(K)

1

Metabolic pathways(K)

1
1

Axon guidance(K)
Tryptophan metabolism(K)

1
1

0.0279

ACTR2,LRP1B,WNT7B,LRP6

0.0288

PRKAR2B,ITPK1,PRKAR1B,ABL1

0.03

PRKAR2B,MAP2K3

0.0333

GNAZ,GNAO1

0.0365

IQGAP1,ACTR2,CSK,ABL1

0.0367

RANBP3,LRP6

0.0384

PLCB1,CACNA1A

0.0384

TRPV1,GRIN2A,GRM6,GRIA3,F2R,HTR2A

0.0384

CSK,NFATC1,PLCG2

0.0384

PRKAR2B,PLCB1

0.0384

GRIN2A,GNAS,GRIA3

0.0384

PRKAR2B,PLCB1

0.0384

ENAH,ABL1

0.0395

C4B,CR1,F2R

0.041
0.0426

CDH4,CDH13,CDH10
ADCY2,PLCB1,GNAS

0.045

PLCB1,MAP2K3

0.045

GNAZ,GNAO1

0.045

PLCB1,MAP2K3

0.045

GNA14,GNAL

0.047

RAMP1,GRM6,GNAS,NMB,GPR4,F2R,HTR2A

0.0472

ENAH,GNA12,IQGAP1,DIAPH2,F2R

0.0476

ADCY2,PLCB1,GNAS
UQCRC2,ATP5B,AP2B1,ATP5J,SLC25A6,
NDUFA10,NDUFB3,NDUFA3,ITPR1,SDHD

5.12E-04

UQCRC2,ATP5B,OGDH,ATP5J,NDUFA10,
NDUFB3,ATP5J2,NDUFA3,SDHD
UQCRC2,ATP5B,ATP5J,NDUFA10,NDUFB3,
ATP5J2,NDUFA3,SDHD
UQCRC2,ATP5B,ATP5J,SLC25A6,NDUFA10,
NDUFB3,NDUFA3,SDHD
UQCRC2,ATP5B,ATP5J,NDUFA10,NDUFB3,
NDUFA3,ITPR1,SDHD
UQCRC2,INSR,IRS2,NDUFA10,NDUFB3,NDUFA3,
SDHD

7.72E-03

ATP2B2,INSR,IRS2,SLC25A6,ATP1A2,ITPR1

8.87E-03

OGDH,G6PD,ACAT1,HADHA,SDHD
UQCRC2,ATP5B,QARS,OGDH,ATP5J,NDUFA10,
NME4,FOLH1,G6PD,NDUFB3,ACAT1,
HADHA,CEPT1,ATP5J2,NDUFA3,SDHD
PLXNA1,L1CAM,SEMA3F,SEMA3B,PLXNB2
OGDH,ACAT1,HADHA

9.56E-03
0.0119
0.0255

193

1
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
3
3

3
3
4
4
4
4
4
4
4

Lysine degradation(K)
Transcriptional regulation of
white adipocyte
differentiation(R)
Fatty acid, triacylglycerol, and
ketone body metabolism(R)
RXR and RAR
heterodimerization with other
nuclear receptor(N)
Base-Excision Repair, AP
Site Formation(R)
Regulation of cholesterol
biosynthesis by SREBP
(SREBF)(R)
Signaling by TGF-beta
Receptor Complex(R)
Resolution of Abasic Sites (AP
sites)(R)
Generic Transcription
Pathway(R)
TGF-beta signaling pathway(P)
Base excision repair(K)
Bladder cancer(K)
Notch-mediated HES/HEY
network(N)
Notch signaling pathway(K)
Cell cycle(K)
Validated targets of C-MYC
transcriptional repression(N)
Circadian Clock(R)
Regulation of retinoblastoma
protein(N)
map kinase inactivation of smrt
corepressor(B)
mets affect on macrophage
differentiation(B)
cyclins and cell cycle
regulation(B)
Signaling by NODAL(R)
E2F transcription factor
network(N)
Regulation of nuclear
SMAD2/3 signaling(N)
Endocytosis(K)
Meiotic synapsis(R)
RNA Polymerase I, RNA
Polymerase III, and
Mitochondrial
Transcription(R)
Processing of Capped IntronContaining Pre-mRNA(R)
Acute myeloid leukemia(K)
Ubiquitin mediated
proteolysis(K)
Prolactin receptor signaling(R)
APC/C-mediated degradation
of cell cycle proteins(R)
Hedgehog 'off' state(R)
ErbB4 signaling events(N)
Circadian rhythm(K)
Signaling by ERBB4(R)

0.0486

OGDH,ACAT1,HADHA

1.02E-05

TGFB1,CCND3,SREBF1,CEBPD,CREBBP,SREBF2
,NCOR2

1.02E-05

LPIN1,MTF1,NPAS2,SREBF1,CPT1B,FADS1,
CREBBP,SREBF2,NCOR2

4.42E-04

THRA,TGFB1,SREBF1,NCOR2

5.56E-04

UNG,TDG,OGG1

4.48E-03

MTF1,SREBF1,CREBBP,SREBF2

0.0101

TGFB1,RBL1,PPP1R15A,NCOR2

0.0101

UNG,TDG,OGG1

0.0101

THRA,NR2F6,RBL1,CREBBP,NOTCH4,NCOR2

0.0101
0.0101
0.0174

GDF1,TGFB1,JUND,CREBBP
UNG,TDG,OGG1
DAPK2,DAPK3,FGFR3

0.0226

TCF3,CREBBP,NCOR2

0.0226
0.0342

CREBBP,NOTCH4,NCOR2
TGFB1,RBL1,CCND3,CREBBP

0.0342

RBL1,CLU,CEBPD

0.0353

NPAS2,SREBF1,CREBBP

0.036

CCND3,CEBPD,CREBBP

0.0364

THRA,NCOR2

0.0364

RBL1,NCOR2

0.0373

RBL1,CCND3

0.0373

GDF1,DRAP1

0.038

RBL1,CCND3,CREBBP

0.0492

TCF3,CREBBP,IRF7

0.0492
5.93E-04

LDLR,TGFB1,BIN1,FGFR3,SH3GLB2
H2AFX,STAG2,LMNA,REC8

7.40E-03

MTA1,CDK7,MBD3,PTRF

7.40E-03

SNRPD2,PRPF8,PTBP1,CDC5L,CPSF1

0.0244

PML,CCNA1,TCF7

9.68E-04
0.025

FZR1,UBE3B,BTRC,CDC34,CUL5
BTRC,PRL

0.025

FZR1,BTRC,PSMA1

0.025
0.0362
0.0362
0.0362

BTRC,GLI2,PSMA1
PRL,WWOX
BTRC,PER1
BTRC,PRL,WWOX,PSMA1
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5

Focal adhesion(K)

8.18E-12

5

ECM-receptor interaction(K)

6.27E-11

5

Extracellular matrix
organization(R)

6.77E-10

5

Integrin signalling pathway(P)

1.79E-07

5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5

Arrhythmogenic right
ventricular cardiomyopathy
(ARVC)(K)
PI3K-Akt signaling
pathway(K)
Hypertrophic cardiomyopathy
(HCM)(K)
Dilated cardiomyopathy(K)
Regulation of actin
cytoskeleton(K)
Cell junction organization(R)
CDC42 signaling events(N)
Reelin signaling pathway(N)
Protein digestion and
absorption(K)
agrin in postsynaptic
differentiation(B)
GP1b-IX-V activation
signalling(R)
oxidative stress induced gene
expression via nrf2(B)
Beta1 integrin cell surface
interactions(N)
Beta5 beta6 beta7 and beta8
integrin cell surface
interactions(N)
Response to elevated platelet
cytosolic Ca2+(R)
Proteoglycans in cancer(K)
NCAM signaling for neurite
out-growth(R)
Amoebiasis(K)
Smooth Muscle Contraction(R)
MAPK signaling pathway(K)
Retinoid metabolism and
transport(R)
Beta3 integrin cell surface
interactions(N)
Signaling by PDGF(R)
RAC1 signaling pathway(N)
Viral myocarditis(K)
Signaling events mediated by
focal adhesion kinase(N)

ITGB4,ITGB5,ITGB8,PAK4,COL6A2,COL4A3,
COL4A1,TNXB,ACTN1,FLNC,FLNA,VWF
DAG1,ITGB4,ITGB5,ITGB8,COL6A2,COL4A3,
COL4A1,TNXB,VWF
COL21A1,DAG1,ITGB4,ITGB5,ITGB8,DMD,
COL6A2,COL4A3,COL4A1,ACTN1,NRXN1
ITGB4,ITGB5,ITGB8,COL6A2,COL4A3,COL4A1,
ACTN1,FLNA

9.77E-07

DAG1,ITGB4,ITGB5,ITGB8,DMD,ACTN1

4.44E-05

ITGB4,ITGB5,ITGB8,COL6A2,COL4A3,COL4A1,
TNXB,VWF

4.44E-05

DAG1,ITGB4,ITGB5,ITGB8,DMD

5.53E-05

DAG1,ITGB4,ITGB5,ITGB8,DMD

2.40E-04

ITGB4,ITGB5,ITGB8,PAK4,LIMK2,ACTN1

3.76E-04
3.76E-04
5.74E-04

ITGB4,ACTN1,FLNC,FLNA
PAK4,MAP2K7,LIMK2,MAP3K11
MAP2K7,LRP8,MAP3K11

9.00E-04

COL21A1,COL6A2,COL4A3,COL4A1

2.22E-03

DAG1,DMD,PAK4

2.65E-03

FLNA,VWF

4.92E-03

MAFG,MAFF

4.92E-03

COL6A2,COL4A3,COL4A1

6.62E-03

ITGB5,ITGB8

8.14E-03

ACTN1,FLNA,VWF

0.0114

COL21A1,ITGB5,FLNC,FLNA

0.0143

COL6A2,COL4A3,COL4A1,MAP3K11

0.0143
0.0174
0.0215

COL4A3,COL4A1,ACTN1
ITGB5,SORBS1
MAP2K7,FLNC,FLNA,MAP3K11

0.0217

GPC5,LRP8

0.029

COL4A3,COL4A1

0.0311
0.036
0.0412

COL6A2,COL4A3,COL4A1,MAP3K11
MAP2K7,MAP3K11
DAG1,DMD

0.0454

ITGB5,ACTN1
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